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Glucocorticoid excess is associated with adverse effects on a number of 
physiological parameters, leading to obesity, dysfunction of the hypothalamic-
pituitary-adrenal (HPA) axis and behavioural changes such as anxiety and impaired 
learning and memory. Circulating and local tissue glucocorticoid levels are tightly 
controlled by the HPA axis but an additional level of control exists in tissues such as 
brain, liver and adipose tissue. In these structures, enzymes including 5α-reductase 1 
(5αR1), catalyse the conversion of corticosterone to A-ring reduced metabolites, 
which have a different spectrum of activities. This thesis investigates the role of 
5αR1 in regulating central glucocorticoid actions which control HPA axis function 
and behaviour in a mouse model with genetic disruption of 5αR1 (5αR1-KO). 
Preliminary data showed 5αR1-KO mice were susceptible to developing insulin 
resistance and obesity and had reduced HPA axis responses to acute stress. 
Additionally, male 5αR1-KO mice were more prone to obesity than wild-type (WT) 
when fed a high-fat diet whilst female 5αR1-KO mice gained more weight than WT 
even on a normal chow diet. Intriguingly, female 5αR1-KO mice subjected to social 
isolation stress lost this extra weight and became comparable to WT controls. This 
study tested the hypothesis that 5αR1-KO mice are less able to inactivate 
glucocorticoids in the periphery and within tissues, resulting in a predisposition to 
metabolic disturbances and behavioural alterations. These were hypothesised to 
include hyperphagia, weight gain, impaired stress responses, anxiety (exacerbated by 
environmental stress) and cognitive deficits. It was also thought that many of these 
features would be more pronounced in female vs. male mice.  The main aims of this 
study were to determine if 5αR1-KO induced weight gain and if this was correlated 
to altered gene expression of key hypothalamic neuropeptides which regulate 
appetite, to determine the central mechanisms which underpin attenuated HPA axis 
responses to acute stress and to determine whether behaviours such as anxiety and 
learning and memory ability are affected by global 5αR1 loss. 
 
It was hypothesised that female 5αR1-KO mice have increased appetite and reduced 
locomotor activity compared with WT and male 5R1-KOs. However, male 5αR1-




a normal chow diet but did not gain extra weight, while female 5αR1-KO mice 
gained more weight vs. WT despite hypophagia. Free ambulatory activity was 
unaffected by genotype in either sex. Male 5αR1-KO mice appeared less anxious but 
responses of female 5αR1-KO mice in tests of anxiety did not differ from WT 
controls. Mice lacking 5αR1 generally had a poorer metabolic profile with impaired 
glucose tolerance and hyperinsulinaemia; with hepatic steatosis evident in female 
mice. There was evidence of compensatory changes in hypothalamic orexigenic and 
anorexigenic peptides. Phenotypes were sexually dimorphic such that male mice had 
a poorer metabolic profile vs. females, which was particularly marked in male 5αR1-
KO animals. 
 
5αR1-KO mice were previously shown to have attenuated HPA axis responses to 
acute stress and it was hypothesised that disruption of 5αR1 would result in altered 
expression of genes related HPA axis regulation with a view to increased negative 
feedback. Here, male and female 5αR1-KO mice demonstrated altered corticosteroid 
receptor expression within the hippocampus and the pituitary, two key structures in 
the HPA cascade. In situ hybridisation showed reduced mRNA for MR in the 
hippocampus and for Crh in the hypothalamus of 5αR1-KO mice. These 
modifications along with decreased Crhr-1 mRNA (CRH‘s main receptor) may be 
due to a lack of corticosterone metabolism within the brain resulting in enhanced 
negative feedback and reduced HPA axial drive. 
 
In order to study behaviour in detail and also to test whether potential central 
glucocorticoid excess may predispose to cognitive decline with ageing, a separate 
cohort of female 5αR1-KO backcrossed onto a uniform C57Bl/6j background was 
studied both when young (6 months) and when aged (14-15 months). Additionally, 
mice were housed in either groups or singly (social isolation) to investigate the 
potentially additive effects of environmental stress. It was hypothesised that local 
glucocorticoid increases in the brains of 5αR1-KO mice would be associated with 
anxiety and cognitive deficiencies and that these phenotypes would be exaggerated 
by the stress of social isolation as well as ageing. Behavioural differences were not 




increased anxiety and had higher plasma corticosterone levels than group-housed 
mice. Moreover, aged mice lacking 5αR1 performed less well than WT in tests of 
memory and had a marginally greater cognitive decline when learning ability at 14-
15 months old was compared to that of the same animals tested at 6 months old.  
Overall, mice with global 5αR1 loss appeared susceptible to anxiety as well as some 
degree of age-associated cognitive impairment, but only when subjected to social 
isolation stress which is a known chronic stressor. 
 
The final set of experiments aimed to determine the effect of mouse strain on 5αR1-
KO phenotypes. It was hypothesised that glucocorticoid clearance would be 
attenuated to a lesser degree in 5αR1-KO mice bred onto a congenic C57Bl/6j strain 
compared to those of the mixed strain and that this would manifest as less disruption 
of metabolism and less suppression of HPA axis stress responses.  Although social 
isolation again induced weight-loss in female mice and more so in 5αR1-KO 
animals, mice on the C57Bl/6j background strain did not show dampened HPA axis 
responses to acute stress as seen previously.  It was subsequently shown in 
adrenalectomised mice that animals bred on the C57Bl/6j strain cleared active 
corticosterone from plasma and liver faster than mixed strain mice. This may have 
rendered mixed strain 5αR1-KO mice more susceptible to excessive corticosterone 
levels producing a more exaggerated phenotype in this group. 
 
In conclusion, these data suggest a role for the enzyme 5αR1 in modifying 
glucocorticoid concentrations in the brain and liver, influencing not only metabolic 
and peripheral effects such as weight gain and insulin resistance, but also in 
modifying cognition, appetite stimulation and affective behaviours. It has been 
highlighted that outside factors such as housing and age can modify these phenotypes 
and are important considerations for future studies. This study has also highlighted 
the importance of choosing an appropriate genetic background for genetically 
modified animals since phenotypes can be enhanced or attenuated depending on 
strain. Finally, 5αR inhibitors are used to treat disorders such as benign prostatic 
hyperplasia in men, and it is important to consider that these drugs may have a wide 
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DG     Dentate gyrus 
DHC     Dihydrocorticosterone 
DHT     Dihydrotestosterone 
DIO     Diet-induced obesity 
DNA     Deoxyribonucleic acid 
DPX     Dibutyl phthalate xylene 
DTT     Dithiothreitol 
EDTA    Ethylene diamine tetra-acetic acid 
ELISA    Enzyme-linked immunosorbent assay 
EPM     Elevated plus maze 
FBGRKO     Forebrain-specific GR knock-out 
G6P     Glucose-6-phosphatase 
GABA    γ-aminobutyric acid 
GABAA    γ-aminobutyric acid receptor type A 
GAPDH     Glyceraldehyde-3-phosphate dehydrogenase  
gDNA    Genomic deoxyribonucleic acid 
GDX     Gonadectomy 
GnRH    Gonadotropin-releasing hormone 
GR     Glucocorticoid receptor 






     Glucocorticoid over-expressor 
GTT     Glucose tolerance test 
HET     Heterozygous 
HF     High-fat diet 
HPA axis    Hypothalamic-pituitary-adrenal axis 
HPG axis    Hypothalamic-pituitary-gonadal axis 
HPLC    High-performance liquid chromatography 
Hsp     Heat shock protein 
HRP     Horse-radish peroxidase 
Hr     Hour 
i.c.v      Intracerebroventricular  
IL-10    Interleukin-10 
i.p.     Intraperitoneal 
IR     Insulin receptor 
ITI     Inter-trial interval 
ITT     Insulin tolerance test 
Kd     Dissociation constant 
Km     Michaelis-Menten constant 
KO     Knock-out 
LBD     Ligand-binding domain 
LTP     Long-term potentiation 
MC3/4R    Melanocortin receptor types 3 and 4 
MCH    Melanin-concentrating hormone 
MDD    Major depressive disorder 
mGR     Membrane-bound glucocorticoid receptor 
Min     Minute 
MR     Mineralocorticoid receptor 
MR
CamKCre 
Forebrain-specific mineralocorticoid receptor knock-
out 
MR-Tg     Mineralocorticoid receptor over-expressor 
mRNA    Messenger ribonucleic acid 




NAD     Nicotinamide adenine dinucleotide 
NADP    Nicotinamide adenine dinucleotide phosphate 
NADPH    Nicotinamide adenine dinucleotide phosphate-reduced 
NEFA    Non-esterified fatty acid 
nGREs     Negative glucocorticoid response elements 
NPY     Neuropeptide Y 
Ob     Obese gene 
OFT     Open field test 
P450scc     P450 cholesterol side-chain cleavage enzyme 
PBS     Phosphate buffered saline 
PCOS    Polycystic ovarian syndrome 
PCR     Polymerase chain reaction 
POMC    Pro-opiomelanocortin 
PPAR    Peroxisome proliferator-activated receptor γ 
PPIA     Cyclophilin A 
PR     Progesterone receptor 
PTSD     Post-traumatic stress disorder  
PVN      Paraventricular nucleus 
PXR     Pregnane-X receptor 
qPCR    Quantitative polymerase chain reaction 
RIA     Radioimmunoassay 
RIN     Ribonucleic acid integrity number 
RMT     Room temperature 
RN18S    18s ribosomal ribonucleic acid 
RNA     Ribonucleic acid 
rRNA    Ribosomal ribonucleic acid 
RSD     Relative standard deviation 
RT     Reverse transcription 
s.c.     Subcutaneous 
SDR     Steroid displacement reagent 
Sec     Second 




SNPs     Single nucleotide polymorphisms 
SPA     Scintillation proximity assay  
SSC     Saline sodium citrate 
STAT3    Signal transducer and activator of transcription 3 
TAT     Tyrosine aminotransferase 
TBE     Tris/borate/ethylene diamine tetra-acetic acid 
TE     Tris/ethylene diamine tetra-acetic acid 
TBP     TATA box-binding protein 
TBS     Tris-buffered saline 
TMB     3,3‘,5,5‘-tetramethylbenzidine 
Tris     Trisma base 
TF     Transcription factor 
tRNA    Transfer ribonucleic acid 
Wks     Weeks 
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Obesity (and associated metabolic disease) is rapidly becoming a global pandemic.  
In 2013, The World Health Organisation reported that the incidence of obesity 
worldwide has nearly doubled since 1980 and records from 2008 show over 1.4 
billion adults aged 20 and over were overweight; of these approximately 500 million 
were medically obese, representing 7% of the global population (The World Health 
Organisation 2013).  Amongst other obesity-related diseases, cardiovascular disease 
(CVD) is one of the most common, killing an estimated 17 million people each year 
(Mackay et al. 2004), making it the single leading cause of death today, in spite of 
improved cardiological interventions.  Mathers and Loncar predict that by 2030, 
almost 23.3 million people will die from CVD annually, mainly from heart disease 
and stroke (Mathers et al. 2006).  Therefore, understanding the mechanisms which 
underlie the progression of CVD, and associated disorders, is crucial in minimising 
the incidence of obesity-related diseases.  Moreover, investigating the role of 
modifiable factors such as steroid hormones is essential in any attempt to curb the 
rapid progression of metabolic and cardiovascular dysfunction.  Here we focus on the 
role of glucocorticoids in both health and disease. 
 
1.1 Glucocorticoids 
The term ―glucocorticoids‖ originates from their role in glucose metabolism, their 
synthesis in the adrenal cortex and their steroidal structure (GLUCOse, CORTex 
and sterOID).  Glucocorticoids (cortisol in humans and corticosterone in rodents) are 
lipophilic ketosteroid hormones with a ∆
4,5
,3-oxo structure (Figure 1.1).  They have 
the capacity to modulate the expression of approximately 10% of our genes and can 
act in almost every cell type in the body (Buckingham 2006).  Glucocorticoids can 
therefore influence the function of many physiological processes and organ systems.  
Glucocorticoids act to maintain or restore physiological homeostasis both basally and 
following an emotional or physical stressor; rendering them ―stress-protective‖.  
They do this by mobilising fuel via the breakdown of carbohydrate and protein from 
storage and also exert a spectrum of effects on lipid breakdown and deposition.  






Figure 1.1  The generic keto steroid cyclopentanoperhydrophenanthrene structure 
All ketosteroids comprise this basic 3 cyclohexane (A-C), 1 cyclopentane (D) ring structure 
made up of 21 carbon atoms (numbered 1-21).  The specificity of individual steroids is 
defined by the addition of various side-chains.  For example, both corticosterone and cortisol 
have carboxyl groups at C3 and C20 and hydroxyl groups at C11 and C21 which defines 





have highly integrated effects on behaviour and play a role in promoting the 
resolution of infection and inflammation.  This last property has led to their use 
clinically as anti-inflammatory agents.  However, though many glucocorticoid-
mediated actions are beneficial and necessary, some can be detrimental, especially 
when exposure is prolonged or excessive.  For this reason, circulating glucocorticoid 
levels must be maintained within a normal physiological window, achieved mainly 
through the hypothalamic-pituitary-adrenal axis (discussed later). 
 
1.1.1 Glucocorticoid biosynthesis 
Glucocorticoids are synthesised in the zona fasciculata of the adrenal gland from the 
precursor cholesterol.  This synthetic pathway, which also leads to the de novo 
synthesis of other steroids, is catalysed by cytochrome P450 oxidative enzymes in 
conjunction with other oxidase and reductase, steroidogenic enzymes (Figure 1.2). 
 
1.1.2 Corticosteroid receptors 
Glucocorticoids can mediate their effects through different mechanisms of action 
which can be either rapid (non-genomic in minutes), intermediate (transcriptional 
effects in hours) or long (nuclear protein-protein interactions which can last days; 
Keller-Wood et al. 1984).  The cellular and physiological actions of glucocorticoids 
are mainly mediated through interactions with two nuclear hormone receptors each 
with differing affinities, the mineralocorticoid receptor (MR; the type I receptor; 
Nr3c2) and the glucocorticoid receptor (GR; the type II receptor, Nr3c2;(Reul et al. 
1985; Lu et al. 2006).  GR is widely distributed in the mammalian body and is 
present in most cell types.  Compatible with its ubiquitous expression, GR is 
involved in many physiological processes from energy mobilisation and stress 
adaptations to modulation of brain and immune functions (Miller et al. 1995).  Two 
GR isoforms (α and β), arise from alternative splicing of the pre-mRNA.  GRα is the 
functional isoform and is expressed in abundance throughout the body.  On the other 
hand, GRβ does not bind glucocorticoids and acts instead as a dominant-negative 
inhibitor of glucocorticoid action by binding to DNA and interfering with GRα-DNA 





Figure 1.2  The biosynthesis and metabolism of glucocorticoids and related steroids 





1.1.2.1 Tissue distribution and specificity of corticosteroid receptors 
Whilst the physiological effects of glucocorticoids are primarily mediated via GR, 
MR is the higher affinity receptor for endogenous glucocorticoids (approximately 
10-fold higher affinity than GR for corticosterone and cortisol; Seckl 1997) and has 
almost equal affinity for corticosterone and the mineralocorticoid aldosterone 
(approximate Kd = 0.5 - 2 nM; Reul et al. 1985; Arriza et al. 1987).  MR expression 




 balance, such as the distal tubule 
epithelial cells of the kidney, exocrine glands and the colon (Buckingham 2006).  In 
these tissues where MR activation by mineralocorticoids (as opposed to 
glucocorticoids) is important for function, the glucocorticoid-metabolising enzyme 
11β-hydroxysteroid dehydrogenase type 2 (11βHSD2) is highly expressed allowing 
mineralocorticoid-MR activation. 
 
By contrast to MR, GR is widely distributed throughout the body but has a much 
lower affinity for endogenous glucocorticoids (approximate Kd = 2.5-5 nM for 
corticosterone; Reul et al. 1985), thus receptor activation is dependent on the 
glucocorticoid load within the tissue.  At the circadian nadir the tissue levels of 
endogenous glucocorticoids are within the affinity range of MR (0.5 - 1 nM) 
suggesting MR mediates glucocorticoid effects at very low concentrations.  By 
contrast, during a stressful event or at the peak of the circadian rhythm, when free 
glucocorticoid levels can exceed 300 nM, MR becomes saturated allowing GR 
occupation and mediation of biological effects (Buckingham 2006).   
 
Both corticosteroid receptor types are expressed in the brain (Reul et al. 1985; 1986; 
de Kloet 1991).  GR is abundantly expressed throughout the central nervous system 
(CNS) in most neurons and glia (De Vellis et al. 1974; Sousa et al. 1989; Ahima et 
al. 1990); indeed it is thought the receptor is present in every cell type in the 
mammalian CNS (Seckl 1997).  However, highest GR expression is seen in the 
paraventricular nucleus (PVN) of the hypothalamus and the hippocampus (Reul et al. 
1985).  MR has a more restricted distribution in the CNS than GR with high 
expression confined to the hippocampus, lateral septum and some brain stem nuclei 




More modest MR expression is also seen in other neuroendocrine brain regions 
including the PVN where MR is expressed at very low levels (Swanson et al. 1989; 
Seckl et al. 1993).  However, there is evidence to suggest co-localisation of 
aldosterone and 11βHSD2 in neurons in the CNS, such as those in the nucleus of the 
solitary tract (Geerling et al. 2009), allowing access to the receptor.  There remain 
many questions though, regarding the direct effects of aldosterone-induced MR 
activation in the brain due to its poor penetration of the blood brain barrier (BBB) 
and glucocorticoid-dominant occupation of MR (glucocorticoid concentrations in the 
brain are 1000-fold higher than aldosterone concentrations; Geerling et al. 2009).   
 
1.1.3 Glucocorticoid activation of corticosteroid receptors 
Intracellular corticosteroid receptors (GR and MR) belong to the nuclear receptor 
superfamily of ligand-activated transcription factors, which exert their effects by 
attaching to specific DNA sequences (glucocorticoid response elements; GREs), 
classically as homodimers (Glass 1994) and altering the transcription of a plethora of 
target genes.  All nuclear receptors have the following structure (see Figure 1.3 for 
more information): the N-terminal (A/B) domain, the DNA-binding (C) domain 
(DBD), the hinge region (D-domain) and the ligand-binding (E/F) domain (LBD; 
Buckingham 2006; Beck et al. 2009).  The N-terminal domain shows the most 
variability within the family of nuclear steroid receptors.  It contains the 
transactivation domain, activation function-1 (AF-1), which associates with 
transcription factors such as CREB-binding protein (CBP) and TATA box-binding 
protein (TBP) and is crucial for GRs transcriptional activity (Kumar et al. 2005).  
The central DBD targets the receptor towards GREs within the DNA sequence and 
has two highly conserved zinc finger structures which are unique to nuclear receptors 
and crucial for dimerisation (Berg 1989; Klug et al. 1995).  The hinge region 
facilitates translocation to the nucleus upon ligand binding and receptor dimerisation 
whilst the C-terminal LBD containing a second transactivation domain (AF-2), 
comprises of 11 helical structures which form the ligand-binding pocket ensuring 







Figure 1.3  Structure of the glucocorticoid receptor 
This schematic diagram highlights the N-terminal activation function 1 (AF-1), the DNA-
binding domain (DBD) and the ligand-binding domain (LBD).  The specific domains 





Unliganded, GR is held in the cytoplasm adhered to a protein complex consisting of 
mainly heat-shock proteins (Hsp) including Hsp70 and Hsp90 as well as other 
Hsp90-binding proteins which bind to the LBD and work to stabilise the complex 
inducing a conformation favourable to ligand binding (Pratt et al. 2006).  Upon 
steroid binding to the LBD, the Hsp chaperone complex dissociates inducing an 
allosteric change which shifts the receptor into a transcriptionally active state.  
Activated corticosteroid receptors then undergo phosphorylation and are generally 
believed to act as ligand-induced homodimers which translocate from the cytoplasm 
to the nucleus to bring about transcriptional changes.  GR activation results in waves 
of gene regulation which either positively (transactivation) or negatively 
(transrepression) affect the transcription of glucocorticoid responsive genes (De 
Bosscher et al. 2003; Newton et al. 2007; Datson et al. 2008; Beck et al. 2009).  
 
1.1.3.1 Genomic effects of glucocorticoids 
1.1.3.1.1 Glucocorticoid-induced transactivation 
It is accepted that the majority of endocrine and metabolic actions of glucocorticoids 
are mediated via the direct interactions of corticosteroid receptors with distinct DNA 
regions which influence transcription (Schäcke et al. 2004; Buckingham 2006).  
Although the DBDs of MR and GR are almost identical, it is noteworthy that there is 
less than 30% overlap in the genes whose transcription is activated or repressed 
subsequent to receptor activation (Datson et al. 2008).  This is somewhat 
unsurprising since the two receptors show distinct tissue localisation, especially in 
the brain as highlighted previously (1.1.2.1). 
 
Following ligand binding, dissociation of chaperone proteins and translocation into 
the nucleus, the activated GR homodimer binds directly to consensus sequences 
(GREs) in the promoter region of glucocorticoid-sensitive genes to induce 
transcription (transactivation) of genes such as tyrosine aminotransferase (Tat).  Tat 
encodes an hepatic enzyme of gluconeogenesis and glucose-6-phosphatase (G6p) 
which catalyses another important step of gluconeogenesis (Jantzen et al. 1987; 
Rigaud et al. 1991; De Bosscher et al. 2003; Beck et al. 2009).  By upregulating the 




gluconeogenesis and therefore induce overall fuel mobilisation (Yoshiuchi et al. 
1998).  GR can also upregulate transcription of target genes in an indirect manner via 
the tethering of a GR monomer to DNA-bound transcription factors.  For example 
the GR monomer has been shown to bind to and enhance the transcriptional activity 
of signal transducer and activator of transcription 3 (STAT3), ultimately increasing 
expression of the gene coding for interleukin-10 (IL-10; Unterberger et al. 2008; 
Beck et al. 2009).  Moreover, evidence suggests the potential for the formation of 
GR/MR heterodimers with transcriptional activity at multiple GREs (Trapp et al. 
1994; Liu et al. 1995).  
 
1.1.3.1.2 Glucocorticoid-induced transrepression 
As with transactivation, ligand-activated GR can directly or indirectly associate with 
negative GREs (nGREs) to regulate the transcription of glucocorticoid-responsive 
genes.  In the case of direct transrepression, the binding of GR monomers to the 
promoter region of specific genes actively inhibits their transcriptional activity as is 
seen in the repression of the osteocalcin gene in response to glucocorticoids.  
However, indirect transrepression mechanisms also exist via the tethering of GR 
monomers to transcription factors recruited to the DNA (Beck et al. 2009).  
Multimers of GR can also form and regulate gene expression.  One such example 
includes pro-opiomelanocortin (POMC; the precursor of adrenocorticotropic 
hormone; ACTH), the promoter of which is repressed following binding of GR 
multimers to an nGRE (Drouin et al. 1993).  This defines one mechanism by which 
glucocorticoids exert negative feedback upon forward drive of the hypothalamic-
adrenal-pituitary (HPA) axis. 
 
1.1.3.1.3 The role of co-regulators 
Access of the ligand-receptor complex to GREs is regulated not only by the presence 
of specific transcription factors but is also influenced by the actions of intracellular 
co-activator and co-repressor proteins.  These co-regulators, which often show cell- 
or tissue-specific expression patterns, are recruited by the ligand-bound receptor 
itself and have the ability to influence (both positively and negatively), GR-mediated 




1998; Fryer et al. 1998; Buckingham 2006).  This involves either acetylation or 
deacetylation of core histone proteins that support the helical structure of the DNA.  
Histone acetylation, facilitated by co-activators, induces an unwinding and opening 
of the DNA double helix allowing access of RNA II polymerase and transcriptional 
complexes thus promoting transcription whilst histone deacetylation induces 
tightening of the DNA helix around the histone core thus repressing gene 
transcription (Beato et al. 1995; Goulding 2004; Buckingham 2006). 
 
1.1.3.2 Non-genomic effects of glucocorticoids 
Although glucocorticoids exert their biological effects mainly through the activation 
and repression of gene transcription, some of their actions occur too rapidly to be 
explained by such mechanisms.  For example, cortisol hyperpolarises hippocampal 
neurones within 1-2 mins of ligand binding and dexamethasone infusion can 
feedback to depress the release of ACTH from the anterior pituitary within a similar 
time period (Maier et al. 2005; Buckingham 2006).  The latter has been suggested to 
occur via the association of membrane-bound GR (mGR) with specific G-proteins in 
the lipid membrane of cells in the pituitary (Bartholome et al. 2004; Maier et al. 
2005).  Moreover, Stahn et al. demonstrated that high concentrations of 
glucocorticoids incorporate into both the lipid and mitochondrial membranes altering 







(Stahn et al. 2007).  Other research suggests that conventional, intracellular GR is 
also capable of inducing rapid, non-genomic effects involving stimulation of a 
complex kinase cascade (Buckingham 2006).  Moreover, the activated, intracellular 
GR complex may rapidly and indirectly affect gene expression by regulating post-
transcriptional events such as mRNA stability and translation as well as post-
translational processing (Buckingham 2006). 
 
1.2 The hypothalamic-pituitary-adrenal (HPA) axis. 
Glucocorticoids exert their effects in the cells of almost every tissue type in the 
mammalian body.  Therefore, maintenance of their levels at normal biological 
concentrations or return to the physiological set-point post-stress, is vital to sustain or 




ordinates a complex series of direct influences and feedback interactions between the 
hypothalamus, the anterior pituitary and the adrenal glands in order to control 
circulating levels of endogenous glucocorticoids.  When perceived negative feedback 
on the axis is low or during acute stress, corticotrophin-releasing hormone (CRH) 
and arginine vasopressin (AVP) are secreted from parvocellular neurons in the PVN 
of the hypothalamus into the portal blood vessel of the hypophyseal stalk (Plotsky 
1987).  By these means, they reach corticotrophe cells in the pituitary gland, 
inducing cleavage of ACTH from its precursor pro-POMC before ACTH is secreted 
from the anterior pituitary lobe into the systemic circulation (Burns et al. 1989; 
Trainer et al. 1995).  When ACTH reaches the adrenal glands, it elicits biosynthesis 
and release of corticosteroids (mainly glucocorticoids and but also 
mineralocorticoids) from the adrenal cortex into the circulation (Ganguly et al. 
1984).  Corticosterone (rodents) or cortisol (humans) is transported around the body 
bound to corticosteroid-binding globulin (CBG) and directed to peripheral target 
tissues, where its bioavailability is dependent upon the activity of tissue-specific 
metabolic enzymes such as 5α-reductase (5αR) and 11β-hydroxysteroid 
dehydrogenase (11βHSD); a detailed discussion of which will follow below. 
 
The biological effects of glucocorticoids are also dependent on the extent of their 
binding (> 90%; Breuner et al. 2002) to CBG which is believed to hold steroids in an 
inactive state in the circulation therefore regulating the amount of hormone which is 
freely able to enter target tissues (Mendel 1989).  For example, although the CBG-
knock out (KO) mouse does not exhibit features of enhanced glucocorticoid 
signalling, HPA axis activity in these mice was increased with an exaggerated 
response to stress (Petersen et al. 2006).  This phenotype was apparent even though 
free corticosterone levels were increased 10-fold suggesting an active role for CBG 
in bioavailability, transportation and cellular signalling which determine the overall 
target tissue responsiveness to glucocorticoids.  The rapid chain of events from 
stimulus to adrenal steroid release means that systemic glucocorticoids can rise 





1.2.1 HPA axis regulation in health 
The HPA axis, like most other physiological body systems, demonstrates circadian 
rhythmicity (Pincus 1943). Glucocorticoid concentrations rise just prior to wakening 
(light phase in humans, dark phase in rodents) e.g. the major activity period of the 
organism, and reach the diurnal nadir before sleep (dark phase in humans, light phase 
in rodents; Lupien et al. 1998; Windle et al. 1998).  As well as circadian control, 
corticosteroids are released in hourly pulses (the ultradian rhythm) which essentially 
maintains the responsiveness of target tissues i.e. to peaks in corticosteroid release 
following a stressor (Young et al. 2004; Lightman et al. 2010).  In addition to 
circadian regulation, activity of the HPA axis is also under negative feedback control 
by glucocorticoids themselves in order to reduce the biosynthesis and release of CRH 
and ACTH, dampening axial drive (Dallman et al. 1992).  Within minutes of their 
release, glucocorticoids act to inhibit further CRH, AVP and ACTH secretory 
responses in both humans and rodents (Dallman et al. 1972; Fehm et al. 1979; 
Keller-Wood et al. 1984; Widmaier et al. 1984; Dallman 2005; de Kloet et al. 2005).  
This regulation is achieved via conventional actions on GR (and to some extent MR) 
but also by rapid, non-genomic negative feedback actions (discussed below), 
mediated by glucocorticoids themselves acting at the levels of the pituitary and the 
PVN to return circulating levels to a basal set-point post-stress (Widmaier et al. 
1984; Jacobson et al. 1991; Herman et al. 1997; Di et al. 2003).  Glucocorticoids 
inhibit transcription and cleavage of POMC, therefore preventing ACTH production 
and release from the pituitary, whilst upstream in the hypothalamus CRH 
transcription is inhibited (Stewart 2002); the net effect being reduced HPA drive to 
prevent further glucocorticoid secretion. 
 
Many studies suggest that recovery from and adaptation to stressful stimuli is a 
coordinated effort involving not only the HPA axis but also parts of the limbic 
system including the hippocampus, amygdala and prefrontal cortex; projections from 
which influence functionality of the PVN (Ulrich-Lai et al. 2009).  The 
hippocampus, which expresses high levels of both MR and GR, is particularly 
sensitive to glucocorticoids and works to reduce hypothalamic stimulation in 




the hippocampus, systemic glucocorticoid levels are decreased or increased 
respectively, suggesting an inhibitory role for the hippocampus also (Jacobson et al. 
1991; Herman et al. 1997; de Kloet et al. 1998).  Moreover, being the memory centre 
of the brain, the hippocampus facilitates a memory trace of stressful events which 
can be either facilitated or inhibited by glucocorticoids, depending on concentration. 
 
1.2.1.1 Sex-specific regulation of the HPA axis 
There is a sex-related influence over HPA axis function which may act to prevent the 
deleterious effects of HPA activation on reproductive processes since glucocorticoids 
are known to inhibit gonadotropin-releasing hormone (GnRH) and thus gonadotropin 
secretion (Selye 1939; Dubey et al. 1985; Ringstrom et al. 1985). Basally, female 
rodents have increased corticosterone secretion compared to males (Critchlow et al. 
1963; Handa et al. 1994). 
 
The magnitude of the HPA axis stress response is also determined by sex.  Post-
stress ACTH and corticosterone levels are consistently shown to be higher in female 
preclinical models vs. males (Kitay 1961; Handa et al. 1994; Armario et al. 1995).  
This is unsurprising since testosterone has been shown to reduce HPA axis responses 
to stress (Gaskin et al. 1971; Handa et al. 1994) whilst oestrogen administration 
increased both basal and stress-induced activity of the HPA axis in both males and 
females (Burgess et al. 1992; Handa et al. 1994). 
 
The effect of sex is not so clear in human subjects since some studies have shown 
males to have greater increases in cortisol and ACTH following psychological stress 
compared to female subjects (Kirschbaum et al. 1992; Kirschbaum et al. 1995; 
Kirschbaum et al. 1995).  These studies were done using young human subjects and 
in an elderly cohort, HPA axis hormonal responses to stress are shown to be higher 
in females vs. males (Seeman 1995; Seeman et al. 2001).  There are also disparities 
within age groups though (Collins et al. 1978; Kudielka et al. 1998) meaning studies 
investigating the impact of sex on HPA axis stress responses are largely 





1.2.2 The HPA axis and the stress response 
Selye (1950) defines ―stress‖ in three stages: an initial alarm reaction, characterised 
by an immediate sympathoadrenomedullary discharge, a subsequent "stage of 
resistance" characterised by the activation of the HPA axis (Figure 1.4), and, finally, 
by exhaustion (Selye 1950).  Whilst under normal circumstances the activity of the 
HPA axis is tightly constrained, during periods of emotional, psychological or 
physical stress (both chronic and acute) the axis plays a key role in conjunction with 
a general discharge of the sympathetic nervous system.  The hypothalamus is a 
highly evolved sensing center and is able to receive, integrate and relay information 
from a number of neural and humoral sources.  It is the hypothalamus that initiates 
the stress response.  The stress response is a physiological or emotional consequence 
of any real or perceived threat or ―stressor‖, the purpose of which is to maintain or 
restore homeostasis following any adverse circumstance.  Under basal conditions, 
physiological levels of glucocorticoids are tightly controlled to avoid prolonged 
periods of glucocorticoid excess which is known to be deleterious to a number of 
physiological systems. 
 
1.2.2.1 The role of corticosteroid receptors in regulating the HPA axis 
MR and GR play distinct roles in regulating HPA axis activity both basally and post-
stress.  Having high affinity for corticosterone, MR remains activated in between 
ultradian pulses (hourly bursts of corticosterone release of 20 mins duration) and 
basally in the absence of stress (Reul et al. 1985; Young et al. 2004) which allows 
this receptor to play an active role in the maintenance of homeostasis (Joels et al. 
2008).  In contrast, GR with its much lower affinity only becomes occupied and 
activated following exposure to stress and at the circadian and ultradian peaks 
(Kitchener et al. 2004; Young et al. 2004) when it plays an active role in a) 
facilitating the stress-response by influencing brain activity and energy mobilisation 
and distribution and b) recovery from the stress response by mediating negative 








Figure 1.4  Hypothalamic-Pituitary-Adrenal (HPA) axis-regulation of the stress response 
Schematic diagram illustrating the roles of hippocampal, hypothalamic, pituitary and adrenal formations involved in the control of the hypothalamic-




Evidence for the crucial role of corticosteroid receptors in HPA axis regulation 
comes from mutagenic animal studies.  Lack of GR activity in a forebrain-specific 
GR-KO mouse model (GR
NesCre
) resulted in dysregulation of the HPA axis with 
raised Crh but not Avp expression in the PVN, along with increased abundance of 
transcripts for Acth in the pituitary (Tronche et al. 1999). Such modifications are 
consistent with impaired negative feedback regulation of the HPA axis.  Moreover, 
these GR
NesCre
 mice had elevated circulating corticosterone levels at both the 
circadian peak and nadir but retained similar levels to control post restraint stress 
(Tronche et al. 1999).  Conversely, specific GR overexpression in forebrain had no 
effect on HPA axis activity with morning and evening corticosterone and ACTH 
levels, and those immediately following a stressor, were comparable to WT controls 
(Wei et al. 2004).  There was also no change in the abundance of transcripts for Crh 
in the PVN (Wei et al. 2004). 
 
The MR/GR balance hypothesis put forward by de Kloet in 1991 suggests that 
increased MR relative to GR would be indicative of reduced HPA responsiveness to 
stressful stimuli (de Kloet 1991).  This is suggestive that MR functionality is critical 
for the sensitivity and feedback of the HPA axis.  Indeed, MR activation following 
corticosterone binding regulates ACTH secretion during both the trough and peak of 
the circadian rhythm (Dallman et al. 1989; Ratka et al. 1989; Bradbury et al. 1994) 
and MR antagonism via intracerebroventricular (i.c.v.) administration of RU28318 to 
rats, resulted in elevated plasma corticosterone basally and prolonged elevations 
post-stress compared to vehicle (Ratka et al. 1989).  The same study also showed 
that specific GR antagonism via i.c.v. administration of RU38486, did not alter basal 
glucocorticoid levels in the circulation but did prolong stress-related elevations in 
corticosterone following a novel environment stress (Ratka et al. 1989).  Taken 
together these results are suggestive of a largely MR-driven regulation of basal 
glucocorticoid levels whilst both MR and GR work synergistically to regulate HPA 





1.2.2.2 The role of rapid, non-genomic glucocorticoid effects in HPA 
axis regulation 
Conventionally, regulation of the axis has been thought to occur mainly via negative 
feedback in a delayed, genomic fashion e.g. corticosterone acting via GR in the PVN 
(de Kloet et al. 1998).  However, it is now known that HPA stress responses are 
regulated, in part, by glucocorticoid mediated feedback which can occur on both fast 
and slow time-frames (Jones et al. 1976; Keller-Wood et al. 1984; Dallman 2005).  
Even as early as 1947, it was shown that ―adrenal gland products‖ inhibited further 
biosynthesis in the adrenal glands within 30 mins by acting upon extra-adrenal 
tissues (Sayers et al. 1947); consistent with the time-frame of fast, non-genomic 
effects.  Moreover, HPA inhibition has been shown to occur within even shorter 
time-frames, for example animals exposed to a immobilisation stress followed by 
another episode 5 mins later, did not elicit a CRH response subsequent to the second 
stressor (Sakakura et al. 1976).  In more recent electrophysiological studies rapid 
negative feedback has been shown to occur via the inhibition of glutamate release 
onto CRH-containing cells in the PVN and was suggestive of actions at a membrane-
bound receptor (Di et al. 2003; Malcher-Lopes et al. 2006).  Further evidence from 
the same studies revealed this was achieved via endocannabinoid synthesis and 
retrograde activation of presynaptic cannabinoid receptors (which reduced the release 
of neurotransmitter from presynaptic terminals), all mediated by mGR. 
 
Rapid, non-genomic actions on HPA function have also been observed at the level of 
the anterior pituitary where high expression of GR and relatively low MR has been 
demonstrated (Reul et al. 1990).  ACTH release from the pituitary was inhibited 
following corticosteroid administration; an effect which was not ameliorated by 
protein synthesis inhibitors suggesting a non-genomic mechanism (Keller-Wood et 
al. 1984).  The cellular basis of these rapid effects is somewhat ambiguous and there 
is opposing evidence for the involvement of GR.  Some authors have reported that 
pretreatment with the GR antagonist RU486 did not prevent rapid, corticosterone 
inhibitory effects on CRH-induced ACTH release in vivo (Hinz et al. 2000) 
indicating that the receptor plays no part in mediating these effects.  Conversely, 




at the level of the pituitary.  For example, annexin-I was required for rapid inhibition 
of ACTH release which in turn seemed to be dependent upon the actions of GR since 
this effect was blocked by the administration of the GR antagonist mifepristone 
(Buckingham et al. 2003; Solito et al. 2003; Tierney et al. 2003). 
 
1.3 Glucocorticoids in health and disease 
1.3.1 Metabolic effects of glucocorticoids  
In health, glucocorticoids play a role in regulating metabolism and energy 
homeostasis such that energy is mobilised to be used as fuel.  These metabolic effects 
of glucocorticoid hormones include the upregulation in the expression of enzymes 
involved in gluconeogenesis (primarily in the liver), resulting in glucose synthesis 
from non-hexose substrates, such as amino acids and glycerol.  One mechanism by 
which this is achieved is by opposing or blocking the effects of insulin in inducing 
glucose storage in the liver.  Glucocorticoids also stimulate lipolysis which mobilises 
fatty acids to be used for energy production in muscles, and glycerol as a substrate 
for gluconeogenesis.  This process is beneficial when food is scarce or during periods 
of acute stress (i.e. the ―fight or flight‖ response) where energy must be mobilised for 
survival.  However, glucocorticoids, when present at concentrations exceeding 
normal physiological levels (for prolonged periods of time), can be detrimental in a 
number of aspects (Reaven 1988; Kahn et al. 2005). 
 
Glucocorticoid effects mediated through corticosteroid receptors can be described as 
immunomodulatory, metabolic/endocrine or toxic and although glucocorticoid 
treatment is of benefit in treating many disorders, side effects are common; the 
severity of which is dependent upon the dose given and the duration of exposure 
(Goodwin 1994).  Across several decades now, glucocorticoids have been used 
clinically as anti-inflammatory agents in the treatment of chronic diseases such as 
asthma, inflammatory bowel disease, rheumatoid arthritis and other autoimmune 
diseases associated with increased inflammatory gene expression (Barnes 1998).  
Therapeutic glucocorticoid use can result in metabolic and cardiovascular 
disturbances associated with glucocorticoid excess including dyslipidaemia, insulin 




(Schacke et al. 2002; Walker 2007); the aforementioned being symptomatic of 
Cushing‘s syndrome.  Cushing‘s syndrome is the collective name used for several 
rare disorders resulting from chronic glucocorticoid exposure from either 
endogenous or exogenous sources. 
 
Dysregulation of the HPA axis and its regulatory parameters (e.g. CRH, MR and 
GR) which results in glucocorticoid excess is also linked to syndromes of metabolic 
tissue systems including diabetes mellitus types I and II (Ray et al. 1993; Tsigos et 
al. 2002; Tsigos et al. 2002), obesity (Devenport et al. 1989; Hautanen et al. 1993; 
Weaver et al. 1993; Pasquali et al. 1996; Andrew et al. 1998; Rosmond et al. 1998) 
and appetite stimulation (Tempel et al. 1994).  In turn, the most common effects of 
long-term glucocorticoid exposure largely affect the normal function of the HPA 
axis.  Obesity, particularly upper body obesity, almost always correlates with HPA 
axis dysfunction.  For example, glucocorticoid secretion is increased in obese 
patients compared to lean control subjects; however, levels in the peripheral 
circulation remain unchanged which is suggestive of enhanced glucocorticoid 
clearance via metabolic enzymes (Boscaro et al. 2001; Walker 2007). 
 
Much is now known about the role of 11βHSDs (type I and type II activate and 
inactivate glucocorticoids respectively) and A-ring reductases such as 5αR1 (reduces 
glucocorticoid potency) in intracellular glucocorticoid metabolism and their link to 
metabolic disorders.  Enhanced tissue regeneration of glucocorticoids inferred from 
increased adipose 11βHSD1 expression has been shown in genetic studies of both 
rodent and human models of obesity (Livingstone et al. 2000; Masuzaki et al. 2001; 
Rask et al. 2001; Lindsay et al. 2003; Wake et al. 2003) whilst in transgenic mouse 
models of 11βHSD1 disruption, glucose tolerance and insulin sensitivity were 
improved even whilst fed a high-fat diet (Kotelevtsev et al. 1997; Morton et al. 2001; 
Morton et al. 2004).  However, regeneration of active corticosterone by 11βHSD1 in 
the liver is reduced in obese Zucker rats in comparison to lean controls (Livingstone 
et al. 2000), and this is also seen in comparisons between obese and lean human 
subjects (Stewart et al. 1999).  Alterations in glucocorticoid metabolism in a highly 




also affecting feedback regulation of the HPA axis.  Moreover, studies over the last 
decade have shown both obesity and the metabolic syndrome are associated with 
chronic inflammation (Hotamisligil 2006).  HPA axis activity is stimulated by pro-
inflammatory cytokines whilst in turn glucocorticoids downregulate the production 
of cytokines and other related inflammatory mediators, providing evidence for cross-
talk between the HPA axis and the inflammatory cascade (Lee et al. 1988; Cronstein 
et al. 1992).  This may therefore be the mechanism which underpins the role of HPA 
axis alterations in the aetiology of obesity.  
 
1.3.1.1 Energy balance and the role of glucocorticoids 
As well as the development and advancement of obesity, glucocorticoids are also a 
key requirement for normal food intake and metabolism.  Germano et al. observed a 
significant reduction in food intake following bilateral adrenalectomy (ADX) in rats 
(Germano et al. 2007).  Additionally, normal rats infused centrally for 3 days with 
synthetic glucocorticoids (dexamethasone) demonstrated a sustained increase in food 
consumption with accompanying body weight gains (Green et al. 1992; Zakrzewska 
et al. 1999).  In human obesity, especially of visceral distribution, elevated 
glucocorticoid levels and hyperactivity of the HPA axis are seen (Weaver et al. 
1993). Furthermore, observational studies have demonstrated the effect of 
glucocorticoid excess (e.g. in Cushing's syndrome) showing that food intake is also 
increased in these individuals (Castonguay 1991; de Herder et al. 1996).  Adrenal 
glucocorticoids and pancreatic insulin have opposing effects on feeding responses 
(Strack et al. 1995) but insulin secretion is also driven by glucocorticoids.  These 
feeding responses are mediated through modulating the expression of various 
hypothalamic neuropeptides which are key in the regulation of appetite and energy 
balance (Solano et al. 1999; Savontaus et al. 2002; Drazen et al. 2003; Coll et al. 
2005). 
 
1.3.1.1.1 Glucocorticoid control of neuropeptides 
Much of appetite regulation (and neuropeptide expression) occurs in structures such 
as the pituitary and the hypothalamus where 5αR enzymes are also expressed in close 




al. 2008).  The hypothalamus is the key structure in regulating appetite, food 
consumption and satiety.  The hypothalamic neuropeptides which mediate these 
parameters can be described as anorexigenic, causing loss of appetite and reduced 
food consumption, or orexigenic, an appetite stimulant increasing feeding behaviours 
and food intake.  Examples of orexigenic peptides include cocaine- and 
amphetamine-regulated transcript (CART), neuropeptide Y (NPY) and agouti-related 
peptide (AgRP) which is co-expressed with NPY, whilst neuropeptides with 
anorexigenic properties include melanin-concentrating hormone (MCH) and  
proopiomelanocortin (POMC); a precursor for the generation of α-melanocyte 
stimulating hormone (α-MSH) which acts upon melanocortin receptors type 3 and 
type 4 (MC3R and MC4R) in the hypothalamus and medial amygdala to mediate its 
anorexigenic effects (see Figure 1.5; Solano et al. 1999; Savontaus et al. 2002; 
Drazen et al. 2003; Coll et al. 2005; Densmore et al. 2006; Smart et al. 2006).  CRH 
has appetite regulating properties which are less well defined but it is most often 
described as having anorexigenic properties (Heinrichs et al. 1993; Ahima et al. 
1996; Huang et al. 1998). 
 
Glucocorticoids mediate their effects on food intake through cross-talk with feeding 
regulators including CRH, NPY, leptin and insulin, and can therefore induce either 
orexigenic or anorexigenic effects depending on which neuropeptide regulatory 
system is activated (see Figure 1.5 for details).  However, expression of GR within 
hypothalamic regions key in appetite regulation (i.e. PVN and the arcuate nucleus), 
suggest more direct pathways also exist (Morimoto et al. 1996).  Glucocorticoids can 
increase appetite and feeding behaviour by increasing NPY secretion and decreasing 
the release of CRH from the hypothalamus (Zakrzewska et al. 1999; Cusin et al. 
2001), effects which may be counteracted by leptin release from the adipose tissue 
shortly after a meal (Cavagnini et al. 2000).  Importantly though, it has been shown 
that high levels of glucocorticoids induced during periods of psychological stress can 







Figure 1.5  Glucocorticoid regulation of appetite and feeding. 
Glucocorticoids released from the HPA axis (with or without a stressful stimulus) can 
directly (through GR) or indirectly (through altering the expression of neuropeptides and 
hormones) alter food intake.  GR stimulation in the hippocampus reduces CRH expression 
(negative feedback) thus reduces CRHR-1/2 activation in the hypothalamus. Glucocorticoids 
also alter the expression of insulin and leptin and other neuropeptides (both anorexigenic and 
orexigenic); the balance between which determines the ultimate effect on food intake.  
Insulin and leptin mediate their effects on feeding behaviour through hypothalamic appetite 
regulatory neuropeptides.  HPA=hypothalamic-pituitary-adrenal axis, GR=glucocorticoid 
receptor, CRH=corticotrophin-releasing-hormone, CRHR-1/2=corticotrophin releasing 
hormone receptor type 1/type 2, NPY=neuropeptide Y, AgRP=agouti-related peptide, 
CART=cocaine- and amphetamine-regulated transcript, POMC= proopiomelanocortin, α-
MSH=α-melanocyte stimulating hormone, MCH=melanin-concentrating hormone, 





1.3.1.1.2 Glucocorticoid control of leptin 
Glucocorticoids also induce changes in feeding responses through interactions with 
the adipose-derived hormone, leptin; a key regulator of appetite and food intake 
(Cavagnini et al. 2000).  Leptin is a 166 amino acid protein transcribed by the obese 
(Ob) gene and is secreted mostly from adipocytes of the white adipose tissue 
(Masuzaki et al. 1995) but also from other organs such as the stomach (Bado et al. 
1998; Sobhani et al. 2000).  Leptin is an appetite suppressant and, in health, 
circulating levels are directly proportional to the total amount of fat in the body.  
Leptin reduces appetite and food intake through actions such as promoting the 
synthesis and release of anorexigenic peptides including α-MSH whilst also 
counteracting the effects of NPY and other orexigenic peptides in the hypothalamus.  
Glucocorticoids can directly increase leptin levels (Mostyn et al. 2001).  
Furthermore, rats receiving high dose dexamethasone (1 mg/kg/day) for 4 days, had 
hyperleptinaemia associated with dose-dependent appetite suppression, reduced food 
intake and resulting weight loss compared to saline controls (Jahng et al. 2008).  
Similar leptin increases have been demonstrated in both lean and obese human 
subjects (Miell et al. 1996; Dagogo-Jack et al. 1997).  Although leptin is an appetite 
suppressant, its increased levels in models of obesity points to a role of 
glucocorticoids in reducing leptin sensitivity (Solano et al. 1999). 
 
1.3.1.1.3 Glucocorticoid control of insulin 
Increased plasma glucose levels give rise to insulin secretion from β-cells in the 
pancreas which promotes glucose metabolism and energy storage in tissues such as 
muscle and fat (Baskin et al. 1999).  Insulin secretion is in proportion to the degree 
of adiposity in the body.  High levels of ligand activation of the insulin receptor (IR) 
e.g. in the hypothalamus (Schwartz et al. 1992), can desensitise the receptor leading 
to insulin insensitivity, reduced receptor signalling, insufficient glucose uptake 
leading to hyperglycaemia and ultimately type II diabetes mellitus, a condition often 
found concomitantly with obesity 
 
Glucocorticoids and insulin have opposing effects on glucose uptake and storage.  




bloodstream in a number of tissues including the liver, skeletal muscle and adipose 
tissue and promote storage as glycogen in the liver and skeletal muscle or 
triglycerides in adipocytes (Moloney et al. 1955; Wright 1959; Antoniades et al. 
1960; Slater et al. 1961; Dixit et al. 1963; Froesch et al. 1963; Jefferson et al. 1968) .  
Conventionally, glucocorticoids are known to mediate carbohydrate metabolism 
(Dallman et al. 1993), in the opposite direction to that of insulin.  Glucocorticoids 
have also been shown to have a number of effects on the activity of insulin through 
the impairment of insulin-dependent glucose uptake in the periphery (e.g. skeletal 
muscle), potentiating glucose uptake and energy storage in adipose tissues and 
enhancing gluconeogenesis in the liver (Rizza et al. 1982; Rooney et al. 1993; 
Chrousos 2000).  Moreover, glucocorticoids also oppose the actions of insulin in 
terms of food intake where the steroid hormones oppose insulin-induced reductions 
in central appetite (Chavez et al. 1997). 
 
An antagonistic interaction between glucocorticoids and insulin exists in most 
adipose depots, whereby glucocorticoids promote lipolysis whilst insulin stimulates 
the synthesis of new fat molecules (Fried et al. 1993).  During periods of 
hyperactivation of the HPA axis (e.g. in chronic stress), persistent glucocorticoid 
excess stimulates gluconeogenesis and inhibits glycolysis resulting in increased 
insulin secretion from the pancreas and hyperinsulinaemia; a condition which has 
been associated with an increased incidence of abdominal fat deposition and a poor 
cardiovascular risk profile (Pasquali et al. 2006; Nieuwenhuizen et al. 2008).  In the 
presence of insulin, this metabolic consequence of visceral energy storage is thought 
to inhibit activity of the HPA axis (Dallman et al. 2005) e.g. metabolically-induced 
negative feedback on the axis to reduce glucocorticoids and their antagonistic effect 
upon insulin-dependent processes.  Leptin then attempts to antagonise the effects of 
high glucocorticoid concentrations by stimulating the release of NPY to increase 
food intake via CRH inhibition (Cavagnini et al. 2000). 
 
Glucocorticoid-stimulated insulin secretion is inversely correlated with CRH mRNA 
expression in the PVN of the hypothalamus, which contributes to reduced activity of 




how glucocorticoids and insulin work synergistically in increasing the intake of 
palatable food which largely contributes to increases in visceral fat depots (Pecoraro 
et al. 2004; Warne 2009). 
 
1.3.2 CNS disturbances linked to glucocorticoid exposure 
1.3.2.1 Glucocorticoid control of behaviour and psychiatric disorders 
Glucocorticoids exert an array of biological effects in the brain affecting behaviour 
as well as neuronal survival, metabolism and neurotransmission.  This first became 
apparent with the discovery of glucocorticoid receptors in the brain many years ago, 
establishing the CNS as an important target for glucocorticoids (McEwen et al. 1968; 
1969).  Moreover, glucocorticoid levels outside the normal physiological range can 
be detrimental and indeed treatment with synthetic glucocorticoids is associated with 
an array of CNS side-effects which are often underestimated or misdiagnosed 
initially (Sirois 2003; McDonough et al. 2008).  There is a high incidence (57 - 83%) 
of psychiatric disturbances amongst individuals with Cushing‘s syndrome and 
hypercortisolaemia (Haskett 1985; Hudson et al. 1987; Dorn et al. 1995; Kelly 1996) 
with depression being the most common amongst anxiety, mania and psychosis 
(Dorn et al. 1995; Kelly 1996; Kelly et al. 1996).  The propensity for Cushing‘s 
patients to develop depression has stimulated an interest in the role of 
glucocorticoids (namely in their excess) in the brain and their modulatory effects on 
behaviour.  Glucocorticoid excess can occur from exogenous sources following 
treatment with synthetic glucocorticoids, from adrenal tumours and from disruption 
of the HPA axis (e.g. suppressed peak responses or delayed recovery).  High 
glucocorticoid levels are associated with neurological conditions such as anxiety, 
depression, anorexia nervosa and age-related cognitive dysfunctions (Kaye et al. 
1987; Rybakowski et al. 1992; Andreatini et al. 1994; Korte et al. 1995; Karanth et 
al. 1997).  Paradoxically though there are reports of associations between low 





1.3.2.1.1 Glucocorticoids in the aetiology of anxiety 
Glucocorticoids have repeatedly been implicated in the development and progression 
of CNS diseases such as anxiety.  One such example includes the 11βHSD1-KO 
mice which are less anxious in elevated plus maze (EPM) and open field test (OFT; 
two tests designed to quantify anxiety-like behaviours) possibly due to reduced 
glucocorticoid amplification centrally (Yau et al. 2003).  Moreover, mice treated 
with the synthetic glucocorticoid prednisolone displayed increased anxiety-like 
behaviours in the above two tests also (Kajiyama et al. 2010).   
 
Anxiety is regulated by many neuropeptides including CRH; a 41 amino acid 
neuropeptide which is widely accepted as a key physiological regulator of stress.  
CRH is synthesised and expressed in the PVN of the hypothalamus, and amygdala 
and is an essential component of the stress response mediated via the HPA axis; 
dysregulation of which is linked to affective disorders.  Its neuromodulatory role has 
been demonstrated in animal studies highlighting that the incidence of anxiety- and 
depression-like behaviours was increased following administration of either CRH or 
CRH fragments to rodents, and also in CRH overexpressing transgenic mice 
(Stenzel-Poore et al. 1994). 
 
CRH acts upon its receptors in the pituitary (of which there are two subtypes) to 
induce ACTH release.  CRH predominantly elicits its effects through associations 
with the CRH receptor type 1 (CRHR-1; a G-protein coupled receptor) which is 
located on corticotrophes of the anterior pituitary.  Encouragingly, several, selective, 
non-peptide antagonists of this receptor are currently in development to treat anxiety 
and depression (Holsboer 1999; Kunzel et al. 2003; Holsboer et al. 2008).  However, 
it is unclear whether the anxiolytic effects of CRHR-1 antagonists are mediated 
through the HPA axis, extra-pituitary CRHR-1 or both, although some studies have 
found evidence for the mediating effect of central CRHR-1 (Philbert et al. 2012).  
The specific brain regions involved have yet to be determined.  
 
CRH has modulatory effects on a number of neurotransmitter systems involved in 




et al. 2001; Valentino et al. 2005).  CRH modulation of these neurotransmitter 
systems (especially serotonin and noradrenaline) supports the role of neuropeptides 
in emotional behaviours as these neurotransmitter systems are implicated in affective 
behavioural responses such as anxiety (both normal and disorderly; Koob 1999; 
Charney 2004).  Therefore, there is strong evidence for the role of CRH in 
modulating circuits involved in emotion. 
 
Finally, altered expression of GR and MR has also been linked to elevated 
glucocorticoids, anxiety and other neurological disorders.  Depression is associated 
with HPA axis malfunction characterised by elevated plasma corticosterone (Carroll 
et al. 1976) and treatment with the antidepressant fluoxetine induced up-regulation of 
GR in hippocampal regions (Yau et al. 2004).  Forebrain specific GR knock-out mice 
(FBGRKO) who have increased HPA axis activity due to loss of GR regulation 
(Boyle et al. 2005), also show increased anxiety-related behaviours in the EPM (Wei 
et al. 2004; Boyle et al. 2006).  Paradoxically, forebrain specific over-expression of 
GR (GR
ov
) in mice also leads to increased anxiety-like behaviours but in this instance 
in the absence of changes in circadian or mild stress induced HPA axis activity (Wei 
et al. 2004).  Over-expression of MR in transgenic mice (MR-Tg) led to reduced 
anxiety compared to WT controls (Lai et al. 2007) even though HPA axis activity 
was unaffected (Rozeboom et al. 2007).  On the other hand, mice with MR knock-
out in the forebrain specifically (MR
CamKCre
), show normal basal circadian and post-
stress HPA axis activity but anxiety levels were no different to control (Berger et al. 
2006). 
 
1.3.2.1.2 Glucocorticoids, cognition and the caveat of ageing 
In neuroscience, long-term potentiation (LTP) is a persisting enhancement in the 
signal transmission occurring between two neurons which results from their 
synergistic excitation (Cooke et al.).  It is this phenomenon that underlies synaptic 
plasticity, the capacity of chemical synapses to alter their strength.  It is widely 
considered that LTP is one of the major cellular mechanisms underlying learning and 
memory since memories are thought to be associated with modifications in synaptic 




biological changes including learning and memory deficits in both humans and non-
human mammals.  Various theories exist which describe the mechanisms which 
drive the ageing process of the brain; these include the involvement of glucocorticoid 
hormones and their ability to induce structural and functional changes within the 
hippocampus when they are present at abnormally high concentrations. 
 
Approximately 30% of human and mammalian populations develop age-associated 
cognitive impairments, much of which is linked to hippocampal dysfunction.  The 
main established parameter used to study hippocampal function in rodents is spatial 
memory which can be manipulated using tests such as the Y-maze and Morris water-
maze.  The Morris water-maze is widely used in behavioural neuroscience to study 
spatial learning and memory. It was developed by neuroscientist Richard G. Morris 
in 1981 (Morris 1981) who showed that hippocampal lesions impaired spatial 
learning in rats (Morris et al. 1982).  The Y-maze is designed to test rodents in much 
the same way as the water-maze.  However, it is a two-trial recognition memory test 
and exploits the rodent‘s natural spontaneous novelty exploration behaviours and 
their ability to recognise novel areas of the maze using spatial cues.  Performance in 
each of the above mazes has been shown to be modified by glucocorticoids, 
corticosteroid receptors and ageing (Hellemans et al. 2004; Wei et al. 2007; Yau et 
al. 2007). 
 
Normal ageing is potentially exacerbated by glucocorticoids since their basal levels 
are generally higher in aged rodents (Sencar-Cupovic et al. 1976; Tang et al. 1978; 
Brett et al. 1983; Sapolsky et al. 1983; 1983; DeKosky et al. 1984; Brett et al. 1986; 
Sapolsky 1992).  Indeed, in aged rats basal plasma corticosterone levels are closely 
correlated with the degree of hippocampal dysfunction and spatial learning 
impairments (Landfield et al. 1978; Landfield et al. 1981).  Moreover, only rats with 
elevated plasma corticosterone levels show evidence of spatial memory deficits (Issa 
et al. 1990) and ADX at middle age followed by low level glucocorticoid 
replacement ameliorates cognitive decline by preventing hippocampal degeneration 




however, human data is more ambiguous with cortisol levels being shown to 
increase, decrease or stay the same during ageing (Lupien et al. 1996). 
 
The hippocampus plays an important role in behaviour and is a key locus for 
neuroendocrine control and cognitive function.  There are reports of glucocorticoid-
mediated cognitive decline where memory and cognition are negatively influenced at 
very high glucocorticoid concentrations via direct alterations in hippocampal 
structure and function (Wolkowitz et al. 1997; Yau et al. 2007).  Hippocampal tissue 
has been shown to have the highest expression of GR and MR in the brain (Jacobson 
et al. 1991) and is known to be particularly sensitive to glucocorticoids which can 
cause a premature aging phenotype in their excess (McEwen 1999; Wei et al. 2007; 
Yau et al. 2007); see Hibberd, Yau and Seckl 2000 for review).  Indeed, human 
subjects suffering from Cushing‘s syndrome have been shown to have cognitive 
impairments in domains such as auditory attention, working memory and spatial 
orienting, even after treatment when long-term remission has been achieved 
(Ragnarsson et al. 2012).  In rodent models such as the 11βHSD1 knock out mouse 
(lacking glucocorticoid regeneration), hippocampal LTP and spatial learning was 
enhanced, even in aged animals (Yau et al. 2007).  It should be noted that although 
many of the deleterious (and beneficial) effects of glucocorticoids upon memory are 
mediated via the hippocampus, other brain structures are also susceptible and studies 
have shown associations between chronic corticotherapy and cerebral atrophy 
(Bentson et al. 1978; Zanardi et al. 2001). 
 
To summarise, the ability of glucocorticoids to cause changes in both central and 
peripheral phenotypes demonstrates close inter-relationships between glucocorticoid 
secretion, behaviour, feeding, metabolism and energy storage.  Conversely, it is 
important to mention that glucocorticoid insufficiency (e.g. in the autoimmune 
disorder Addison‘s disease) can be also be detrimental in terms of vulnerability to 





1.4 Steroid metabolising enzymes 
With reference to the importance of maintaining physiological glucocorticoid 
concentrations, an additional level of control of intracellular concentrations involves 
the metabolism of glucocorticoids by metabolic enzymes.  Disruption of these 
enzymes, either by genetic mutation or pharmacologically, can critically influence 
GR signalling within tissues (Kotelevtsev et al. 1997; Rask et al. 2001; Wake et al. 
2003), thus these pathways have a role to play in modulating the same physiological 
features and disease states mentioned above. 
 
In addition to the control of the HPA axis via negative feedback loops, 
glucocorticoid levels in the body and their biological activity are tightly regulated via 
the action of metabolising enzymes.  Glucocorticoid inactivation and clearance is 
largely a hepatic process and mainly involves the action of non-P450, A-ring 
reducing enzymes such as 5α-reductase (5αR), 5β-reductase (5βR) and 3α-
hydroxysteroid dehydrogenase (3αHSD); referred to as A-ring reductases (Walker et 
al. 2006).  However, there is one cytochrome P450 enzyme involved in 
glucocorticoid metabolism.  The cytochrome P450 3A (CYP3A) enzyme family is 
abundant in the human liver and accounts for roughly 30% of the total P450 content 
(Watkins 1994). The type 4 enzyme (CYP3A4) shows the highest expression in 
human liver (Aoyama et al. 1989), is transcriptionally activated by glucocorticoids 
(Ogg et al. 1999) and has been shown to contribute towards hepatic metabolism of 
synthetic glucocorticoids (Moore et al. 2012).   In addition to 5αR, 5βR and 3αHSD, 
other non-P450 enzymes include the 11β-hydroxysteroid dehydrogenases (11βHSDs; 
Figure 1.6) which provide an additional major route of glucocorticoid metabolism, 
where the two isozymes 11βHSD1 and 11βHSD2 can activate or inactivate local 
glucocorticoids, respectively (Walker et al. 2006).  The P450 and non-P450 enzymes 







Table 1.1  Summary of the enzymes involved in metabolising keto steroids 
This table highlights the two main groups of enzymes involved in steroidogenesis; the non-
P450 enzymes which are A-ring reductases, and the cytochrome P450 group which 
comprises of haem-thiolate proteins.  Non-P450 enzymes such as 5α-reductase use NADPH 
as a co-factor to facilitate electron transfer (H+) onto the substrate, resulting in a reduced 
form of the steroid substrate e.g. 5α-dihydro metabolites,  plus NADP+.  Microsomal P450 
enzymes catalyse steroidogenesis via cytochrome P450 reductase and electron transfer from 
NAPDH.  Mitochondrial systems employ adrenodoxin reductase and adrenodoxin as co-
factors for electron transfer from NADPH. HSD = hydroxysteroid dehydrogenase, NADP+ = 
nicotinamide adenine dinucleotide phosphate, NAPDH = reduced form of nicotinamide 
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1.4.1 5β-Reductase (5βR) 
5βR belongs to the aldo-keto reductase (AKR) superfamily and catalyses the 
reduction of the ∆
4,5
 double bond within the A-ring of steroids in the same way as 
5αRs but the resulting metabolite in this case is cis 5β-dihydro steroids (Berseus et 
al. 1965).  It is believed that the actions of 5βR are mainly catabolic, as it is thought 
that 5β reduced products (which are further metabolised by 3αHSD (Usui et al. 
1986)) are biologically inactive at classical steroid receptors (McInnes et al. 2004).  
The enzyme plays a role in the inactivation of glucocorticoids (corticosterone and 
cortisol) as well as androgens (androstenedione and testosterone) and progesterone 
thus regulating their ability to activate their target nuclear receptors (Berséus 1967; 
Wilson 1987; McInnes et al. 2004; Penning et al. 2007).  Evidence for 5βR 
expression in the brain is lacking and although small amounts are found in the 
kidneys, expression is restricted to the liver where its activity is dependent upon 
nicotinamide adenine dinucleotide phosphate-reduced (NADPH) as an electron donor 
(Okuda et al. 1984; Furuebisu et al. 1987; Onishi et al. 1991; Kondo et al. 1994).  
The predominant function of 5βR involves the processing of bile acids as a result of 
cholesterol metabolism within the liver, as demonstrated by congenital defects in this 
metabolism pathway resulting from mutations in 5βR (Palermo et al. 2008).  5βR 
also generates a range of steroids with the 5β-pregnane configuration, which are 
natural ligands for the pregnane-X receptor (PXR; Bertilsson et al. 1998; Moore et 
al. 2000).   PXR indirectly facilitates the metabolism of a large proportion of drugs in 
the liver by enabling the induction of CYP3A4 (Shimada et al. 1996; Huang et al. 
2006).  However, what is most important for this thesis is that 5βR (in parallel with 
5αR1 and 3αHSD) plays a role in the metabolism and excretion of glucocorticoids in 
the liver (Andrew et al. 2002). 
 
1.4.2 3α-Hydroxysteroid dehydrogenases (3αHSDs) 
5α- and 5β- dihydro steroids formed via the action of 5α- and 5β-reductases can be 
further reduced into their 5α- or 5β-tetrahydro forms by 3αHSDs.  Moreover, in vivo, 
3αHSDs have the capacity to function in both directions allowing them to also 
catalyse the reverse oxidative reaction.  One dominant soluble 3αHSD in the rodent 




to have 69% sequence identity with each of the human types at the amino acid level.  
In humans, at least four isozymes exist which share ~84% amino acid homology with 
each other (Khanna et al. 1995; Khanna et al. 1995; Penning 1997; Penning et al. 
2000), but are each transcribed from a different gene: 3αHSD type 1 (Akr1c4), 
3α(17β)HSD type 2 (Akr1c3), 3αHSD type 3 (Akr1c2) and 20α(3α)-HSD (Akr1c; 
Penning 1999).  Distinct tissue distribution of these enzymes is apparent; the rodent 
3αHSD is highly expressed in the brain (Griffin et al. 1999; Compagnone et al. 2000; 
Dong et al. 2001) whilst in humans both brain and liver express all four isozymes, 
lung tissue expresses all except 3αHSD type 1 and in the prostate 3αHSD type 3 and 
3α(17β) HSD type 2 are predominantly expressed (Penning 1999).  For the purpose 
of this study, in the brain 3αHSD is important in the de novo synthesis of 
neurosteroids such as allopregnanolone (ALLO; Karavolas et al. 1991). 
 
1.4.3 11β-Hydroxysteroid dehydrogenases (11βHSDs) 
11βHSD type 1 and 2 catalyse the interconversion between active and inactive 
glucocorticoids.  They are microsomal membrane-bound proteins, expressed in a 
tissue-specific manner allowing them to influence local glucocorticoid exposure 
within tissues.  The type 1 isozyme (11βHSD1) functions mainly as a reductase, 
converting less active 11-keto glucocorticoids (cortisone in humans, 11-
dehydrocorticosterone in rodents) into their biologically active forms (cortisol in 
humans, corticosterone in rodents).  11βHSD1 is highly expressed in various tissues 
including liver, adipose, the CNS, lung and ovary (Monder et al. 1993; Stewart et al. 
1999; Napolitano et al. 1998).  It was more recently established that 11βHSD1 
provides an important intracellular amplification of glucocorticoids, as well as 
contributing to circulating levels of the hormone (Walker 2007).  Highlighting the 
importance role of metabolising enzymes, 11βHSD-KO mice have adrenocortical 
hypertrophy and the adrenal is hyper-responsive to ACTH stimulation (Kotelevtsev 
et al. 1997).  This study also highlighted the resistance of 11βHSD1-KO mice to 
obesity- and stress-induced hyperglycaemia (Kotelevtsev et al. 1997).   
 
Conversely, the type 2 isozyme, 11βHSD2, is known to reduce the biological activity 




inert 11-keto derivatives (Stewart et al. 1988).  This is especially important in 
pregnancy, when high expression of 11βHSD2 in the placenta and foetus itself 
(Burton et al. 1968) protects the embryo from exposure to high glucocorticoid levels.  
Excessive foetal glucocorticoid exposure and loss of this metabolic barrier during the 
early stages of development can result in low birth weight offspring (Holmes et al. 
2006) with a predisposition towards diseases such as hypertension and 
cardiovascular disease in adulthood; an effect known as pre-natal programming or 
―The Barker Hypothesis‖ (Barker et al. 1986; Barker et al. 1990; Barker et al. 1993). 
 
Whilst 11βHSD1 is highly expressed in an array of different tissue types, including 
importantly the liver, 11βHSD2 does not show hepatic expression and is localised to 
mineralocorticoid (aldosterone) responsive tissues such as the kidney, colon and 
sweat glands (where glucocorticoid metabolism by the enzyme allows access of 
mineralocorticoids to MR) as well as in the vasculature and placenta (Rundle et al. 
1989; Cole 1995; Brown et al. 1996; Seckl et al. 2001).  In the absence of 11βHSD2 
activity, glucocorticoids are able to illicitly activate MR in the distal nephron of the 
kidney leading to sodium retention and hypertension which are symptomatic of 
apparent mineralocorticoid excess syndrome (Ulick et al. 1979).  Therefore, in 
addition their role in hepatic steroid clearance, the expression of metabolic enzymes 
in a wide number of other organ systems provides an additional level of endocrine 
control specifically within tissues.  In this way, active glucocorticoid levels can be 
manipulated in a tissue-specific manner, independently of the concentration in the 
systemic circulation.  The expression of 11βHSD isozymes in the brain (e.g. in the 
hippocampus) means that these enzymes, their activity and their expression ratios to 
each other can influence glucocorticoid load in the CNS allowing them influence 
over certain behaviours such as memory, which will be discussed later in detail. 
 
The evidence above highlights the important role of metabolic enzymes in many 
physiological processes and demonstrates the profound impact disruption of their 
function can have.  This thesis focuses on the importance of 5αR type 1 specifically 
and demonstrates the peripheral and central effects of genetic disruption of this 




1.4.4  5α-Reductases (5αRs) 
There are three isozymes of 5αR, type 1 (5αR1), type 2 (5αR2) and type 3 (5αR3), 
encoded by three separate genes (in the mouse, Srd5a1, Srd5a2 and Srd5a3 
respectively), each with individual biochemical characteristics and tissue-specific 
distribution patterns (Andersson et al. 1990; Andersson et al. 1991; Uemura et al. 
2008) which has important physiological implications.  5αR type 1 and 2 (first 
characterised in the 1950s in rat liver sections; Dorfman et al. 1956) catalyse the 
reduction of ∆
4,5
 double bonds in almost all keto steroids.  5αRs are hydrophobic due 
to their particular amino acid content and for this reason are membrane-bound and 
deeply embedded into the lipid bi-layer.  Using NADPH as a cofactor and 
preferentially inserting the 4S-hydrogen of the nicotinamide ring into the 5α 
configuration of the steroid structure (Wilson 1975), these reductases produce 5α-
dihydro metabolites from a number of different steroid substrates.  Genetic 
(Imperato-McGinley et al. 1974) and enzymological (Fisher et al. 1978) studies have 
given evidence for the capacity of these enzymes to convert a large number of 
ketosteroids (virtually all steroids with a ∆
4,5
,3-oxo structure, see Figure 1.1).  These 
include glucocorticoids, progestagens, androgens and mineralocorticoids which 5αRs 
convert into their A-ring reduced metabolites (Martini et al. 1993; Martini et al. 
1996) which retain varying degrees of activity of the parent steroid (McInnes et al. 
2004).  For most metabolites of steroid hormones, reduction of the ∆
4,5
 bond, and 
reduction of their 3-oxo groups, is thought to largely inactivate transcriptional 
signalling rendering them more susceptible to reduction by 3α- and 3βHSDs.  
Additionally, following 5α/5β reduction, metabolites are subject to sulphation and 
glucuronylation which reduces their affinity for binding proteins and renders them 
hydrophilic in order to facilitate excretion.  The 5αR enzymes were first thought to 
catalyse complete inactivation of the active steroid e.g. corticosterone into 5α-
dihydro-corticosterone.  However, contrary to what was previously thought, the 
subsequent metabolite, 5α-tetrahydro-corticosterone has more recently been shown 




1.4.4.1.1 5αR substrates 
The Km values for the various substrates of rat and human 5αR1 have been 
summarised in Table 1.2 (Andersson et al. 1990; Normington et al. 1992). 
 
Glucocorticoids: 
5αR1 clears glucocorticoids from peripheral tissues such as liver and adipose, but 
also in the CNS (Figure 1.6; Lephart et al. 1991; Normington et al. 1992; Gottfried-
Blackmore et al. 2008).  Glucocorticoids are not the only important substrates of 




It has been shown in humans as well as in rodents that 5αR1 (and 5αR2) in the brain 
can convert progesterone into 5α-dihydroprogesterone (5αDHP); a major hormone in 
the circulation of both normal hormonal cycling women and pregnant women 
(Milewich et al. 1975; Milewich et al. 1977).  In the brains of both humans and 
rodents, 5αDHP can be further metabolised by 3αHSD to form 3α-hydroxy-5α-
pregnan-20-one (ALLO; Hara et al. 1988; Pawlowski et al. 1991; Hoog et al. 1994; 
Penning et al. 2003; Penning et al. 2004).  ALLO is a neurosteroid which has potent 
positive allosteric modulatory effects of γ-aminobutyric acid (GABA) binding to the 
GABAA receptor (Mellon et al. 2002) resulting in regulatory effects upon various 
psychophysiological phenomena.  Additionally, neurosteroids such as ALLO affect 
HPA axis function: ALLO treatment of ADX and gonadectomised (GDX) rats 
resulted in reduced ACTH and corticosterone in response to acute stress (Patchev et 
al. 1996) whilst central injection with an ALLO anti-serum prevented the negative 
effects of ALLO upon the HPA axis resulting in an exaggerated stress-induced 














Table 1.2  A comparison of the Km values for rat 5αR1 
Km values for the type 1 5α reductase isozyme were obtained from publications by 








Figure 1.6  Enzymatic glucocorticoid metabolism 
Metabolic pathways by which A-ring reductases (5αR and 5βR) and 11βHSD convert active 
steroid (corticosterone) into its less active metabolites.  5αR = 5α reductase, 5βR = 5 β 
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5αRs are crucial regulators of androgen action.  5αR2 plays the more important role, 
due to its high expression in the male reproductive organs (Andersson et al. 1991), 
but both the type 1 and type 2 isozymes are capable of metabolising testosterone into 
the 50 times more potent 5α-dihydrotestosterone (5αDHT) thus 5αR1 also 
contributes to plasma 5αDHT levels (Gisleskog et al. 1998; Amory et al. 2007). 
 
Androgens are generally thought to exert negative effects on the HPA axis.  
Following GDX in male rats, CRH levels in the hypothalamus were significantly 
increased but this was preventable by androgen replacement therapy (5αDHT) given 
at the time of castration (Bingaman et al. 1994).  Similarly, plasma ACTH and 
corticosterone were higher in GDX vs., intact rats following shock and novel 
environment stress, and treatment with either testosterone or 5αDHT reduced ACTH 
and corticosterone back to levels seen in intact controls (Handa et al. 1994). 
 
The behavioural effects of androgens and how these may be modifiable by 5αR1 is 
less well documented.  However, Frye et al. have reported that the aggression-
enhancing effects of testosterone treatment in GDX mice were abolished in 5αR1-
KO mice (Frye et al. 2002) suggesting that 5αDHT may be the main androgen 
involved in mediating male aggressive behaviours.   
 
Studies have shown that 5αR1 is the dominant isozyme in the rodent brain (Lephart 
1993) where the enzyme is essential in neuroprotective, catabolic processes (Poletti 
et al. 1998).  5αR1 is largely capable of metabolising all ketosteroids, however, the 
main focus of this thesis is 5αR1 and its capacity to metabolise glucocorticoids, most 
interestingly in the CNS.  It is proposed that 5αR1 may regulate the exposure of not 
only peripheral tissues but also the brain to glucocorticoid actions and that the level 
of its activity may determine disease progression or predisposition.  Characterisation 
has largely been carried out using rat tissue and more work is required in the mouse 





1.4.4.1.2 5α-reductase type 1 (5αR1) 
The type 1 isozyme with an alkaline pH optima (6-8.5; Andersson et al. 1991; 
Normington et al. 1992) is abundant in liver in both humans (Thigpen et al. 1993) 
and rodents (Normington et al. 1992; Mahendroo et al. 1999) and brain (Lephart et 
al. 1991) including the nuclei of the hypothalamus (Campbell et al. 1989; Pelletier et 
al. 1994), pituitary (Massa et al. 1972; Yokoi et al. 1996) cerebral cortex and sub-
cortical white matter (Poletti et al. 1990).  It is also expressed at lower levels in 
adipose tissue (Barat et al. 2007; Wake et al. 2007).  5αR1 expression shows sexual 
dimorphism whereby activity and mRNA abundance was 10-20 times higher in 
females compared to males (Yates et al. 1958; Farkash et al. 1988; Andersson et al. 
1989; Normington et al. 1992).  5αR1 is found in the adrenal glands (Fraser 1990) 
where its activity is modifiable by sex steroids.  For example, GDX in both male and 
female rats induces increased adrenal 5αR1 activity and mRNA content (Ando et al. 
1989; Lephart et al. 1991).  Tissue distribution also differs between species.  For 
example, 5αR1 and 5αR2 are detected in the rat ventral prostate whilst in human and 
mouse prostate, 5αR2 shows dominant if not exclusive reductase activity (Russell et 
al. 1994).  Moreover, in the mouse liver 5αR1 is exclusively expressed (Mahendroo 
et al. 1996; Mahendroo et al. 1997) whilst both 5αR1 and 5αR2 show hepatic 
expression in humans (Evans et al. 2003). 
 
1.4.4.1.3 5α-reductase type 2 (5αR2) 
The second 5αR isozyme is the product of a separate gene and differs in its pH 
optima (a narrow acidic pH centered around 5; Andersson et al. 1991; Normington et 
al. 1992) and tissue distribution pattern.  In reproductive tissue (i.e. androgen target 
organs) such as the testes and the ventral prostate, type 2 predominates (Andersson et 
al. 1991) but 5αR2 is also expressed in the human but not rodent liver.  5αR2 is also 
essential for the conversion of testosterone into the 50-fold more potent 5αDHT (the 
principle androgenic stimulant within the prostate gland; Kovacs et al. 1983; 
McConnell 1995; Bartsch et al. 2002; Carson et al. 2003) which determines male 
phenotypic sexual differentiation (e.g. development of the male external organs and 
growth of the prostate) but can also induces hyperplasia of the prostate.  It was the 




specific [finasteride]) in a clinical setting to treat disorders such as benign prostatic 
hyperplasia (BPH) where the underlying etiology requires the action of 5αDHT. 
 
1.4.4.1.4 5α-reductase type 3 (5αR3) 
5αR3 has been less well studied as its discovery is fairly novel (Uemura et al. 2008).  
There remains ambiguity over whether this third isozyme is involved in steroid 
hormone formation.  Some have reported 5αR3 does not play a role in steroid 
hormone formation and sexual development since homozygous Srd5a3 gene 
mutations found via genome-wide linkage analysis and DNA sequencing, did not 
result in abnormalities usually associated with impaired steroid metabolism 
(Cantagrel et al. 2010).  Instead, the same authors suggested a role for 5αR3 in the 
N-linked glycosylation of proteins since the phenotypes related to Srd5a3 mutations 
were strikingly similar to those arising from congenital disorders of glycosylation 
(Cantagrel et al. 2010).  However, there is evidence that 5αR3 does have the ability 
to reduce steroids including testosterone, androstenedione and progesterone but there 
is no suggestion of a role for the type 3 isozyme in glucocorticoid metabolism 
(Azzouni et al. 2012). 
 
1.5 5α-Reductase type 1 and glucocorticoid action 
Many authors investigating 5αRs have focussed on their role in regulating androgen 
action and the enzymes role in glucocorticoid action is less well studied.  Authors 
investigating human (Andrew et al. 1998; Fraser et al. 1999) and rodent (Livingstone 
et al. 2000) obesity report increased excretion of cortisol/corticosterone as 5α-
reduced metabolites compared to lean controls. In the publication by Livingstone et 
al. rats were also hypercorticosteroneaemic suggesting the activity of 5αR1 was 
enhanced to facilitate increased glucocorticoid clearance.  Therefore, 5αR1 plays a 
key role in the aetiology of obesity and other metabolic diseases (Tomlinson et al. 
2008; Baudrand et al. 2011).  It was hypothesised that global loss of 5αR1 would 
release the brake on glucocorticoid action leading to metabolic and CNS disturbances 





1.5.1 Generation of the 5αR1-KO mouse model and an outline 
of the preliminary data leading to this study 
In 1996, Mahendroo et al. generated a mouse model with global disruption (null 
allele) of the Srd5a1 gene, denoted the 5αR1-KO mouse (Mahendroo et al. 1996).  
Since then, this model has been used primarily to study the effect of reduced 
androgen and progesterone metabolism in vivo.  Although male 5αR1-KO mice are 
reproductively sound, females had a serious parturition defect whereby 70% of 
pregnancies failed to end at term due to impaired cervical ripening resulting in foetal 
death in utero (Mahendroo et al. 1996; Mahendroo et al. 1999; Mahendroo et al. 
1999).  However, our group is mostly interested in the resulting phenotype of 
reduced glucocorticoid clearance by 5αR1 which has been much less well studied. 
 
Using the above model, Livingstone et al. established a colony of mice heterozygous 
for the Srd5a1 allele, allowing generation of a 5R1-knock-out mouse model at the 
University of Edinburgh.  It is proposed that global loss of this glucocorticoid 
metabolising enzyme in these animals may lead to the accumulation of active 
glucocorticoids, most notably within the liver and brain, and indeed phenotypic 
changes consistent with increased corticosteroid levels were observed. 
 
1.5.2 Metabolic and peripheral phenotypes 
Preliminary data has shown that the absence of 5αR1 renders 5R1-KO mice more 
susceptible to features of the Metabolic Syndrome. On a high fat (HF) diet, male 
5αR1-KO mice demonstrated greater weight gain (Figure 1.7), possibly in part due to 
increased cumulative food intake compared to wild-type (WT) controls (Livingstone 
et al. 2014a). Moreover, male 5αR1-KO mice were hyperinsulinaemic (insulin 
measured during a glucose tolerance test) compared to WT mice and deposited more 
fat in their livers following the HF diet, leading to hepatic steatosis (Livingstone et 






Figure 1.7 Cumulative weight gain in male 5αR1-KO mice 
This preliminary data (A) showed that male 5αR1-KO mice were comparable in weight to 
wild-type (WT) controls when fed a low fat diet (crossed symbols and square symbols 
respectively).  The phenotype changed when the animals were fed a high fat diet where 
5αR1-KO mice (triangles) gained significantly more weight than WT controls fed the same 
food (diamonds). Panel B shows the final weight at cull where 5αR1-KO animals 
(checkered) weighed more vs. WT (solid) at 12 months of age. KO-HF = 5αR1 knock-out 
animals fed high fat diet, WT-HF = wild-type animals fed high fat diet, KO-C = 5αR1 
knock-out animals fed control low fat diet, WT-C = wild-type animals fed control low fat 





Increased weight gain may be of peripheral origin or explained solely by 
hyperphagia, however the molecular mechanisms underlying increased food intake 
on a HF diet had not yet been fully studied at the undertaking of this Ph.D.  
Furthermore, this adverse metabolic phenotype was particularly marked in female 
5αR1-KO mice who gained more weight even when fed a normal chow diet 
(Livingstone et al. unpublished).  At the outset of this thesis, the reason for this 
sexual dimorphism in susceptibly remained to be elucidated. 
 
1.5.3 Behavioural and central phenotypes 
It appears that the obesity phenotype in female 5αR1-KO mice is modulated by 
factors influencing behaviour.  Intriguingly, this cohort only developed obesity and 
hepatic steatosis when group-housed.  When these females were subjected to social 
isolation (housed in single cages as opposed to in groups) they lost all of the extra 
weight and became comparable to WT littermate controls; a phenomenon which was 
reversible within 4 weeks of reverting to a group-housing scenario (Livingstone et al. 
unpublished). 
 
Although baseline corticosterone levels are maintained in both male and female 5R1-
KO mice, plasma corticosterone concentrations were lower in 5αR1-KO mice 
compared to WT following both minor stress (cage disturbance) and acute restraint 
stress (Livingstone et al. 2014b for male mice and Livingstone et al. unpublished for 
female mice). 
 
1.5.4 Data supporting development of hypotheses 
1.5.4.1 Metabolic disturbances 
In terms of the metabolic phenotype, loss of the braking effects of 5αR1 upon 
glucocorticoid action within tissues led to weight gain and the development of 
symptoms consistent with the metabolic syndrome (Livingstone et al. 2014a).  This 
adverse metabolic phenotype is suggestive of a role for this enzyme in regulating 
tissue glucocorticoid levels and this study aims to determine the mechanisms which 
underlie the poor metabolic profile of 5αR1-KO mice. In this study, it is proposed 




tissues.  Downregulation of corticosteroid receptor expression may be expected in 
the presence of excessively high glucocorticoid levels, suggested to form the basis in 
linking HPA axis function with the aetiology of metabolic diseases and also with 
psychiatric disorders.  Moreover, since changes in both CRH and CRHR-1 are 
known to influence behaviour as well as both basal and peak corticosterone levels 
reached post-stress (Muglia et al. 1995; Smith et al. 1998; Preil et al. 2001; Bale et 
al. 2002; Bale et al. 2002), these parameters may also be modified in 5R1-KO 
mice. 
 
1.5.4.2 The effect of glucocorticoids and 5αR1 in the brain  
Female 5αR1-KO mice have been shown to be predisposed to weight gain when 
housed in groups but weight loss when housed under social isolation stress. An 
important consideration in terms of this observation is that, in rodents, chow intake is 
usually decreased under chronic stress (Dallman et al. 2001) and this can be 
modulated by glucocorticoids (Pralong et al. 1993; Alfarez et al. 2008).  Certainly, a 
large number of studies have used social isolation of rodents as a model of chronic 
stress which induces detrimental changes in central processes such as locomotor 
activity, thermoregulation, learning and memory, anxiety and weight gain (Juraska et 
al. 1984; Bates et al. 1985; Jones et al. 1991; Hellemans et al. 2004; Võikar et al. 
2005).  In this model, it is proposed that environmental stress (social isolation) in the 
milieu of local increases in glucocorticoids within the brain may lead to anxiety, 
manifesting as weight loss in the 5αR1-KO female mice, which was the starting point 
for this study. 
 
1.5.4.3 Neuroendocrine control of food intake in 5αR1-KO mice 
There is evidence for disruption of glucocorticoid clearance in peripheral tissue as 
described in the preliminary data section above (1.5.2).  There is also some evidence 
of CNS disturbances such as a sensitivity to stress (single housing).  It is therefore 
possible that the intricate balance in levels of anorexigenic and orexigenic 
neuropeptides in the brain may be altered in 5R1 KO mice with glucocorticoid 
excess, promoting increased food consumption (hypothalamic regions) and thus 




anorexigenic peptides including POMC would be down-regulated.  However, if 
global loss of 5αR1 in these mice leads to an anxious phenotype and thus chronic 
stress during periods of social isolation, this could be a key mechanism behind 
weight loss in this particular cohort of mice. 
 
1.5.4.4 5αR1, the hippocampus and cognition 
Much research has been published under the umbrella of glucocorticoid-mediated 
learning and memory modifications.  For example, 11βHSD1 is upregulated in the 
aged mouse hippocampus resulting in memory impairments (Holmes et al. 2010) 
whilst mice 11βHSD1-KO mice have reduced intrahippocampal corticosterone levels  
but normal circulating concentrations and are protected from age-related cognitive 
impairments (Yau et al. 2001).  Although 5αR1 has not previously been studied with 
direct relevance to its role in cognition, these data, taken together with the evidence 
outlined in section 1.3.2.1.2 suggests that our model of impaired glucocorticoid 
metabolism and resulting excess may be expected to cause adverse effects upon the 
hippocampus and learning and memory abilities. 
 
To conclude, since 5αR1 is highly expressed within numerous brain structures 
including subcortical white matter, the cerebral cortex and the hippocampus (Celotti 
et al. 1987; Melcangi et al. 1987; Melcangi et al. 1993) it is therefore likely to 
influence behaviour, as has been shown previously (Agis-Balboa et al. 2007).  There 
is supporting evidence from preliminary studies by Livingstone et al. for the role of 
5R1 upon CNS function through altered stress responses (reduced HPA axis 
activation post-stress; Livingstone et al. 2014b) and feeding behaviours (hyperphagia 
and subsequent weight gain; Livingstone et al. 2014a).  The aim of this thesis is to 
assess the effects of impaired glucocorticoid inactivation (through manipulating 
5αR1) on HPA axis responses and behaviours including anxiety and cognitive ability 






Female 5αR1-KO mice are more prone to obesity than male mice due to behavioural 
differences affecting energy balance, including: 
 A predisposition to hyperphagia through changes in neuroendocrine signalling. 
 Reduced locomotor activity. 
Furthermore this predisposition to obesity is modified by the environmental 
influence of housing, due to 5R1-KO mice being more susceptible to anxiety-
induced weight loss.  Reduced ability to clear glucocorticoids predisposes 5R1 
mice to anxiety and features of cognitive decline, becoming more marked with age. 
 
1.7 Aims 
In this Ph.D. thesis, the following research aims will be addressed: 
Aim 1: To determine if loss of 5αR1 modifies the expression of genes coding for 
hypothalamic neuropeptides which may increase food intake, ultimately 
inducing weight gain in female 5αR1-KO mice. 
Aim 2: To investigate the central mechanisms which underpin attenuated HPA 
axial responses to acute restraint stress in 5αR1-KO mice. 
Aim 3: To establish whether 5αR1-KO mice are predisposed to anxiety under the 
chronic stress of social isolation.  Moreover, to investigate if 5αR1-KO 
mice are susceptible to cognitive impairment and whether this is 
exacerbated by social isolation and/or ageing. 
Aim 4: To determine if genetic background has any influence on the metabolic and 
















All chemicals, unless otherwise stated, were purchased from Sigma-Aldrich, Poole, 
UK.  Storage was at room temperature (RMT; 18-22
o
C) unless specified otherwise, 
and away from direct sunlight. Solvents for mass spectrometry assays were glass 




All radioactive isotopically labelled chemicals were purchased from GE Healthcare, 
Buckinghamshire, UK. 
 
2.2 Buffers and solutions 
2.2.1 Borate buffer 
130 mM Boric acid, 68 mM sodium hydroxide, 3.5 mL concentrated hydrochloric 
acid (33% v/v) and 5 g bovine serum albumin (BSA; 0.5% w/v); Cohn fraction V) 
diluted to 1 L with distilled water to intrinsically give pH 7.4. The solution was 
stored at -20C and thawed at RMT immediately before use. 
 
2.2.2 Box buffer 
20% v/v 20xSaline sodium citrate buffer and 50% v/v deionised formamide were 
diluted in DEPC-water (see below). 
 
2.2.3 Cresol red 
Cresol red (4 mg/mL) in 40% w/v sucrose. 
 
2.2.4 DEPC-treated water 
Diethylpyrocarbonate (DEPC) was prepared in double distilled water (300 L/100 





2.2.5 Deionised formamide (for box buffer only/non-
sterile) 
150 mL Formamide was mixed (1 hr) with 15 g Amberlite ion exchange  resin (MB-
6113; BDH, Lutterworth, UK), filtered twice through no.1 Whatman filter paper to 
remove Amberlite and stored at RMT in a brown bottle in the dark. 
 
2.2.6 1 M dithiothreitol (DTT) 
0.15 mg/mL DTT in DEPC water.  The solution was sterilised by filtration and 
prepared as aliquots, stored at -20C. 
 
2.2.7 250 mM ethylene diamine tetra-acetic acid (EDTA; pH 
8.0) 
100 mL DEPC water was added to 46.5 g EDTA. The volume was made up to 500 
mL with DEPC-water and the pH adjusted to 8.0 with 5 M sodium hydroxide 
(NaOH). 
 
2.2.8 Ethanol in ammonium acetate 
300 mM Ammonium acetate was prepared in either 50, 70 or 90% v/v ethanol 
(EtOH) as specified diluted to 1 L in DEPC water. 
 
2.2.9 Ethanolic potassium hydroxide 
Two parts ethanol (EtOH):1 part 30% w/v potassium hydroxide (KOH) prepared in 
distilled water. 
 
2.2.10 2x hybridisation buffer  
1.2 M Sodium chloride (NaCl), 20mM Tris-hydrochloride (Tris-HCl), 400 μl 
50xDenhardts, 2 mM EDTA, 0.2 mg/mL salmon sperm DNA, 0.2 mg/mL yeast 
tRNA and 0.4 mM dextran sulphate in DEPC-treated water (final volume 10 mL).  1 





2.2.11 5 M sodium chloride (NaCl) 
5 M Sodium chloride (NaCl) in DEPC water (500 mL).  The solution was sterilised 
by autoclaving. 
 
2.2.12 4% w/v Paraformaldehyde in 0.1M sodium phosphate 
buffer 
20 mM Sodium dihydrogen phosphate (NaH2PO4) and 80 mM disodium hydrogen 
phosphate (Na2HPO4) were prepared in 1 L DEPC water and heated to 80C prior to 
addition of 1.3 M paraformaldehyde.  The solution was stirred (1 hr) to dissolve, 
allowed to cool and then stored at 4C for up to 1 wk. 
 
2.2.13 1x phosphate buffered saline (PBS) 
140 mM Sodium chloride (NaCl), 20 mM hydrated disodium hydrogen phosphate 
(Na2HPO4.H2O), 1.5 mM potassium dihydrogen phosphate (KH2PO4; both VWR 
International, Leicestershire, UK) and 2.7 mM potassium chloride (KCl) in DEPC 
water (final volume 1 L).  The resulting solution achieved pH 8.0 and was autoclaved 
before use. 
 
2.2.14 10x PBS 
1.4 M Sodium chloride (NaCl), 0.2 M hydrated disodium phosphate (Na2HPO4.H2O), 
15 mM monopotassium phosphate (KH2PO4) and 27 mM potassium chloride (KCl) 
were dissolved in 1 L DEPC-water and sterilised in an autoclave before use. The pH 
was intrinsically 8.0. 
 
2.2.15 2x pre-hybridisation buffer 
1.2 M Sodium chloride (NaCl), 20 mM Tris-hydrochloride (Tris-HCl), 400 µL 
50xDenhardt‘s, 2 mM EDTA, 0.2 mg/mL salmon sperm DNA, 0.2 mg/mL yeast 
tRNA in DEPC-water (final volume 10 mL), prepared as aliquots (1 mL) and stored 





2.2.16 RNase Buffer 
0.5 M sodium chloride (NaCl), 10 mM Tris-hydrochloride (Tris-HCl) and 1mM 
EDTA were dissolved in 10 mL DEPC-water. 
 
2.2.17 10x TBE (Tris/borate/EDTA) buffer 
0.9 M TRIZMA base (NH2C(CH2OH)3), 0.9 M boric acid (H3BO3) and 20 mM 
EDTA were dissolved in 1 L distilled water.  The resulting solution was pH 8.0. 
 
2.2.18 0.5x TBE buffer 
10x TBE (50 mL) was diluted in distilled water (950 mL). 
 
2.2.19 Tris-EDTA (TE) buffer 
10 mM Tris-hydrochloride (Tris-HCl) and 1 mM EDTA were dissolved in 1 L 
DEPC-water.  This yielded a solution of pH 8.0, which was sterilised in an autoclave 
before use. 
 
2.2.20 0.1 M Triethanolamine 
1.3% v/v Triethanolamine (C6H15NO3) was dissolved in 1 L DEPC water. The 
solution was adjusted to pH 8.0 with 10 M hydrochloric acid (HCl).  Sterile 
glassware was used to avoid autoclaving as this solution cannot be autoclaved. 
 
2.2.21 1 M Tris 
1 M Tris-hydrochloride (Tris-HCl) in DEPC water (final volume 550 mL). The pH 
was adjusted to 7.5 with 10 M hydrochloric acid (HCl) and the solution was 
autoclaved prior to use. 
 
2.2.22 Wash Buffer One (2x saline sodium citrate [SSC] 
buffer) 





2.2.23 Wash Buffer Two (0.1x SSC buffer) 
3 mL 20x SSC was diluted to 600 mL with DEPC water. 
 
2.2.24 Yeast tRNA 




2.3 Molecular Biology  
Total RNA was extracted using Qiagen RNeasy kits and DNA digested using Qiagen 
RNase free DNase sets, all from Qiagen, West Sussex, UK.  The following 
procedures were all performed at room temperature (RMT; 21
o
C) unless otherwise 
stated. 
 
2.3.1 RNA extraction and quality control 
The principle of the RNeasy extraction method is as follows.  First biological 
samples are lysed and homogenised in a highly denaturing guanidine-isothiocyanate-
containing buffer (RLT) which immediately inactivates RNases ensuring RNA in the 
sample remains intact during purification.  The added ethanol provides conditions 
which favour RNA binding in high salt conditions to the silica-based membrane 
whilst contaminants including genomic DNA are washed through it and away.  
Subsequent wash steps remove the ethanol and salt breaking the attraction between 
the matrix and the RNA and finally purified RNA is eluted into water. 
 
2.3.1.1 RNA extraction from liver and prostate 
RNA was extracted from liver using the Qiagen RNeasy mini kit sourced as above.  
A small piece of tissue (~30 mg) was excised from the sample on dry ice and 
homogenised in the RLT buffer provided in the kit (600 μL) using a rotor-stator 
homogeniser (Pro 200; PRO Scientific Inc., Monroe, CT, USA) to create a uniform, 
homogenous solution.  All samples were then subjected to centrifugation (16,000xg, 
3 mins, RMT).  The supernatant was then removed by pipetting, transferred to a new 
microcentrifuge tube containing an equal volume of ethanol (50% for liver, 70% for 




spin column placed in a 2 mL collection tube and subjected to centrifugation 
(10,000xg, 15 secs, RMT).  The eluate was discarded and the column washed with 
RW1 buffer (700 μL) before centrifugation (10,000xg, 15 secs, RMT).  If on-column 
DNAse digestion was required (2.3.1.5), it was carried out at this point.  A further 
350 μL RW1 buffer was added into the column and subject to centrifugation 
(9300xg, 15 secs, RMT), the flow through was discarded.  The RNA extraction 
process was then continued as follows.  RPE buffer (500 μL) was added to the 
columns and the centrifugation process repeated.  Further RPE buffer (500 μL) was 
applied to the columns before centrifugation (9300xg, 2 min, RMT) to wash the spin 
column membrane.  The RNeasy spin columns were then placed into new 2 mL 
collection tubes and subject to centrifugation (16000xg, 1 min, RMT) to eliminate 
any RPE buffer carryover.  Using a new 1.5 mL Eppendorf, RNase-free water 
(30 μL) was added directly to the spin column membrane and the eluate was 
collected by centrifugation (9300xg, 1 min, RMT), added back to the column and the 





2.3.1.2 RNA extraction from adipose tissue 
Approximately 60 mg of tissue was excised from frozen samples on dry ice and 
homogenised in Qiazol Lysis Reagent (800 μL, Qiagen) to create a uniform, 
homogenous solution.  Further Qiazol Lysis Reagent was added (200 μL) before 
incubation (5 min, RMT).  Chloroform (200 μL) was added and then all tubes shaken 
vigorously (15 sec) before centrifugation (12,000xg, 15 mins, 4
o
C).  The aqueous 
phase was removed by pipette, transferred to a new microcentrifuge tube containing 
an equal volume of 70% v/v ethanol and mixed well.  The entire volume (in two 
stages) was transferred into an RNeasy mini spin column placed in a 2 mL collection 
tube.  The remainder of the extraction procedure then continued as outlined above for 





2.3.1.3 RNA extraction from brain  
RNA was extracted from brain as described for adipose tissue above (2.3.1.2) with 
the addition of on-column DNAse digestion (2.3.1.5).  Half a brain (cut sagittally) 
was used for each sample. 
 
2.3.1.4 RNA extraction from isolated hypothalamus, pituitary and optic 
chiasm 
As the hypothalamus, pituitary and optic chiasm are so small, the entire amount of 
tissue (<20 mg) was used for each sample.   The tissue was disrupted in RLT buffer 
(350 µL) by pipetting the material up and down vigorously.  The lysate was added 
directly into a QIAshredder spin column and subject to centrifugation (16000xg, 2 
mins, RMT).  The eluate was then added back into the column and the centrifugation 
process repeated.  RNA was extracted from the homogenate as described above 
(2.3.1.1) with the inclusion of the on-column DNAse digestion step (2.3.1.5). 
 
2.3.1.5 On-column DNAse digestion for brain tissue 
Generally speaking, DNase digestion is not required when purifying RNA by these 
methods as the silica-gel-membrane and spin column technology usually removes 
most genomic DNA.  However, more complete DNA removal is required for certain 
RNA applications which are sensitive to very small amount of DNA (i.e. qPCR) and 
also in situations when the weight of the starting sample was very small (i.e. pituitary 
or hypothalamus). The potential for genomic DNA carry-over was precluded by 
DNase treatment of samples as follows.  The DNase 1 stock solution was prepared in 
RNase-free water according to the manufacturer‘s instructions and divided into 
single-use aliquots (stored at -20
o
C).  RW1 buffer (350 μL) was added to the spin 
columns before centrifugation (9300xg, 15 secs, RMT) and the eluate discarded.  A 
master mix of DNase 1 and RDD buffer was prepared and gently inverted allowing 
for 10 μL DNase stock solution and 70 μL RDD per column.  DNase 1 incubation 
mix was then transferred directly onto the RNeasy spin column membrane 
(80 μL/column) and incubated (15 min, RMT).  350 μL RW1 buffer was added by 




flow through was discarded and the RNA extraction process was then continued as 
described for liver in section 2.3.1.1 from the first RPE buffer wash step. 
 
2.3.1.6 RNA integrity 
RNA integrity was evaluated by electrophoresis (100 V, 1 hr, RMT) in agarose 
(Lonza, Berkshire, UK) gels (1.2% w/v in 0.5x TBE) containing 0.01% v/v 
SyBrSafe.  Loading dye (Promega, WI, USA; 1 in 5 diluted in distilled water; 10 μL) 
was added to extracted RNA samples (3 μL) before being loaded into the gel.  
Visualisation of RNA was carried out at 254nm using an UVIPro platform and 
software, v12.4 (UVItec, Cambridge, UK) to ensure only two bands (18s and 28s 
ribosomal (rRNA) bands) were present and to demonstrate exclusion of genomic 
DNA.  RNA integrity was satisfactory when each 28s and 18s rRNA band appeared 
sharp and clear without smearing, and when the ratio of the 28s:18s band intensity 
was ~2:1 indicating the extracted RNA was intact.  The integrity of the extracted 
RNA was further determined using an Agilent 2100 Bioanalyzer.  An RNA integrity 
number (RIN) between 8 and 10 was taken to reflect RNA of acceptable quality. 
 
2.3.1.7 RNA concentration and quantification 
Finally, the concentration of RNA was quantified using a Nanodrop 
spectrophotometer (ND-1000, Thermo Fisher Scientific, West Sussex, UK).  The 
absorbance at 260 nm (A260; the maximum absorbance of the nucleic acid) 
determined the concentration of RNA in the sample.  RNA purity was assessed by 
the ratio of the absorbance at 260nm to the absorbance at 280nm (absorbance of any 
protein contamination; A260:A280).  Purity was deemed acceptable if this ratio was 
~1.8-2.0. 
 
2.3.2 Reverse transcription (RT) to synthesise cDNA 
Total RNA (200 ng/12 μL solution) was reverse transcribed in a 20 µL (final) 
reaction using a Quantitect reverse transcription kit (Qiagen, West Sussex, UK) and a 
G-Storm GS1 thermal cycler (GRI, Essex, UK).  Firstly, DNA digestion was carried 
out: gDNA wipeout buffer (2 μL) was added to the 12 μL RNA samples (total 
volume 14 μL) before incubation (2 min, 42
o




on wet ice.  The following was then added to each sample: 5x quantiscript RT buffer 
(4 μL/tube), RT primer mix (1 μL/tube), quantiscript reverse transcriptase (with 
RNase inhibitor; 1 μL/tube) and the RNA mix containing RNA, water and DNA 
wipeout (14 μL/tube).  Negative controls (one lacking reverse transcriptase enzyme 
and one lacking template to confirm the absence of contamination by genomic DNA 
or RNA, respectively) were also prepared and volumes were corrected to 20 µl using 
RNase-free water.  Samples were then incubated; 42
o
C (15 mins; addition of cDNA 
nucleotides by reverse transcriptase enzyme), 95
o
C (3 mins; denaturation of the 
enzyme) and 4
o
C (1 hr; storage).  All samples were prepared concomitantly to 
compensate for variability in efficiency of reverse transcription, and all negative 





2.3.3 Polymerase Chain Reaction (PCR) 
Primers were designed to detect the presence of transcripts of interest (Table 2.1).  
Primer stocks (100µM) were prepared in TE buffer and stored at -20
o
C.  10x Primer 
mix (2µM each primer) was prepared in ultrapure water.  Using the Multiplex PCR 
Kit (Qiagen, West Sussex, UK) a master mix was prepared allowing the following 
per tube: master mix x2 solution (10 μL), Solution Q (2 μL), 10x primer mix (2 μL) 
and Qiagen water (5 μL).  19 μL of this master mix was added per tube followed by 
sample cDNA (1 μL).  A further negative control was prepared with Qiagen water 
added in place of cDNA to confirm absence of contamination.  The samples were 
then placed into the PCR block (G-Storm GS1 thermal cycler, GRI, Essex, UK) and 
processed under the following programme unless otherwise stated: 
 





C (15 mins) 
Annealing: 30 cycles X (94
o
C (30 secs, denaturation), 60
o
C (1.5 min, primer 
annealing), 72
o
C (1 min, elongation)) 
Elongation: 72
o



































Table 2.1  Details of primers for conventional PCR amplification  
(F = forward; R = reverse; bp = base pair).  Conventional primer sequences for murine 
Srd5a1 and Srd5a2 were previously published (Yang et al. 2011).  The Hsd11b1 primer was 





2.3.3.1 Assessment of PCR products by electrophoresis 
Cresol red loading dye (5 μL) was added to each sample and an aliquot (15 μL) was 
electrophoresed (100 V, 1 hr, RMT) on a 1.5% w/v agarose (Lonza, Berkshire, UK) 
0.5x TBE gel using GelRed fluorescent nucleic acid dye (8 μL/100 μL gel; 
Cambridge BioScience Ltd, UK).  The gel was visualised and photographed using 
the UVIPro platform and software as before.  The presence of one strong band of the 
appropriate size (as compared to a 1Kb ladder; Promega, Southampton, UK) was 
determined as a positive result.  The presence or absence of a band in the positive 
and negative control wells respectively, was confirmed by eye. 
 
2.3.3.2 Purification of PCR products 
A GENECLEAN Turbo Kit (ABgene, Surrey, UK) was used for the purification of 
cDNA PCR products in preparation for sequencing.  Purification was achieved 
through DNA binding to the silica membrane of the column in a high salt 
concentration.  When the salt concentration is lowered during washing, rehydration 
of the silica matrix breaks the attraction between the matrix and the DNA, allowing 
only the purified DNA to be eluted in either water or a low salt buffer.  For 
purification from PCR products, the whole solution was placed in a 1.5 mL 
microcentrifuge tube before the GENECLEAN Turbo salt solution (5 volumes) was 
added and gently mixed.  This mixture (≤600 µL) was transferred to a GENECLEAN 
Turbo cartridge placed inside a cap-less catch tube and subject to centrifugation 
(14,000xg, 5 secs).  The catch tube was emptied.  The wash buffer was added to the 
cartridge (500 µL) before further centrifugation (14,000xg, 5 secs).  The catch tube 
was emptied and the cartridges subject to centrifugation once again (14,000xg, 4 
mins) to drive the last of the wash buffer through the membrane and into the catch 
tube.  cDNA was eluted into a clean catch tube via the addition of the kit‘s elution 
solution (30 µL) directly onto the membrane before incubation (5 mins).  Samples 
were subjected to centrifugation (14,000xg, 1 min) to elute the purified cDNA which 
was then stored at -20
o






Purified DNA samples were quantified using a Nanodrop spectrophotometer 
(ND-1000).  The absorbance at 260 nm (A260) determined the concentration of 
DNA in the sample and the purity was assessed by the ratio of absorbance at 260 nm 
to the absorbance at 280 nm (A260:A280); acceptable if ~1.8.  Each cDNA sample 
was diluted to provide 1.3 ng DNA/5 µL sample and added to 3.2pmol of each 
primer (in separate tubes) used in the initial PCR reaction in 200 µL volume strip-
tubes.  Samples were sequenced by Sanger Sequencing at The Gene Pool, King‘s 
Buildings, The University of Edinburgh using a BigDye Terminator Cycle 
Sequencing ready Reaction Kit which determines the presence of each 
deoxynucleotide base in turn by its unique, identifying fluorescent colour. 
 
2.3.4 Quantitative real-time polymerase chain reaction (qPCR) 
The abundances of selected transcripts were quantified by qPCR using gene specific 
primers and probes (Table 2.2) and the Roche LightCycler® 480 master mix and 
detection system (Roche Diagnostics, Burges Hill, UK).  To prepare the standard 
curve, equal volumes of all cDNA samples to be compared were pooled and serially 
diluted (1/8 through to 1/512) with RNase-free water.  cDNA samples were also 
diluted (1/20) with RNase-free water.  Where possible, custom primers (Table 2.2) 
were designed in order to use the Universal Probe Library provided by Roche 
Diagnostics, Burgess Hill, UK.  Custom primers were synthesised by Life 
Technologies, Paisley.  When using these primers the reaction mix consisted of: 
LightCycler® probemaster mix (5 μL), Roche qPCR grade water (2.7 μL), forward 
primer (0.1 μL), reverse primer (0.1 μL) and the appropriate probe (0.1 μL).  Master 
reaction mix (8 μL) for each gene was added to the 384-well plate, followed by 
diluted cDNA samples (2 μL), standard, or negative control, all in triplicate.  
Excellent qPCR assay efficiency would demonstrate a change of roughly 3.3 cycles 

































F 5‘- gctgccaggaggagaactac-3‘ 
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Table 2.2  Custom primers and probes and ABI primer/probe assays used for qPCR 
Custom primers were designed using the Universal Probe Library (Roche Diagnostics, 
Burgess Hill, UK) and manufactured by Life Technologies, Paisley, UK. 
 




Whenever it was not possible to custom design primer sets, ready-made Taqman 
assays were purchased from Applied Biosystems, Warrington, UK.  When using 
Taqman® assays the reaction mix was prepared as follows: LightCycler
® 
probemaster mix (5 μL), Taqman® combined primer and probe mix (0.5 μL) and 
Roche qPCR grade water (2.5 μL per well). 
 
Plates were sealed and subject to centrifugation (2,000xg, 2 mins, RMT) to ensure all 
solutions were mixed thoroughly in the wells and to remove any air bubbles. 
Reaction conditions were as follows: pre-incubation/ enzyme activation (5 mins, 
95
o
C), amplification (50 cycles x (10 secs at 95
o
C, 30 secs at 60
o
C and 1 sec at 
72
o
C)), followed by cooling (30 secs, 40
o
C).  The LightCycler® software provided 
absolute quantification relative to the standard curve using Cp (crossing point) 
values.  The Cp refers to the point at which the fluorescence in the reaction reaches 
the maximum of the second derivative of the amplification plot.  This corresponds to 
the point where the fluorescent signal has reached its maximum acceleration which 
should always be in the middle of the log-linear portion of the amplification curve.  
Cp is also defined as the point at which the fluorescence in the sample exceeds 
background levels.  Triplicates were averaged and deemed acceptable when the 
standard deviation of the Cp values was < 0.5 cycles.  A standard curve (y axis 
crossing point, x axis log concentration) was generated for each transcript, fitted with 
a straight line and deemed acceptable if reaction efficiency was 1.7-2.1.  The 
abundances of five reference genes, Cyclophilin A (Ppia), 18s ribosomal RNA 
(Rn18s), TATA box-binding protein (Tbp), glyceraldehyde-3-phosphate 
dehydrogenase (Gapdh) and β-actin (Actb) were quantified.  The abundance of 
transcripts of interest were normalised against the abundance of the reference gene 
(or combinations of reference genes) which showed the least variability between 
experimental groups with no statistically significant differences. 
 
2.3.5 Quantification of transcripts via in situ hybridisation 
2.3.5.1 Sectioning of frozen tissue 
Brains were sectioned using a Leica cryostat (10 μm thick slices).  Regions of 




Y before being viewed under the microscope.  Sections were mounted onto 
electrostatic slides and stored in pre-frozen plastic slide boxes at -80
o
C until use.  In  
situ hybridisation was performed using radiolabelled probes to hybridise to 
transcripts of interest in various brain regions. 
 
2.3.5.2 Labelling of radioactive probes 
Prepared cDNA templates were provided by Senior Technician Karen French.  To 
synthesise radiolabelled probes the following reagents (Promega, Southampton, UK) 
were added in the order specified to an RNase-free Eppendorf: 2 μL 5x Transcription 
buffer, 1 μL of a master mix of 10 mM ATP, 10 mM CTP and 10 mM GTP, 0.5 μL 
of 200 mM DTT, 0.4 μL RNase inhibitor, 1 μL template (antisense or sense), 1 μL 
RNA polymerase (T7, T3 or SP6) and 4 μL 
35
S–UTP.  Antisense probes were 
designed to be complimentary to the mRNA of interest allowing binding during the 
hybridisation phase.  Sense probes have an identical sequence to the mRNA of 
interest and therefore will not hybridise and are used as a negative control on a 
representative selection of slides. 
 
The above prepared mixture was gently stirred and incubated (60-90 mins, 37
o
C [T7 
and T3], or 40
o
C [SP6]).  After incubation, 1 μL RNase-free DNase 1 (Promega) was 
added before further incubation (15 mins, 37
o
C).  Both the sense and anti-sense 
probes were purified through Nick size exclusion columns (GE Healthcare) using 
400 μL TE buffer) to elute the probe.  The eluted probe (1 μL) was added to 1 mL 
scintillation fluid (Meridian, Epsom, Surrey, UK) and the β emissions counted in a 
liquid scintillation counter (145 MicrobetaPLUS, Walla, PerkinElmer, UK).  A 
minimum of 10 million counts/mL was required to be used per slide for 
hybridisation.  The remainder was stored at -20
o
C until use. 
 
2.3.5.3 Tissue fixation 
Using sterilised metal racks and glass troughs (baked in an oven to approximately 
170-200
o
C), slides were initially incubated in 4% w/v paraformaldehyde in 0.1M 
sodium phosphate (10 mins, 4
o
C).  They were then washed twice in 1x PBS (2 x 5 




(10 mins), agitating slightly throughout.  Slides were washed in 1x PBS (5 mins) 
before sequential dehydration in 70, 80 and 95% v/v ethanol (2 mins each). 
 
2.3.5.4 Prehybridisation 
The prehybridisation mixture (200 μL) was added to each slide covering all the 
sections equally.  Slides were then placed in RNase-free, plastic boxes lined with 3M 





The hybridisation mixture comprised of DTT (1M, 10 μL), the calculated volume of 
radioactive probe to give counts of 10,000,000 cpm/mL on each slide, volumes of 2x 
hybridisation buffer appropriate to provide enough solution for all slides and 
deionised formamide (500 μL/mL of final mix; sterile solution from Sigma-Aldrich, 
Poole, UK).  The deionised formamide, 2x hybridisation solution and probe were 
mixed and incubated (10 mins, 75
o
C) then cooled on wet ice (1 min) before the DTT 
(10μL, 1M) was added and mixed well.  Slides were removed from the oven and 
excess pre-hybridisation buffer was drained off.  Hybridisation mix (200 μL) 
containing the labelled probe was added evenly to each slide. Additional slides were 
used as controls where a mixture containing the sense probe for each transcript was 
added to separate slides (as described above) to indicate the degree of non-specific 




2.3.5.6 RNase treatment and washes 
Slides were removed from the oven and excess hybridisation mix was drained off.  
The slides were washed in 2x SSC (3x 5 mins).  RNase enzyme (3 μL/mL, Promega, 
Southampton, UK) was added to the appropriate volume of RNase buffer required to 
cover all slides with 200 µl.  RNase buffer (50 mL) was poured into plastic 
incubation boxes lined with 3M paper.  The RNase-containing solution (200 μL) was 
evenly applied onto each of the slides, which were carefully placed into the prepared 
boxes and incubated (1 hr, 37
o
C).  The slides were removed from the oven and 
loaded into plastic racks for washing.  The first wash was in 2x SSC (60 mins).  
Slides were then washed in 0.1x SSC (60 mins, 60
o




were placed in 0.1x SSC (60 mins, pre-heated to 60
o
C and then left to cool to RMT).  
Finally, to dehydrate the sections, the slides were passed through 50, 70 and 90% v/v 
ethanol in ammonium acetate (0.3 M; 2 mins each), before being allowed to air dry 
(16 hrs) in the fume hood and placed against Kodak HyperMax film (GE Healthcare, 
Buckinghamshire, UK) in a light tight cassette for 1 wk.  The films were developed 
using a Konica SRX-101 developer. 
 
2.3.5.7 Dipping, developing and staining 
In the darkroom, NTB2 emulsion (Anachem, Bedfordshire, UK) was placed in a 
water bath (42
o
C) to melt to liquid form.  The emulsion was then diluted 1:1 with 
water and allowed to stand (30 mins), allowing any air bubbles to disperse.  Each 
slide was dipped in turn into the emulsion/water solution, placed in a rack and 
allowed to dry in the darkroom (16 hrs).  The following day the slides were packed 
into light-tight boxes, wrapped in aluminium foil and stored (4 wks, 4
o
C).  The slides 
were unwrapped in the dark room and allowed to return to RMT.  Four troughs were 
prepared containing Kodak developer diluted 1:1 with tap water, fixative  diluted 1:4 
with tap water (both H. A. West Medical Ltd, Edinburgh, UK) and two troughs of 
water only.  All liquids were cooled to 15
o
C.  The slides were processed as follows: 4 
mins developer, 10 secs tap water, 5 mins fixer, 5 mins tap water.  The solutions 
were changed after processing two racks and the slides were then allowed to dry.  
Slides were stained (3 mins) in 1% Pyronin Y (1 g / 100 mL) filtered through 
Whatman paper.  The slides were then passed through three troughs of ultrapure 
water (3x 1 min) and allowed to dry (16 hrs).  They were then passed through 
acetone (2 mins), acetone/xylene, 1:1 (2 mins), xylene (2 mins) and xylene (2 mins) 
before being mounted in dibutyl phthalate xylene (DPX; VWR Int, Poole, UK).  
Cover-slips were applied and the slides were stored at RMT until analysis. 
 
2.3.5.8 Quantification of mRNA abundance 
Using Zeiss KS300 3.0 computer software, silver grains were quantified in the 
dentate gyrus (DG), pyramidal cells at CA1, CA2, CA3 and CA4 of the 
hippocampus, and the PVN of the hypothalamus.  The number of silver grains in 




Only one side of the brain/section/slide was counted for each animal.  The final 
―count‖ was the mean from six randomly placed circles (radius = 43µm) minus 
background count.  This was representative of the count/neuron (pyramidal neurons 
in the hippocampus and parvocellular neurosecretory neurons in the PVN). 
 
2.4 Biochemical assays 
All wash steps were performed using an electronic AW1 microplate washer (Rosys 
Anthos [Biochrom], Cambridge, UK).  Incubations requiring agitation were 
performed using an electronic plate shaker (iEMS incubator/shaker, Thermo 
Scientific, Northumberland, UK).  For all assays, the fitting of a best-fit straight or 
sigmoidal line and the reproducibility of duplicates were acceptable when r
2 
was 
greater than 0.98 and when the results of duplicates were within 10% of the mean, 
respectively.  Intra-assay relative standard deviations (RSD) were calculated using 
the equation shown in section 2.7. 
 
2.4.1 Quantification of plasma insulin concentrations by 
enzyme-linked immunosorbent assay (ELISA) 
Plasma insulin concentrations were quantified using an Ultra-Sensitive Mouse 
Insulin Enzyme-Linked Immunosorbent Assay (ELISA; Crystal Chem Inc., Illinois, 
US).  This is a basic sandwich ELISA where insulin in the sample binds to the 
surface of the well coated with guinea pig, anti-insulin antibodies.  The secondary, 
horse-radish peroxidase- (HRP) conjugated, anti-insulin antibody binds to the guinea 
pig anti-insulin antibody/mouse insulin complex immobilised to the microplate well.  
Addition of 3,3‘,5,5‘-tetramethylbenzidine TMB substrate produces a colourometric 
reaction. 
 
Using the insulin stock solution and sample diluent supplied, a series of standards 
were prepared (0.1 – 12.8 ng/mL) according to the manufacturer‘s instructions.  
Sample diluent (95 μL) and then standards or sample (5 μL) were added in duplicate 
to wells pre-coated with anti-insulin primary antibody (guinea pig) and incubated 
(2 hrs, 4
o
C).  Sample diluent was used for the blank measurement.  After incubation 




the plate (5 x 300 μL) to remove unbound materials prior to the second incubation.  
HRP-conjugated, anti-insulin antibody (100 μL) was added to all wells before 
incubation (30 min, RMT).  To remove unbound HRP-conjugate, the plate was then 
washed for a second time (7 x 300 μL) using the diluted wash buffer as before.  
100μl of the TMB-containing enzyme substrate solution (light sensitive) was added 
to each well and incubated once more (40 min, RMT, in the dark) before the stop 
solution (0.5 M sulphuric acid, 100 μL) was added to arrest the reaction.  The 
absorbance at 450 nm (L1) and 630 nm (L2; background count resulting from 
scratches or artefacts on the plate) were recorded using a spectrophotometer 
(OPTImax tunable microplate reader, Molecular Devices).  L2 values were 
subtracted from L1 values to remove background counts and thus increase the 
accuracy of the reading.  A standard curve (x-axis concentration, y-axis absorbance) 
was drawn and a best-fit straight line applied from which the concentration of 
unknowns could be interpolated. 
 
2.4.2 Quantification of plasma glucose concentrations using 
a hexokinase assay 
Glucose levels were quantified from plasma using an Infinity Glucose Hexokinase 
Liquid Stable Reagent (Thermo Scientific, ABgene, Surrey, UK).  The principles of 
this assay are as follows.  The reagent supplied contains hexokinase, which catalyses 
the phosphorylation of glucose by ATP, producing ADP and glucose-6-phosphate. 
The latter is then oxidised to 6-phosphogluconate with the associated reduction of 
NAD+ to NADH by glucose-6-phosphate dehydrogenase. The concentration of 
NADH formed is proportional to the concentration of glucose in the sample.  Using 
the glucose standard supplied in the kit (200 mg/dL) and distilled water, a series of 
dilutions (50 – 300 mg/dL) were prepared.  Distilled water was also used as a blank.  
Samples and standards (2 μL, in duplicate) were added to 96-well plates before 
addition of the hexokinase reagent (supplied).  Plates were incubated (10 mins, 
RMT) and then the absorbance recorded at 340 nm spectophotometrically (OPTImax 
tunable microplate reader, Molecular Devices).  A straight line was fitted to the 
standard curve where the x-axis = concentration (mg/dL) and the y-axis = absorbance 




2.4.3 Quantification of liver triglycerides 
2.4.3.1 Extraction 
To create a saponified, neutralised extract of liver, ~100 mg of frozen tissue was cut 
and weighed and added to ethanolic potassium hydroxide (KOH; 200 µL) before 
incubation (14 hrs, 55
o
C).  Samples were vortexed until a homogenous solution was 
made.  50% ethanol was added (400 µL) before samples were subjected to 
centrifugation (15,000xg, 5 mins, RMT).   200 µL of the supernatant was transferred 
to a new tube before 1M magnesium chloride (MgCl2) was added (215 µL) and the 
samples vortexed and incubated (10 mins, on wet ice).  After the incubation, samples 
were again subjected to centrifugation (15,000xg, 5 mins, RMT) and the supernatant 




Liver triglycerides were quantified using an Infinity Triglycerides Liquid Stable 
Reagent (Thermo Scientific, ABgene, Surrey, UK).  The assay is based on the 
following: lipoprotein lipase hydrolyses triglycerides into glycerol and non-esterified 
fatty acids (NEFAs).  Glycerol is then phosphorylated by ATP with glycerol kinase 
to produce ADP and glycerol-3-phosphate.  Oxidation of the latter by 
glycerolphosphatase produces hydrogen peroxide which reacts with 
4-aminoantipyrine and 3, 5-dichloro-2-hydroxybenzenesulfonate to produce a red 
colour.  The absorbance of this red-coloured dye is proportional to the concentration 
of triglycerides in the sample. 
 
Serial dilutions of the triglyceride standard provided were prepared (0.565 – 11.3 M) 
using distilled water.  Distilled water was also used as a blank.  Samples or standards 
(duplicate; 2 μL) were added to wells in a 96-well plate, followed by the reagent (200 
μL).  The plate was incubated (5 min, 37ºC, in the dark) before the difference in 
absorbance between 600 nm and 500 nm was recorded for each well.  A standard 





2.4.4 Quantification of corticosterone in plasma using an 
enzyme-linked immunosorbent assay (ELISA) 
A commercially available corticosterone ELISA kit (Enzo Life Sciences, Exeter, 
UK) was used to quantify the concentration of corticosterone in plasma.  The 
corticosterone ELISA uses a polyclonal antibody for corticosterone to competitively 
bind corticosterone in the standard, sample or an alkaline phosphatase molecule 
which has corticosterone covalently attached to it.  After incubation, substrate is 
added to induce the colourometric reaction. 
 
2.4.4.1 Method development 
Samples were thawed from -20
o
C and subject to one of three preparation methods 
(A, B or C) to determine the optimal protocol to yield the most reproducible results. 
 
- Method A used equal volumes (10 μL) of plasma and the steroid displacement 
reagent (SDR; diluted 1/100 with assay buffer) provided in the kit.  The mixture was 
incubated (5 mins, RMT) in sterile glass tubes before the final volume was adjusted 
to 500 μL with the assay buffer 15 (AB15) provided.   
- Method B was identical to method A except after incubation with SDR, samples 
were subject to extraction as follows.  AB15 (280 μL) and ethyl acetate (3 mL) were 
added to each sample, vortexed vigorously, allowed to stand for 2 mins and then 
vortexed once more.  The uppermost, clear, organic layer was removed using a glass 
pipette and bulb and transferred to a fresh glass tube before the samples were 
reduced to dryness under oxygen-free N2 (60
o
C).  When dry, samples were stored (16 
hrs, 20
o
C).  The following day samples were reconstituted into 500 μL AB15 and 
vortexed vigorously.   
- Method C was identical to method B apart from the addition of water (10 μL) 
instead of SDR in the initial incubation step. 
 






2.4.4.2 Corticosterone ELISA procedure 
Using AB15 as the diluent, standard solutions were prepared fresh on the day of the 
experiment and within 1 hour of use, from the 200,000 pg/mL stock solution 
provided.  Serial halving dilutions were made to achieve a series of concentrations 
ranging from 20,000 - 10 pg/mL.  100 μL of standards and samples were added to 
appropriate wells along with the blue conjugate and the yellow antibody solutions 
(50 μL of each) as per manufacturer‘s instructions.  The plate was incubated on a 
plate shaker (400 rpm, 2 hrs, RMT) and then washed using the electronic plate 
washing machine and the wash buffer provided (3 x 300 µL).  The pNpp substrate 
(200 μL) was added to every well and incubated (1 hr, RMT) until the stop solution 
(50 μL) was added.  The absorbance was recorded spectrophotometrically (TECAN, 
infinite M1000) at 405 nm with correction at 580 nm (background).  The absorbance 
at 580 nm was subtracted from that measured at 405 nm.  The absorbance 
measurements were inserted into the Assay Zap software program from which the 
standard curve (inverse sigmoidal) could be plotted (semi-log plot: x-axis log 
[corticosterone], y axis % binding; B/Bo). 
 
2.4.5 Quantification of corticosterone in plasma by 
radioimmunoassay (RIA) 
Plasma corticosterone was quantified using an in-house RIA (Al-Dujaili et al. 1981).  
In this assay, radio-labelled corticosterone ([
3
H]4) competes with corticosterone in 
the sample for antibody sites.  Scintillation occurred when scintillation proximity 
assay (SPA) beads bound to the fraction of primary antibody which was associated 
with [
3
H]4-corticosterone.  Due to the competition between binding of unlabelled and 
labelled corticosterone to the primary antibody, the extent of scintillation decreased 
as the concentration of unlabelled corticosterone increases. 
 
Standards were prepared from a stock solution of corticosterone (32μM in ethanol) 
using borate buffer to obtain a diluted series (0.6-320 nM).  Plasma was thawed on 
wet ice, diluted with borate buffer (10% v/v) and incubated (30 mins, 80
o
C,) to 
denature CBG, before being placed immediately onto wet ice.  Sample (20 μL), 




Volumes of borate buffer/1,2,6,7-[
3
H]4-corticosterone (0.034 MBq/μL; approx. 6 mL 
buffer plus 2 μL [
3
H]4-corticosterone stock) were mixed in appropriate proportions to 
achieve radioactivity counts of around 8-12000 cpm/50µL.  The primary antibody 
stock (anti-mouse raised in sheep, kindly provided by Dr Chris Kenyon) was stored 
at 1/100 dilution.  This solution (60 μL) was added to buffer/[
3
H]4 corticosterone 
mixture (6 mL) to give a final primary antibody dilution of 1/10,000.  An aliquot (50 
μL) was added into each well, followed by SPA beads (50 μL; coated with anti-sheep 
secondary antibody; GE Healthcare Life Sciences, Buckinghamshire, UK and 
prepared in borate buffer).  The plate was sealed, inverted to mix and allowed to 
incubate (16-20 hrs, RMT) prior to scintillation counting in a β-counter (2 min 
cycle/well; 145 MicrobetaPLUS, Walla, PerkinElmer, UK).  A semi-log, inverse 
sigmoidal standard curve was fitted with GraphPad Prism software using B/Bo 
(bound/bound at zero; y axis) vs. log [corticosterone, M] (x axis). 
 
2.4.6 Quantification of plasma leptin levels by ELISA 
Plasma leptin concentrations were quantified using a mouse leptin ELISA kit 
(Crystal Chem Inc., Illinois, US) which is based on the following reactions.  Wells 
are pre-coated with rabbit anti-leptin antibody which first binds endogenous mouse 
leptin in the sample.  In the first reaction, the anti-leptin IgG of the guinea pig anti-
serum added to the plate, binds to the mouse leptin immobilised to the base of the 
microplate well.  In the second reaction, HRP-conjugated anti-guinea pig IgG 
antibody is then bound to the guinea pig anti-leptin IgG of the immobilised ―rabbit 
anti-leptin/mouse leptin/guinea pig anti-leptin IgG‖ complex.  During the enzyme 
reaction, the bound HRP-conjugated antibody is detected by the addition of the 
3,3‘,5,5‘-tetramethylbenzidine (TMB) substrate solution. 
 
From the lyophilised leptin stock solution, a series of standards were prepared (0.1 – 
12.8 ng/mL) in the sample diluent supplied and according to the manufacturer‘s 
protocol.  First, all wells were washed with the diluted wash buffer (2x 300µL).  Into 
each well, sample diluent (45 µL) and guinea pig anti-mouse leptin serum (50 µL) 
were added. Standards or samples (5 μL) were added in duplicate to wells and 
incubated (16-20 hrs, 4
o




incubation, the plate was washed (5x 300μL) to remove unbound leptin before the 
second incubation.  HRP–conjugated anti-leptin antibody (100 μL) was added to all 
wells before incubation (3hrs, 4
o
C).  To remove unbound HRP-conjugate, the plate 
was then washed for a second time (7x 300μl) using the diluted wash buffer as 
before.  100 μL of the TMB-containing enzyme substrate solution (light sensitive) 
was added immediately to all wells and incubated once more (30 mins, RMT, in the 
dark) until the stop solution (0.5 M sulphuric acid, 100 μL) was added to arrest the 
reaction.  Within 30 mins, the absorbance at 450 nm (L1) and 630 nm (L2; 
background count) was recorded using a spectrophotometer (OPTImax tunable 
microplate reader, Molecular Devices).  L2 values were subtracted from L1 values to 
remove background counts and thus increase the accuracy of the reading.  A standard 
curve (x-axis concentration, y-axis absorbance) was drawn and a straight, best-fit line 
applied from which the concentration of unknowns could be interpolated. 
 
2.5 Determination of tissue steroid levels by liquid 
chromatography-mass spectrometry (LC-MS/MS) 
LC-MS/MS was used to measure corticosterone (B) concentrations in liver and brain. 
 
2.5.1 Steroid extraction from tissues 




A stock solution of corticosterone (1 mg/mL) and standards ranging from 0.1 ng to 
100 ng were prepared in methanol.  An internal standard of 2,2,4,6,6,17,21,21-
[
2
H]8B (d8-B; 100 ng; Cambridge Isotopes, MA, USA) was also prepared (1 mg/mL) 
and added to all standards and samples after homogenisation.  ~300 mg of tissue was 
weighed into 2 mL glass tubes on dry ice and methanol:water (7:2, v/v, 2 mL) was 
added.  The tissue was then homogenised using a rotor-stator homogeniser (Pro 200) 
and stored on dry ice before the internal standard (100ng) was added.  Samples and 




Vibramax (x1000, 15 min) and then subject to centrifugation (3200xg, 45 min, 4
o
C).  
The supernatant was transferred to a fresh tube and reduced to dryness under N2 
(60
o
C) then reconstituted in methanol (10 mL) and vortexed.  Hexane (10 mL) was 
added and the solution mixed prior to removal of the top organic layer using a glass 
Pasteur pipette attached to a vacuum.  The remaining methanol layer was transferred 
to a clean tube and reduced to dryness under N2 (60
o
C).  Once the extracted steroids 
were dry, they were reconstituted in 30% methanol (v/v, 5 mL).  Varian C18 
columns (C18; 2 g) were prepared by twice adding 10 mL methanol and allowing it 
to be drawn through the column over a vacuum tank to clean the columns.  This 
process was repeated with 2 x 10 mL water to prime the columns.  The reconstituted 
steroids and samples (5 mL) were then passed through the columns followed by 2 x 
10 mL water and the eluate discarded.  Steroids were eluted into glass collection 
tubes by the addition of methanol (5 mL).  Samples were reduced to dryness under 
N2 (60
o
C) and reconstituted in LCMS mobile phase (50 µL; 50:50; v/v; methanol + 






Stock and standard solutions and the internal standard were prepared as in section 
2.5.1.1.  Half of each sagittally-sectioned brain (~200 mg) was weighed and placed 
into a 2 mL glass tube on dry ice before ethyl acetate:ethanol (1 mL; 1:1, v/v) was 
added.  The tissue was then homogenised using a rotor-stator homogeniser (Pro 200) 
and stored on dry ice before the internal standard (100 ng) was added and mixed.  10 
mL of a prepared solution of ethanol: acetic acid: water (95:3:2 v/v) was added to 
fresh glass tubes and chilled on dry ice before the brain homogenate (or standard) 
was added drip by drip using a glass Pasteur pipette to form a crystal-like structure).  




Samples were brought to 4
o
C on wet ice before sonication (8 x 15 sec bursts, placed 
on ice between bursts) in ice-cold water and then subject to centrifugation (3000xg, 
30 mins, 4
o
C).  The supernatant was transferred to a fresh tube and reduced to 
dryness (under N2, 60
o






C).  The protocol then continued exactly as described in 2.5.1.1 from the 




The following was performed by staff of the Wellcome Trust Mass Spectroscopy 
Core, University of Edinburgh/BHF Centre for Cardiovascular Science.  Analysis 
was performed on a QTrap 5500 Mass Spectrometer (AB Sciex, Warrington, UK), 
interfaced with an Acquity UPLC (Waters, Manchester, UK) and operated with 
Analyst software (v1.5.1).  Samples were injected onto an X-Select HSS PFP column 
(2.5 μm, 3 mm, 100 mm, Waters, Riccarton, UK) maintained at 25
o
C.  Initially the 
mobile phase consisted of water:methanol (each with 0.1% formic acid), 50:50, 
flowing at 0.3 mL/min and the proportions changed across a linear gradient to 40:60 
between 1 and 2.5 mins, and then 35:65 by 5 mins, and maintained until 7 mins 
before re-equilibrating. 
 
Selected reaction monitoring of mono-protonated species was performed to quantify 
steroids of interest as follows: corticosterone, m/z 347.1 - 91.1 and d8-corticosterone 
355.1-337, using a de-clustering potential (66, 116V), collision energy (69, 19V) and 
collision cell exit potential (8, 14V) respectively. The source conditions were as 
follows: curtain gas (N2) 35psi, the nebuliser current 3μA, temperature 450
o
C and ion 
source gas 35 psi. 
 
2.6 In vivo experiments 
2.6.1 Animal breeding 
All mice (WT and 5αR1-KO littermates) were obtained from established in-house 
breeding colonies.  5αR1-KO  mice were originally generated by global disruption of 
the Srd5a1 gene on a mixed genetic background (C57BL/6j/SvEv/129; denoted 
mixed strain; Mahendroo et al. 1996).  These mice were also bred onto the uniform 
C57BL/6j strain (mice from Harlan Olac, Bicester, UK; denoted C57Bl/6j strain) by 
continuous back-crossing for 10 generations.  Heterozygous female mice were bred 




experimentally.  Both mixed strain and C57Bl/6j mice were used in vivo and their 
tissues in vitro where specified.  Sex and genotype ratios were all produced at the 
expected Mendelian ratios and all mice were bred under licensed approval from the 
U.K. Home Office. 
 
2.6.2 Genotyping for WT and 5αR1-KO mice  
2.6.2.1 DNA extraction 
DNA was extracted using the DNeasy Blood and Tissue Kit (Qiagen; West Sussex, 
UK).  The basic principles of the DNeasy extraction method consist of cell lysis 
using the enzymatic action of proteinase K.  The addition of guanidine hydrochloride 
and ethanol provide optimal conditions for the binding of DNA to the spin column 
membrane whilst simple centrifugation forces contaminants such as proteins to pass 
through.  Remaining contaminants and enzyme inhibitors are removed in the two 
wash steps before the low salt buffer is used to elute the pure extracted DNA from 
the membrane. 
 
Samples obtained from ear marking (<25 mg tissue) were digested overnight (16 hrs, 
55
o
C, under rotation) in 180 µL supplied buffer ATL plus 20 µL of the supplied 
proteinase K (>600 mAU/ml solution).  The subsequent steps were all performed at 
RMT.  Following digestion, samples were vortexed (15 secs) before buffer AL was 
added (200 µL) and vortexed again thoroughly.  100% ethanol was then pipetted into 
the samples (200 µL) and mixed thoroughly.  The mixture was pipetted into DNeasy 
mini spin columns placed in 2 mL collection tubes and subject to centrifugation 
(6000xg, 1 min).  Spin columns were placed in new 2 mL collection tubes before 
buffer AW1 was added (500 µL) and subjected to centrifugation (6000xg, 1 min).  
Again placing the columns into new 2 mL collection tubes, buffer AW2 was added 
(500 µL) before centrifugation (20,000xg, 3 mins).  The columns were placed into a 
1.5 mL Eppendorf and the DNA eluted using AE buffer (200 µL) by centrifugation 






PCR was performed as described in section 2.3.3 using the following primers:  
5αR1-KO primer (5‘-GATTGGGAAGACAATAGCAGGCATGC-3‘), common 
primer (5‘-CCAGACACGAACTTCCACGCTTCTG-3‘) and the WT primer (5‘-
ATGGAGTTGGATGAGTTGTGC-3‘). This primer combination results in the 
amplification of a 400bp band in the presence of the WT allele and a 360bp band in 
the presence of the disrupted allele.  Bands were visualised as in section 2.3.3.1.  WT 
mice were identified when one band was seen at 400bp, 5αR1-KO mice when a band 
was seen at 360bp and heterozygous (HET) mice when two bands were seen, one at 
both 360 and one at 400bp (both the WT and the 5αR1-KO allele present; see Figure 
2.1 for clarification). 
 
2.6.3 Animal husbandry 
Animals were studied in accordance with the guidelines of the UK Home Office 
(Project Licence P60/3962 Holmes, Personal Licence P60/12166 Di Rollo).  WT and 
5αR1-KO mice on each background were bred from in-house colonies (generated as 
described above).  After weaning, mice were housed in groups of 4-6 animals 
according to their genotype, unless specified otherwise.  They were given food 
(chow, RM1 801002; Special Diet Services, Witham, UK) and water ad libitum, 
room temperature was maintained at 22-23
o
C and lights in the facility were on 
between 0700 and 1900 hours.  All animals were weighed weekly.  
 
2.6.4 Body weight and food intake 
Body weight was measured once weekly throughout the experiment and again just 
prior to cull using a set of CS 200 scales (OHAUS, UK) which weigh accurately to 2 
decimal places.  To determine food intake, chow pellets were weighed and placed in 
the cage food hopper.  The weight of the chow pellets remaining in the food hopper 
the following week was subtracted from the initial food weight to calculate weekly 
consumption in grams which was then multiplied by the calorific content in 1g of the 
standard mouse chow to calculate kcal consumed per week, cumulatively.  Food was 







Figure 2.1  Genotyping result of experimental animals 
Representative image of gel electrophoresis result for the purpose of genotyping.  In WT 
animals one band was seen at 400 bp, 5αR1-KO mice had one band at 360 bp and HET mice 
had a band at both 400 and 360 bp, representing the presence of both the WT and 5αR1-KO 
allele.  WT = wild-type mouse, HET = heterozygous mouse and KO = 5α-reductase type 1 





2.6.5 Plasma collection 
Basal (non-stressed; 0730 – 0830 hrs) blood samples were obtained by tail 
venesection and collected into EDTA dipotassium salt-coated vials (Microvette 
CB300, Sarstedt, Numbrecht, Germany).  The same process was also performed 
during any experiment where blood was collected via tail venesection.  At cull, trunk 
blood was collected following decapitation and immediately mixed with EDTA 
solution (0.5M, 50μl).  In both cases, the plasma fraction was then separated by 
centrifugation (2000xg, 4°C, 15 min), carefully transferred to a fresh Eppendorf and 
stored at -20°C. 
 
2.6.6 Insulin Tolerance Test 
Mice were fasted for 4 hours (1000 hrs – 1400 hrs) before being weighed and 
immediately prior to injection of the insulin bolus, a basal blood sample was taken 
(time 0).  One drop of blood was placed onto a Freestyle glucose strip and inserted 
into a Freestyle blood glucose monitoring system which gave an automatic read out 
of glucose concentrations.  Mice were then given an intraperitoneal injection of 
insulin (0.5 mU/g body weight for males and 0.75 mU/g body weight for females).  
Subsequent blood samples were taken at 15, 30, 60 and 90 mins post-injection; each 
time the glucose concentration was measured using the hand-held Freestyle blood 
glucose monitoring system.   
 
2.6.7 Glucose Tolerance Test 
Mice were fasted in individual cages for 6 hrs (0800 hrs – 1400 hrs) before animals 
were weighed and a basal blood sample (time 0) was taken.  Glucose (40% w/v in 
distilled water) was administered by intraperitoneal injection to give a dose of 2 mg 
glucose per kg body weight.  Blood was collected via tail nick (section 2.6.5) at 15, 
30, 60 and 90 mins after the glucose load.  Animals were then transferred to clean 
cages with free access to food and water.  Plasma was prepared as described (section 
2.6.5) and used in an ELISA to quantify insulin concentrations (section 2.4.1) across 
the time course.  The concentration of glucose both basally and across the time 
course of the experiment were also quantified from the collected plasma via a 




2.6.8 Behavioural analyses. 
2.6.8.1 Dry Mazes 
All animals were moved to a designated quiet room for 48 hrs before behavioural 
tests designed to investigate anxiety and learning and memory were initiated.  Tests 
were carried out during the light period; 0900 to 1300 hrs.  On the day of the 
experiment, animals were brought into the behavioural suite and allowed to 
acclimatise at the rear of the room in dim light for 30 mins prior to testing.  All 
behavioural tests were recorded using the ANY maze tracking system and computer 
software (Stoelting, Illinois, US) which enabled full data analysis.  The maze was 
dimly lit with free standing lights and a Lux meter was used to ensure all areas of the 
maze apparatus were illuminated by equal light intensities (between 10 and 12 lux).  
The observer was blinded to genotype during all behavioural experiments, which 
were carried out in the order specified below (from the test most sensitive to stress to 





2.6.8.1.1 Elevated plus maze 
In the elevated plus maze (EPM; a test of anxiety), four arms were designated either 
―closed‖ or ―open‖, and the ―central zone‖ comprised the area where the four arms 
met (see Figure 2.2, I for clarification).  The mouse was initially placed into the 
central zone facing one of the open arms and recording began.  The time spent in 
each zone, number of open and closed arm entries, speed and distance were recorded 
over 5 mins when the animal was allowed to explore freely.  Relative movement and 
time spent in each zone was considered a reflection of the anxiety level of the animal 
due to the natural preference of rodents for small, dark and enclosed spaces. 
 
2.6.8.1.2 Open field test 
To further assess anxiety, exploratory behaviour in the open field test (OFT) was 
investigated.  The animals were placed one at a time into the centre of the open field 
box, placed on the floor, and allowed to roam freely for 5 mins (Figure 2.2, ii further 
highlights the OFT protocol used).  Parameters measured from observed recordings 




each zone), time spent in each zone (inner or outer), speed and distance travelled in 
each zone (Lai et al. 2007).  General activity was assessed by total movement, and 
general movement within the inner zone was considered a reflection on the anxious 
state of the animal. 
 
2.6.8.1.3  Y maze 
Spatial memory-was assessed using the Y-maze apparatus which consisted of three 
enclosed arms made of black Plexiglas (see Figure 2.2, iii for details) and was 
elevated onto a round table sitting about 50 cm above the ground.  The arms were 
labelled A, B or C whilst ―centre‖ was the triangular area where are three arms met.  
Spatial cues (e.g. stuffed toy, Lego model etc.) were set up around the maze and 
positioned appropriately to allow the animals to visualise them clearly whilst inside 
the maze.  The end of each arm was also labelled with a black and white image.  The 
maze floor was spread with sawdust from each of the animal‘s cage and mixed in 
between trials to block olfactory cues.  The complete test consists of two trials 
separated by a time interval (inter-trial interval; ITI) of either 1 min or 2 hrs. 
 
1 min ITI – on the first day the animal was placed at the end of a randomly assigned 
arm and allowed to roam freely for 5 mins.  During this acquisition trial the 
entrance to one of the arms (again randomly assigned) was prevented with a plastic 
stopping block.  After the elapsed time the animal was taken out for 1 min (placed on 
its cage lid) and then put back in for a further 2 mins, this time allowing the animal to 
freely explore all three arms of the maze (retention trial).  The extra-maze spatial 
cues should aid the animal‘s ability to recognise the novel arm and due to their 
naturally inquisitive nature, should spend more time exploring this arm during the 
retention trial.  The animal is expected to freely explore the novel arm more than the 
other two arms during this time.  The purpose of the 1 min ITI test was to ensure the 
apparatus, testing environment and computer software was all set up appropriately 






2 hr ITI – 4-5 days after the 1 min ITI trial, animals were re-tested in the maze with 
an ITI of 2 hrs.  The animal was placed into a novel start arm with a novel closed 
arm and the cues arranged outside the maze were different compared to initial 1 min 
ITI test.  The animal was in the maze for 5 mins, taken out and returned to the home 
cage for 2 hrs before being put back into the maze for a final 2 mins with all arms 
open during this final retention trial. 
 
The time spent in the novel arm post-ITI was calculated as a percentage of the total 
test time (2 mins).  Values were compared with a random ―chance‖ level (33%) for 







Figure 2.2  Schematic diagram of the mazes used to assess behaviour 
i) shows the elevated plus maze (measure of anxiety) where the apparatus, elevated 50 cm from the ground consisted of two opposing open arms (30x5 
cm), two opposing closed arms (30x5x15 cm) and a central area of 5 cm
2
. Closed arms (A, dark grey, least anxiogenic), were enclosed by opaque 
Perspex walls 15 cm high. Open arms (B; white) were considered most anxiogenic. The central zone (C; light grey) although neutral is more anxiogenic 
than A but less than B. ii) shows the open field test (a test of anxiety) where the apparatus (50x50x25 cm) was divided into 16 equal squares. The 
perimeter of the test field was designated ―outer zone‖ (A, grey, least anxiogenic) and the centre of the test field constituted the ―inner zone‖ (B, white, 
most anxiogenic). iii) shows the Y-maze apparatus (a test of memory) consisting of 3 arms (50x11x10 cm) A, B or C (progressively darker grey 
tones) made from black Plexiglas and set at 120
o
 to each other. Plastic images (triangle, circles or square) were permanently in place at the 
end of each arm but the cues placed around the maze to aid spatial memory were changeable. A small, black, Perspex block could be 




2.6.8.2 Morris water maze 
To further asses learning ability and spatial memory retention, mice were trained in 
an open-field water maze (120 cm diameter) surrounded by prominent extra-maze 
visual cues (from which they can build a spatial memory of the area).  These cues 
were placed at various points around the room and maintained in a fixed position 
throughout testing.  The pool was filled with water (26°C) and made opaque using 
liquid latex (Strathbond Ltd, Ayrshire, UK).  The task required the mouse to navigate 
towards and climb onto a hidden platform (diameter 15 cm) submerged 1-2 cm under 
water.  Like the extra-maze cues, the platform remained in a fixed position 
throughout testing (in the centre of one of four quadrants in the pool).  The animals 
were given 4 trials/day and released into the pool from a different compass point 
(North, East, South or West) at the beginning of each trial.  When the mouse was 
placed into the pool facing the wall the trial began and was ended when the platform 
was located.  If however, the animal did not find the platform within the allocated 
time (120 secs) it was placed there by the experimenter and left for 30 secs.  After 
each trial the animal was briefly dried with a towel and returned to its home cage 
placed on a heating pad.  Each trial was performed on all the animals before the next 
trial was started.  The latency (to the platform) and swim paths of the mice were 
monitored by a video camera mounted
 
on the ceiling and by a computerised tracking 
system (Water maze software; Actimetrics Inc., IL, US).  Initially the mice had been 
subjected to non-spatial training (2 days) where curtains were pulled around the 
perimeter of the pool.  On this occasion the location of the platform was made visible 
by placing a Lego block (8 cm tall) onto the platform.  This tested for visual, 
motivational or motor deficits in all groups of mice and if any animals were unable to 
locate the platform within 30s by the end of day 2 they were excluded from the 
spatial memory training. 
 
The animal‘s spatial learning ability was then tested where the curtains were pulled 
back to reveal the extra-maze cues located around the room.  This time the platform 
was completely invisible whilst submerged under water.  The animals were then 
tested in the same format as above (for 5 consecutive days), using their spatial 




and on day 6 (24 hrs after the last training trial), mice were subject to
 
a retention 
(probe) test where the platform was removed from the pool and the mice allowed to 
swim freely for 60 secs.  The swim path was recorded along with the total time spent 
in the platform ("training")
 
quadrant and platform crossings during the 60
 
sec test.  
Each training day, the average latency (in seconds) of all 4 trials was calculated for 
each animal.  The mean of this average latency was then calculated for each 
group/day and graphed. 
 
2.6.8.3 Free ambulatory activity 
AM524 single layer X, Y, IR Locomotor Activity Monitors and associated Amonlite 
software were used to measure basal nocturnal activity (Linton Instrumentations, 
Norfolk, UK).  The AM524 uses an array of infrared beams to determine activity and 
mobility of a subject.  The beams are arranged on a single level in an 8 x 16 pitched 
grid which allows normal X,Y movement to be measured.  Pilot studies determined 
that equal locomotive activity was recorded from the same mice on three consecutive 
days demonstrating no acclimatisation period was necessary before experimental 
testing began.  On the evening of testing, group-housed mice were placed into single 
cages before being positioned within the infrared frames.  Nocturnal activity was 
then recorded for 14.5 hrs to encompass the dark phase (1800 hrs – 0830 hrs the 
following day).   When the IR light beams were broken by the animals‘ movement, 
total activity counts were recorded by the Amonlite software.  Total active time as 
well as distance covered was also recorded.  During testing, animals had free access 
to chow and water and were left alone in the room for the duration of testing in order 
to minimise external visual, auditory and olfactory stimuli that might alter their 
normal activity.  
 
2.6.9 Assessment of HPA axis function and glucocorticoid 
clearance 
2.6.9.1 Acute Restraint Stress 
In order to determine differences in HPA axis responses between WT and 5αR1-KO 
mice on a C57Bl/6j background, animals were subjected to a highly stressful 




experiment, a basal (0730 hrs; time 0 mins) blood sample was taken by venesection 
as described in section 2.6.5 1 hr prior to restraint stress before the animals were 
allowed to recover quietly in their home cage.  At 0830 hrs the animals were placed 
one by one into a small Perspex tube, small enough that they could not move or turn 
around, before a stopper was placed into the end to prevent escape.  Mice were held 
in position for 15 mins after which a blood sample was taken prior to recovery in 
their home cages.  Further blood samples were taken throughout the recovery phase 
at 30, 60 and 90 mins post-stress.  Plasma samples were then prepared and stored as 
described (section 2.6.5) to be used to quantify circulating corticosterone levels by 
ELISA (see section 2.4.4.2 for details). 
 
2.6.9.2 Adrenalectomy surgery 
The following was performed by Dr Dawn Livingstone of the University of 
Edinburgh/BHF Centre for Cardiovascular Science.  Immediately prior to surgery 
mice were injected subcutaneously with the analgesic buprenorphine (0.05 mg/kg 
body weight; B. Braun Melsungen AG, Germany) before bilateral adrenalectomy 
was carried out through dorsal incisions under inhaled isoflurane anaesthesia (2-4%; 
Merial Animal Health Ltd, Essex, UK).  Following surgery, wounds were closed 
with internal sutures and external staples and mice were placed into a heated 
compartment.  When consciousness was restored, animals were transferred to a clean 
cage to recover fully for two weeks before experimentation began to allow clearance 
of all endogenous adrenal steroids.  For the remainder of the experiment, 
adrenalectomised animals were given 0.9% saline in their drinking bottles. 
 
2.6.9.2.1 Mini-pump loading and implantation 
The following was performed by Dr Dawn Livingstone of the University of 
Edinburgh/BHF Centre for Cardiovascular Science.  Solutions of vehicle or drug 
were prepared immediately prior to loading of mini-pumps. Osmotic mini-pumps 
(Model 2002, Alzet, CA, USA) were prepared as per manufacturer‘s instructions and 
loaded to deliver 100 μg of corticosterone per day in 1:1 DMSO:propylene glycol.  
The pumps were then primed in saline at 37°C for 24 hrs before surgery.  These 




compartment within the pump and the tissue environment in which the pump is 
implanted.  This causes an influx of water into the area around the loading 
compartment, displacing the test solution from the pump at a controlled rate 
(0.5 μL/hr for 14 days).  To implant the mini-pumps, animals were injected 
subcutaneously with the analgesic buprenorphine (0.05 mg/kg body weight; B. Braun 
Melsungen AG, Germany) and anaesthetised with inhaled isoflurane (2-4%).  
Loaded osmotic mini-pumps were implanted subcutaneously between the scapulae 
through dorsal incisions which were closed with staples. Following surgery, animals 
were allowed to recover on a heat mat before being transferred to individual clean 
cages. 
 
2.6.10 Terminal procedures and tissue collection 
Animals were killed by decapitation in the morning (0800 hrs-1100 hrs) and trunk 
blood was collected as described above (2.6.5) before tissues were excised, wet-
weighed and snap frozen on dry ice within 10-15 mins of the cull: whole brain, liver, 
prostate, adipose depots (gonadal/epididymal, omental, mesenteric and 
subcutaneous),  kidney and one adrenal.  In some experiments, the excised whole 
brain, the hypothalamus and pituitary were further dissected.  Whilst dissecting the 
hypothalamus from the brain, extra care was taken to ensure the optic chiasm (white 
neuronal matter which highly expresses the 5αR enzymes) was not collected along 
with the sample.  The optic chiasm (which shows high Srd5a1 expression) when 




2.7 Data Analysis 
Data are presented as mean values ± standard error of the mean (SEM).  All 
statistical comparisons were conducted using Graph Pad Prism or Statistica software 
to perform appropriate statistical tests as detailed in specific experimental chapters.  
Where significance was found by 2-way ANOVA using Graph Pad Prism, 
Bonferroni post-hoc tests were used to determine if particular pairs of values were 
significantly different from each other.  However, this test is conservative and often 
lacks statistical power so occasionally data would instead be analysed by 2-way 




of significance was taken as p<0.05 (*) and trends were identified where the p value 
was between 0.05 and 0.1.  Where samples were run in duplicates or triplicates the 
RSD was calculated as follows: 
 









Chapter 3: The role of 5αR1 in 







Obesity and other features of the metabolic syndrome may be associated with subtle 
changes in HPA axis activity in combination with altered glucocorticoid metabolism 
in extra-adrenal tissues (Pasquali et al. 2000; 2000; Pasquali et al. 2006).  Even in 
the absence of exogenous stress, HPA activity is stimulated by both feeding and 
fasting (Dallman et al. 1993) showing food intake pathways and HPA axis activity 
are interlinked.  A propensity towards developing the metabolic syndrome was 
observed in previous investigations in our group when glucocorticoid clearance was 
impaired by disruption of 5R1, and notably, the weight gain phenotype of 5αR1-
KO mice was particularly marked in females, which develop obesity even when fed a 
standard chow diet.  The same was not true for male mice which only developed 
obesity compared to WT controls during a period of high-fat feeding.  The reason for 
this sexual dimorphism in susceptibly is not yet understood but given that 
glucocorticoids are not the only substrates of 5αR1 and sex steroids are also subject 
to metabolism by the enzyme, sex differences are not altogether surprising. 
 
Corticosterone is not absolutely necessary for the diurnal rhythm of the HPA axis 
and rhythmic activity of the HPA axis also follows the pattern of food consumption. 
For example, overnight food deprivation in rats leads to dampened HPA axis 
responses to acute restraint stress and reduced corticosteroid feedback the following 
morning (Akana et al. 1994; Hanson et al. 1994).  Furthermore, administration of the 
selective murine 11βHSD1 inhibitor BVT .2733 reduced food intake and inhibited 
body weight gain in both lean and diet-induced obesity (DIO) mice (Wang et al. 
2006).  Similarly, the 11βHSD1-KO mouse is also resistant to DIO (Morton et al. 
2004; Densmore et al. 2006) and 11βHSD1 knock-down reduces chow intake (Li et 
al. 2011).  In light of this, a lack of glucocorticoid metabolism by 5αR1 may lead to 
hyperphagia, underpinning weight gain in 5αR1-KO mice. 
 
As early as the 1940s, it was shown that lesions of the hypothalamus resulted in a 
hyperphagic and obesigenic phenotype (Hetherington et al. 1942).  In this chapter, 




neuropeptides which regulate appetite and feeding as a potential driver of 
hyperphagia and weight gain. 
 
In addition to increased food consumption, altered activity (most likely reduced 
locomotion) is a potential mechanism for obesity in 5αR1-KO mice.  CRH is a key 
regulator of the HPA axis but also plays a role in regulating locomotor activity and 
feeding (Sutton et al. 1982; Krahn et al. 1986).  Reduced food intake and increased 
locomotor activity in an unfamiliar environment have been shown following 
intracerebroventricular CRH administration (Contarino et al. 2000).  Additionally, 
the same authors reported CRH increased activity in WT mice but not CRHR1-KO 
mice.  In the same study, food intake was decreased in both WT and CRHR1-KO 
mice following CRH treatment, suggesting a role for the CRHR2 receptor in 
mediating CRH-regulated feeding behaviours.  Given that HPA activity (at least in 
response to stress) is dampened in 5αR1-KO mice where glucocorticoid clearance is 
impaired (Livingstone et al. 2014b), expression of transcripts which positively drive 
the axis (such as CRH and AVP) may be downregulated in 5αR1-KO mice (explored 
in further detail in Chapter 4).  Potential reductions in CRH signalling would be 
hypothesised to result in reduced physical activity in conjunction with increased food 
intake; the net result of which could be significant weight gain in mice lacking 5αR1.  
 
It was noted previously, that female 5R1-KO mice gained more weight but were 
susceptible to losing it again during a period of social isolation.  The underlying 
cause is unclear but may relate to increased susceptibility to stress and anxiety; 
certainly it has been noted that these mice display suppressed stress responses 
(Livingstone et al. unpublished for female mice).  Many authors have reported 
instances of glucocorticoid-induced anxiety, either through increased ligand 
availability or up-regulation of corticosteroid receptors (Seckl 2004; Kajiyama et al. 
2010).  For example, anxiety was reduced in a forebrain-specific GR-KO mouse 
model (Boyle et al. 2006) whilst prednisolone-treated mice displayed more anxiety-
like behaviours in the EPM and OFT, possibly related to hippocampal remodelling 
and damage (Kajiyama et al. 2010).  Moreover, repeated administration of 




Kalynchuk et al. 2004; Gregus et al. 2005; Zhao et al. 2008) whilst 50% of  humans 
who are diagnosed with Cushing‘s syndrome (a model of glucocorticoid excess 
within tissues) show an associated development of major depression (Sonino et al. 
1998).  Therefore, 5αR1-KO mice may be predisposed to developing affective 
disorders, although other explanations of weight loss on single housing should also 
be considered e.g. maladaptive thermogenesis. 
 
3.1.1 Hypothesis 
Our overall hypothesis was that female 5αR1-KO mice have increased appetite and 
reduced locomotor activity compared with WT and male 5R1-KOs, and that female 
5αR1-KO mice are more prone to anxiety. 
 
3.1.2 Aims 
The main aims of this set of experiments were:  
 To investigate whether changes in the balance of hypothalamic anorexigenic 
and orexigenic peptides, indicative of increased appetite, were associated 
with weight gain in the 5R1-KO mice. 
 To investigate whether locomotor activity of 5R1-KO mice was less than 
WT mice. 
 To determine if 5αR1-KO mice display more anxiety-like behaviours than 
WT mice under basal (group housed) conditions. 






3.2.1 Metabolic and behavioural effects of 5αR1-KO  
3.2.1.1 Experimental outline 
Male and female, WT and 5αR1-KO mice (C57BL/6j/SvEv/129 [mixed] strain) were 
maintained on chow diet and assessed for body weight and food consumption.  At 6 
months, mice were assessed for anxiety first, followed by free ambulatory nocturnal 
activity using infrared cage frames.  To confirm that 5αR1-KO mice demonstrated 
similar insulin resistance and steatosis as previously described, glucose and insulin 
tolerance tests were performed in vivo.  Following cull, the expression of 
hypothalamic neuropeptides which are known to drive feeding behaviours were 
quantified by qPCR.  
 
3.2.1.2 Animal maintenance  
All animals were obtained from an in-house breeding colony (2.6.1), housed in 
groups of 4 animals/cage and maintained as described in methods section 2.6.3.  Four 
experimental groups were studied: 
 
 Male WT mice (n = 19) 
 Male 5αR1-KO mice (n = 18) 
 Female WT mice (n = 20) 
 Female 5αR1-KO mice (n = 20) 
 
3.2.1.3 Body weight and food intake 
Between 5 and 7 months old, animals and their remaining food were weighed once 
weekly in the afternoon to quantify body weight gain and calorific intake (see section 
2.6.4 for details).  This time frame encompassed the periods of experimental 
investigation. 
 
3.2.1.4 Glucose tolerance test (GTT) 
A glucose tolerance test (2.6.7) was used to determine how quickly WT and 5αR1-
KO mice could clear excess glucose from the circulation therefore indicating their 




60 and 90 min intervals, were quantified by ELISA (2.4.1) and hexokinase assay 
(2.4.2) respectively.  
 
3.2.1.5 Insulin tolerance test (ITT) 
The acute effects of insulin injection on blood glucose levels were assessed in WT 
and 5αR1-KO mice by glucometer over a 90 minute time course (2.6.6).  Basal 
glucose levels were also determined prior to injection of the insulin bolus. 
 
3.2.1.6 Assessing relative anxiety levels in the elevated plus maze 
(EPM) 
To determine if lack of 5αR1 led to an anxious phenotype, WT and 5αR1-KO mice 
were tested in the EPM (2.6.8.1.1) at 6 months of age. 
 
3.2.1.7 Free ambulatory activity 
Nocturnal activity of WT and 5αR1-KO mice was assessed using a non-invasive 
procedure whereby frames containing infrared beams in a 2D plane (X-Y) were 
placed around the animal‘s cage overnight (14 hrs).  Further details are highlighted in 
section 2.6.8.3. 
 
3.2.1.8 Terminal procedures 
Animals were culled and tissues collected as described in methods section 2.6.10. 
 
3.2.1.9 Quantification of liver triglyceride content 
Triglycerides were extracted from the livers of WT and 5αR1-KO mice and 
quantified as described (2.4.3). 
 
3.2.1.10 Quantification of plasma leptin levels by ELISA 
Trunk blood was collected from WT and 5αR1-KO mice at cull (2.6.10) and used to 





3.2.1.11 Quantification of mRNA expression by qPCR 
Total RNAs were extracted from snap frozen hypothalami from male WT and 5αR1-
KO mice (2.3.1.4) and used to synthesise first strand cDNA by RT (2.3.2).  qPCR 
was performed (2.3.4) to quantify the expression of transcripts for hypothalamic 
feeding peptides including the orexigenics Npy and Agrp and the anorexigenics 
Cartpt1/2, Mc3r and Mc4r.  The abundances of transcripts of interest were expressed 
as a ratio to the mean of the transcript levels of the reference gene.  These 
combinations of reference genes were selected due to their lack of change in 
expression between experimental groups (WT and 5αR1-KO; see Table 3.1 for p 
values).  Primer sequences and probe numbers can be found in Table 2.2. 
 
3.2.2 Statistical analyses 
All data are presented as mean ± SEM and were compared using Student‘s unpaired 
t-test, 2-way ANOVA or 2-way repeated measures ANOVA with Bonferroni post-







Table 3.1  Reference gene used for hypothalamic qPCR 
Gapdh was used as the reference gene for transcripts of interest in the male and female 
hypothalamus.  P value indicates the results of a Student‘s unpaired t-test, for each sex, 
showing there were no significant differences in reference gene expression between WT and 
5αR1-KO mice. 
  










3.3 Results 1 – Metabolic profiling 
Concomitant to behavioural assessment, indices of metabolism were assessed to 
ensure continuity of the original phenotype as described in the chapter introduction 
(3.1) i.e. a propensity towards features of the metabolic syndrome such as obesity 
and insulin resistance. 
 
3.3.1 Body and tissue weights 
There was no difference in the body weight of male 5αR1-KO mice vs. WT 
littermates either expressed as weight over time (Figure 3.1, A) or at the time of cull 
(Figure 3.1, B).  Female 5αR1-KO mice were significantly heavier than WT across 
the period (Figure 3.1, C, p<0.01) and at the time of cull (Figure 3.1, D, p<0.01).  
There were no significant differences in wet tissue weights between male WT and 
5αR1-KO mice. 
 
In females, absolute wet weight of the gonadal fat pad was significantly increased in 
5αR1-KO mice vs. WT (Table 3.2, p<0.05) with a trend towards the same pattern in 
mesenteric adipose tissue (Table 3.2, p=0.076).  Total fat mass (i.e. the sum of the 
gonadal, mesenteric, omental and subcutaneous adipose tissue mass) was increased 
in female 5αR1-KO mice compared to WT controls reaching significance as absolute 
total adipose weight (Table 3.2, p<0.05) with a trend when total adipose weight was 
corrected for body weight (Table 3.2, p=0.072). 
 
3.3.2 Glucose tolerance 
3.3.2.1 Plasma glucose 
Fasting plasma glucose was not different between WT and 5αR1-KO mice in either 
males (Figure 3.2, A) or females (Figure 3.2, B).  Plasma glucose levels in 5αR1-KO 
mice following intraperitoneal (i.p.) injection of an exogenous glucose solution did 
not differ vs. WT in either male or female mice (Figure 3.2, C).  However, there was 
an overall sex difference whereby plasma glucose levels were higher post-glucose 







Figure 3.1  Body weight gain and final weight at cull 
Male 5αR1-KO mice (dashed black line) did not differ from WT (solid black line) in body 
weight when measured between 19 and 23 weeks old (A). At cull, there was no effect of 
genotype on body weight in male mice (B). Female 5αR1-KO mice (grey dashed line) were 
heavier than WT (sold grey line) throughout the measurement period (C, p<0.01). Panel D 
shows female, 5αR1-KO mice (grey checkered) weighed significantly more than WT 
controls (sold grey) at the time of cull (D, p<0.01).  Data are mean ± SEM for n=19-
20/group.  Comparisons were made by 2-way ANOVA for repeated measures with 
Bonferroni post-hoc tests where appropriate or Student‘s unpaired t-test * = p<0.05, ** = 
p<0.01.  Mice were aged 7 months at cull. WT = wild-type and 5αR1-KO = 5α-reductase 














Body (g) 36.11±0.78 37.22±1.12 0.419 26.78±0.60 29.25±0.60 0.006 
Absolute Tissue Weight (mg) 










Gon 1098.40±97.89 1284.02±107.68 0.209 806.94±65.06 1016.14±57.05 0.021 
Omen 31.75±2.93 39.11±5.52 0.239 40.78±18.52 29.70±3.31 0.559 
Mes 534.38±26.24 556.71±50.55 0.693 391.14±25.28 448.10±26.06 0.125 
S/C 629.64±72.85 617.59±67.45 0.904 561.19±53.51 717.95±67.27 0.076 
Total 2294.16±179.33 2497.42±196.01 0.449 1800.05±115.54 2211.88±119.95 0.018 
Tissue Weight/Body Weight (mg/g body weight) 











Gon 29.78±2.20 34.06±2.50 0.205 30.03±2.30 34.76±1.88 0.119 
Omen 0.89±0.09 1.03±0.13 0.352 1.44±0.61 1.01±0.10 0.487 
Mes 14.72±0.51 14.64±1.04 0.944 14.42±0.79 15.24±0.75 0.453 
S/C 16.96±1.70 16.09±1.37 0.696 20.63±1.80 24.23±1.99 0.188 
Total 62.34±3.73 65.82±3.78 0.517 66.52±3.41 75.25±3.25 0.072 
 
Table 3.2  Body and tissue weights at cull 
In male animals, there were no differences in either body or tissue weights between WT and 
5αR1-KO mice but female 5αR1-KO mice weighed significantly more than WT controls at 
cull (p<0.01).  Also in females, absolute mass of the gonadal (p<0.05), subcutaneous (trend, 
p=0.076) and total of all the fat pads combined (p<0.05) was increased in 5αR1-KO mice vs. 
control.  When tissue weights were expressed as a ratio to body weight, the increased total 
adipose tissue weight in female 5αR1-KO mice vs. WT was a trend only (p=0.072) and there 
were no differences in weight of any other tissues.  Data are mean ± SEM for n=19-20 per 
group. Comparisons between WT and 5αR1-KO were made by Student‘s unpaired t-test, in 
each sex.  Mice were aged 7 months at cull. Gon = gonadal adipose tissue, omen = omental 
adipose tissue, mes = mesenteric adipose tissue, S/C = subcutaneous adipose tissue, total = 
sum of the four adipose depots combined, WT = wild-type and 5αR1-KO = 5α-reductase 







Figure 3.2  Plasma glucose levels during a glucose tolerance test 
Basally, fasting plasma glucose concentrations were not different between WT (solid) and 
5αR1-KO (chequered) mice in both males (black, A) and females (grey, B). Following 
glucose injection, there were no genotype differences in plasma glucose concentrations for 
either of the two sexes (C).  However, there was an overall sex effect whereby plasma 
glucose was higher in males vs. females (C, p<0.001).  Post-hoc testing showed significantly 
higher plasma glucose in 5αR1-KO males (black dashed) vs. 5αR1-KO females (grey 
dashed) at 15 and 60 mins post-glucose injection (C, p<0.05).  Data are mean ± SEM for 
n=19-20 per group. Comparisons were made by Student‘s unpaired t-test or 2-way ANOVA 
for repeated measures with Bonferroni post-hoc tests where appropriate and # = p<0.05 for 
the effects of sex.  Mice were aged 6 months. WT = wild-type and 5αR1-KO = 5α-reductase 





3.3.2.2 Plasma insulin 
Male 5αR1-KO mice had significantly higher fasting insulin levels basally compared 
to control (Figure 3.3, A, p<0.05), whilst female 5αR1-KO mice also showed a trend 
towards higher fasting plasma insulin concentrations vs. WT (Figure 3.3, B, p = 
0.053).  Overall, male mice had higher fasting plasma insulin vs. female mice (Figure 
3.3, C, p<0.0001).  The release of insulin following a single glucose bolus was 
measured to determine glucose tolerance.  Female 5αR1-KO mice produced 
significantly higher concentrations of insulin compared to WT (Figure 3.3, C, 
p<0.05).  Male 5αR1-KO mice also trended towards an exaggerated insulin response 
vs. WT controls following glucose injection (Figure 3.4, C, p = 0.069).  Sex 
differences were apparent such that male mice reached a higher insulin peak vs. 
females for the WT genotype (Figure 3.3, C, p<0.05) and insulin was higher across 
all time-points in males vs. females for the 5αR1-KO genotype (Figure 3.3, C, 
p<0.001-p<0.01). 
 
3.3.3 Insulin tolerance 
The clearance of glucose from the circulation following a single insulin bolus was 
measured to determine insulin sensitivity.  Figure 3.4, A and B show fasting glucose 
levels prior to the insulin injection.  Male 5αR1-KO mice had significantly higher 
fasting glucose concentrations vs. WT (Figure 3.4, A, p<0.05) whereas female mice 
did not (Figure 3.4, B).  Following injection with exogenous insulin, there were no 
differences in glucose clearance from the circulation between WT and 5αR1-KO 
mice of either sex (Figure 3.4, C). 
 
3.3.4 Liver triglyceride content 
Liver triglycerides were not different between male WT and 5αR1-KO mice (Figure 
3.5, A).  Female, 5αR1-KO mice had significantly higher liver triglyceride content 






Figure 3.3 Plasma insulin levels during a glucose tolerance test 
Fasting insulin levels were increased in male 5αR1-KO mice (chequered black, A, p<0.05), 
whilst there was a trend towards elevated fasting plasma insulin in female 5αR1-KO mice 
(chequered grey, B, p=0.053,) all vs. WT controls (solid fill). Additionally, male mice had 
higher basal insulin levels in plasma (p<0.0001). C shows the insulin release curve in 
response to a single glucose injection for both male and female mice. Compared to WT 
littermates (solid lines), 5αR1-KO mice (hatched lines) of both sexes released significantly 
more insulin during the glucose tolerance test and reached a higher peak at 15 mins, with a 
slower recovery back to basal levels (p=0.069 for males and p<0.05 for females).  Moreover, 
there were strong sex differences. Between WT animals, male mice reached a higher insulin 
peak at 15 mins vs. females (C, p<0.05) but between 5αR1-KO mice, the male insulin 
response to the glucose bolus was greatly exaggerated compared to female genotype 
equivalents across all time points (C, p<0.001–p<0.01). Points/bars are mean ± SEM for 
n=19-20 mice/group. Comparisons were made by 2-way ANOVA for repeated measures 
with Bonferroni post-hoc tests where appropriate, or Student‘s unpaired t-test. * = p<0.05 
and ** = p<0.01 and determines genotype differences. # = p<0.05, ## = p<0.001 and ### = 
p<0.001 for the determination of sex differences with matched genotype.  Mice were 6 





Figure 3.4 Plasma glucose levels during an insulin tolerance test 
Male (black), 5αR1-KO mice had significantly elevated fasting plasma glucose levels vs. 
WT (A, p<0.05), but fasting plasma glucose was not different in female (grey), 5αR1-KO 
mice vs. WT littermates (B). Glucose clearance over time following a single bolus injection 
of exogenous insulin was not different in 5αR1-KO mice compared to WT littermates 
(dashed and solid lines respectively; C).  This was true for both sexes.  Points/bars are mean 
± SEM for n=19-20 mice/group.  Comparisons were made by 2-way ANOVA for repeated 
measures, or Student‘s unpaired t-test where * = p<0.05.  Mice were aged 6 months. WT = 






Figure 3.5  Liver triglyceride levels 
Panel A shows liver triglyceride content was not different between male WT and 5αR1-KO 
mice.  However, female 5αR1-KO mice had a significantly higher concentration of 
triglycerides in the liver in comparison to WT littermates (B).  Data are mean ± SEM for 
n=19-20 mice/group.  Comparisons were made by Student‘s unpaired t-test where * = 






3.3.5 Food intake 
Male 5αR1-KO mice consumed significantly more calories cumulatively vs. WT 
littermates (Figure 3.6, A, p<0.01) and also on an average weekly basis (Figure 3.6, 
B, p<0.001).  Female WT and 5αR1-KO mice consumed the same number of calories 
cumulatively (Figure 3.6, C) and when expressed as an average weekly consumption 
(Figure 3.6, D). 
 
3.3.6 Abundance of transcripts for appetite-regulating genes  
There was reduced expression of orexigenic peptides in 5αR1-KO mice. Npy mRNA 
was significantly downregulated in the hypothalamus in 5αR1-KO mice vs. WT 
(Figure 3.7, A, p<0.05).  There was also a trend towards lower Agrp mRNA 
expression in 5αR1-KO animals compared to control (Figure 3.7, B, p = 0.09). 
Anorexigenic peptides, Cartpt1/2 and Mc3r were not different between genotypes 
(Figure 3.7, C-E) but a trend was found in Mc4r transcripts being more abundant in 
the hypothalamus in 5αR1-KO mice vs. WT controls (Figure 3.7, F, p = 0.067). 
 
In females, expression levels of all the hypothalamic neuropeptides quantified were 
not different in 5αR1-KO mice compared to WT (Figure 3.8, A-E).   
 
3.3.7 Plasma leptin levels 
There was no effect of genotype on plasma leptin levels (Figure 3.9) however female 







Figure 3.6  Cumulative and weekly calorific consumption 
Male 5αR1-KO mice (black dashed) consumed significantly more calories vs. WT (solid 
black) both cumulatively (A, p<0.01) and as a weekly average intake (B, p<0.001). 
However, in females there was no difference in cumulative (C) or weekly (D) calorific 
consumption between 5αR1-KO (grey dashed) and WT (solid grey) mice.  Data are mean ± 
SEM for n=4-5/group.  Comparisons were made by 2-way ANOVA for repeated measures 
with Bonferroni post-hoc tests or Student‘s unpaired t-test where appropriate. *** = 







Figure 3.7  Expression of transcripts for hypothalamic neuropeptides involved in 
appetite regulation (Males) 
Npy mRNA abundance was downregulated in 5αR1-KO mice (checkered) vs. WT (solid, A, 
p<0.05).  There was a trend towards lower Agrp mRNA expression in 5αR1-KO animals 
compared to control (B, p=0.009). Cartpt1/2 and Mc3r were not different between genotypes 
(C-E) but trends were found in Mc4r transcripts being upregulated in 5αR1-KO mice vs. WT 
controls (F, p=0.067).  Data are mean ± SEM for n=19-20/group and comparisons were 
made by Student‘s unpaired t-test where * = p<0.05. Mice were aged 7 months. WT = wild-
type, 5αR1-KO = 5α-reductase type 1 knock-out, Npy = neuropeptide-Y, Agrp = agouti-
related protein, Cartpt1/2= cocaine-amphetamine-regulated transcript variants 1 and 2 








Figure 3.8  Expression of transcripts for hypothalamic neuropeptides involved in 
appetite regulation (Females) 
In female mice, abundance of transcripts for hypothalamic feeding-regulatory peptides was 
not different between WT and 5αR1-KO mice. Data are mean ± SEM for n=11/group.  
Comparisons were made by Student‘s unpaired t-test. Mice were aged 7 months. WT = wild-
type, 5αR1-KO = 5α-reductase type 1 knock-out, Npy = neuropeptide-Y, Agrp = agouti-
related protein, Cartpt1/2= cocaine-amphetamine-regulated transcript variants 1 and 2 







Figure 3.9  Plasma leptin levels 
There was no difference between plasma leptin levels in WT and 5αR1-KO mice of either 
sex.  However, female mice overall had lower circulating leptin in comparison to male mice 
(p<0.01).  Bars represent mean measurements ± SEM for n = 18-20/group.  Comparisons 
were made by 2-way ANOVA with Bonferroni post-hoc testing. Mice were aged 7 months. 





3.4 Results 2 – Behavioural profiling 
3.4.1 Free ambulatory, nocturnal activity 
Frames with infrared detectors in the X and Y plane were used to measure free 
ambulatory activity overnight.  Figure 3.10 shows total activity (A), distance 
travelled (B), active time (C) and inactive time (B) over a 14.5 hour period.  No 
differences were found in nocturnal activity between WT and 5αR1-KO mice, 
neither males nor females.  However, it does seem that male mice overall are more 
active than females with males having a trend to increased total activity levels 
(Figure 3.10, A, p = 0.07) and time spent active (Figure 3.10, C, p<0.05) whilst 
females spent more time in an inactive state (Figure 3.10, D, p<0.05).  There was no 
difference in distance travelled between the sexes (Figure 3.10, B). 
 
3.4.2 Assessing anxiety using the elevated plus maze (EPM) 
Mice were tested in the EPM to determine any differences in anxiety levels between 
genotypes.  Across all experimental groups, mice spent most time in the closed zone, 
less in the centre and less still in the open zone, which is the most anxiogenic area of 
the maze (Figure 3.11, males A, females, D, both p<0.001).  In both sexes the overall 
distribution of time spent between the three zones differed by between WT and 
5αR1-KO mice (Figure 3.11, A for males, D for females, both p<0.01).  In males, 
there were no differences in % time spent in the open or centre zones but 5αR1-KO 
mice did spend less time in the closed zone vs. WT controls (Figure 3.11, A, 
p<0.05).  Moreover, male 5αR1-KO mice made significantly more entries into the 
open, most anxiogenic zone compared to WT (Figure 3.11, B, p<0.05).  Similar to 
males, female 5αR1-KO mice spent less time in the closed zone of the EPM vs. WT 
(Figure 3.11, D, p<0.05) but the % time spent in each of the other two zones did not 
differ between genotypes.  The number of entries into the open, anxiogenic zone was 
comparable between female WT and 5αR1-KO mice (Figure 3.11, E).  The distance 






Figure 3.10  Nocturnal locomotor activity 
No differences were seen in the total locomotor activity, distance travelled or active and 
inactive times of WT and 5αR1-KO mice (A-D, respectively).  Irrespective of genotype 
however, it was apparent that male mice overall were significantly more nocturnally active 
than females (p=0.07 for total activity, A; p<0.05 for active time, C; p<0.05 for inactive 
time, D) although there was no difference in distance travelled (B).  Bars are mean ± SEM 
for n=19-20 mice/group.  Comparisons were made by 2-way ANOVA with Bonferroni post-
hoc tests.  Mice were aged ~ 6 months at the time of testing. WT = wild-type and 5αR1-KO 






Figure 3.11  Anxiety-like behaviour in the elevated plus maze (EPM) 
As expected, mice spent most time in the closed zones, less in the centre and least in the 
open, anxiogenic area (A and D, p<0.001). Both male (black, A) and female (grey, D) 5αR1-
KO mice (chequered) spent significantly less time in the closed zone vs. WT (solid, p<0.05). 
There was no genotype difference in the time spent in each of the other zones (A and D). 
Male 5αR1-KO mice made more entries into the most anxiogenic zone when compared to 
WT littermate controls (B, p<0.05) but there was no such effect in female animals (E). There 
was no genotype difference in distance travelled during testing for either males (C) or 
females (F). Bars are mean ± SEM for n=19-20 mice/group. Comparisons were made by 2-
way ANOVA with Bonferroni post-hoc testing where appropriate or Student‘s unpaired t-
test where * = p<0.05. Mice were aged 6 months at the time of testing. WT = wild-type and 






In this study and in keeping with previous cohorts, female, but not male, 5αR1-KO 
mice were heavier than their WT controls.  5R1-KO mice of both sexes were less 
glucose tolerant, but retained similar sensitivity to an insulin challenge.  These 
changes were associated with hyperphagia in males, but not reduced locomotion in 
either sex. 
 
Male 5αR1-KO mice were hyperinsulinaemic and hyperglycaemic in the fasting state 
i.e. demonstrating progression towards type II diabetes.  In the early development of 
type II diabetes mellitus, insulin secretion from pancreatic β-cells is increased 
leading to hyperinsulinaemia as a compensatory reaction to reduced insulin 
sensitivity in tissues (Carlsson et al. 1996; Pettersson et al. 2012), but here this was 
insufficient to control fasting glucose.  Male 5R1-KO mice were also intolerant of 
exogenous glucose with a trend towards exaggerated endogenous insulin response in 
order to maintain the same plasma glucose concentrations as those seen in WT 
controls.  However, male 5αR1-KO mice were tolerant of an exogenous insulin 
challenge and glucose levels were decreased similar to WT across the time-course 
indicating insulin sensitivity was intact.  Female 5αR1-KO mice demonstrated 
features of the Metabolic Syndrome, namely obesity, fasting hyperinsulinaemia and 
hepatic steatosis.  Also indicative of insulin insensitivity was the markedly increased 
plasma concentrations of insulin released by female 5αR1-KO mice to counteract a 
single fixed dose of glucose i.e. following glucose injection mice lacking 5αR1 
elicited an exaggerated and prolonged insulin response to counteract 
hyperglycaemia.  However, although plasma insulin was raised in 5αR1-KO mice, 
glucose levels over the time course of the test were maintained similar to WT in 
5αR1-KO mice (both sexes). 
 
It is possible that a lack of glucocorticoid inactivation in 5R1-KO mice could 
promote insulin resistance.  ADX in mice genetically predisposed to obesity (ob/ob 
mice) improves hyperinsulinaemia (Naeser 1974; Turkenkopf et al. 1991), reduces 
blood glucose levels (Bray et al. 1979) and also abolishes hyperphagia (Vander Tuig 




glucocorticoid signalling, have an improved metabolic profile with improved glucose 
tolerance (Morton et al. 2001) and are resistant to the hyperglycaemic effects of 
chronic high-fat feeding (Kotelevtsev et al. 1997).  Conversely, and similar to our 
findings, at least in male 5αR1-KO mice, dexamethasone-treated mice have impaired 
glucose tolerance combined with hyperphagia and weight gain (Gounarides et al. 
2008).  However, it is possible that there may be a significant contribution towards 
the above phenotypes from altered androgen metabolism (most notably in males) in 
5αR1-KO mice. 
 
Male animals overall presented with higher insulin levels, both fasting and 
stimulated, compared to females.  Females (both pre-menopausal humans and 
animals) are known to be somewhat protected from metabolic disease.  For example, 
female DIO mice are protected from features of the metabolic syndrome such as 
hyperinsulinaemia and islet hypertrophy (Pettersson et al. 2012).  Also reported in 
the same study, male DIO mice had low-grade systemic inflammation.  Again this 
phenotype was absent in female mice possibly due to increased anti-inflammatory 
mediators such as Foxp3+ T lymphocytes (Treg) in adipose tissue in response to 
obesity (Pettersson et al. 2012).   
 
Androgen deprivation therapy in men with prostate cancer very often results in the 
development of metabolic syndrome (Braga-Basaria et al. 2006; Smith et al. 2008) 
with the risk of new onset type II diabetes mellitus being greatly increased due to 
hyperinsulinaemia (Dockery et al. 2003; Basaria et al. 2006; Smith et al. 2006; 
Kintzel et al. 2008; Smith et al. 2008; Alibhai et al. 2009; Keating et al. 2010).  A 
lack of contribution from 5αR1 in 5αDHT formation may lead to reduced 
concentrations of this most potent androgen in male 5αR1-KO mice which may also 
predispose male mice to a poorer metabolic outlook, albeit in the absence of obesity, 
compared to females. 
 
Despite not gaining extra weight, hyperphagia was observed in male 5R1-KO mice 
whilst calorific consumption of the obesity-prone female 5αR1-KO mice was 




Secretion of glucocorticoids from the adrenal cortex is under tight control of the 
HPA axis via the release of neuropeptides including CRH which acts upon CRHR1 
in the pituitary.  Based on preliminary data from previous studies (Livingstone et al. 
2014b) which showed attenuated HPA axis stress responses, it is proposed that key 
mediators which drive the HPA axis such as CRH and its main receptor CRHR-1 
may be downregulated as a result of greater glucocorticoid negative feedback in 
5αR1-KO mice (HPA axis regulation explored in greater detail in Chapter 4).  
Indeed, alterations in Crh and Crhr-1 expression within selected brain areas have 
been shown to affect appetite, feeding behaviours and food intake (Krahn et al. 1986; 
Menzaghi et al. 1994; Contarino et al. 2000; Challis et al. 2004).  CRH has 
anorexigenic properties implicated in the regulation of feeding indices by mediating 
suppression of appetite and thus food intake (Krahn et al. 1986).  Therefore we may 
expect the attenuation of anorexigenic influences such as CRH to alter feeding 
circuits in the brain resulting in increased food intake and an accompanying weight 
gain in 5αR1-KO mice. 
 
The hypothalamus is a key regulator of food intake and its neurones express 
orexigenic and anorexigenic peptides which can either promote or repress feeding 
respectively, in conjunction with signals from other peptides including leptin and 
insulin.  Important orexigenic peptides of interest include NPY and AgRP which are 
expressed in the arcuate nucleus of the hypothalamus (Gehlert 1999; Smith et al. 
2008; Valassi et al. 2008) whilst anorexigenic peptides such as CART1 and 2 and 
CRH are expressed in the PVN (Schwartz et al. 2000; Valassi et al. 2008).  The 
abundance of transcripts for Cart is reduced in mice genetically predisposed to 
developing obesity (ob/ob mice; Vettor et al. 2002).  Moreover, in rats, central 
administration of CART reduces food intake in a dose-dependent manner (Vettor et 
al. 2002). Glucocorticoids usually stimulate NPY release together with AgRP i.e. 
Npy and AgRP mRNA is reduced by ADX but stimulated by corticosterone 
replacement (Akabayashi et al. 1994; Savontaus et al. 2002). 
 
However, in the male 5R1-KO mice, hyperphagia was not driven by increased 




hypothalamus are less abundant in male 5αR1-KO mice vs. WT whilst transcripts for 
Mc4r were upregulated.  Thus altered balance i.e. a net decrease and increase in 
orexigenic and anorexigenic drive respectively, may be a compensatory change in 
hypothalamic neuropeptide expression to maintain body weight in spite of 
hyperphagia, thus allowing weight maintenance.  Moreover, insulin receptors are 
found in the arcuate nucleus of the hypothalamus and central administration of 
insulin decreases Npy expression (Marks et al. 1990; Sipols et al. 1995; Benoit et al. 
2002) but increases the hyperpolarisation of AgRP neurones in the arcuate nucleus 
(Claret et al. 2007; Konner et al. 2007).  Therefore in male 5αR1-KO mice, higher 
fasting insulin may have a modulatory effect on appetite and neuropeptide expression 
in the hypothalamus over and above that of glucocorticoids.  
 
Circulating leptin did not differ between genotypes, although it may have been 
anticipated to rise with increased body weight and fat mass in female 5αR1-KO 
mice.  Glucocorticoids up-regulate leptin signalling (Cavagnini et al. 2000); 
dexamethasone treatment leads to hyperleptinaemia in both lean and obese states 
(Miell et al. 1996; Dagogo-Jack et al. 1997).  Furthermore, androgens have a 
suppressive effect on leptin (Wabitsch et al. 1997; Machinal et al. 1999).  Female 
mice overall had reduced plasma leptin levels compared to males.  This may have 
been due to reduced 5αDHT production and removal of the androgen-induced leptin 
suppressive effects thus causing leptin to rise, more so in male animals.  However, 
since this effect was seen in both WT and 5αR1-KO animals, this theory does not 
explain the sex-differences seen in plasma leptin concentrations.  Moreover, 
increased adipose mass in female 5αR1-KO mice may have been expected to result 
in increased leptin levels compared to WT, which was not seen here. 
 
In normophagic female 5αR1-KO mice, the abundance of mRNA coding for 
hypothalamic neuropeptides key in the regulation of food intake was not different 
compared to controls.  Thus, excess weight gain in the female 5R1-KO mice could 
not be explained by increased feeding drive or calorific consumption.  Therefore it 




increased in male 5αR1-KO mice who were hyperphagic whilst maintaining a 
normal body weight. 
 
Locomotor activity was tested in two settings; once in the home cage overnight and 
the other during moderately stressful behavioural testing.  No differences were seen 
in the nocturnal locomotor activity between genotypes.  There was however, a sex 
difference whereby, although both sexes covered a similar distance in their home 
cage over the 14 hr test period, male animals overall spent more time ―active‖ than 
females.  There are very few publications which outline the normal nocturnal 
activities of male and female mice whilst undisturbed in their home cage.  Chen et al. 
showed that male mice had reduced locomotor activity compared to female mice 
overall (Chen et al. 2000) which is the opposite of our data.  There are also numerous 
reports of increased activity in female over male animals during stressful or anxiety-
inducing test scenarios such as the open field test (Archer 1975; Norton 1977; 
Dulawa et al. 1999) which are also usually performed during the day.  However, in 
the setting of behavioural testing in the EPM, physical activity (i.e. distance 
travelled) did not differ by either genotype or sex in the study here presented.  This 
also highlights the differences between testing in the basal non-stressed state vs. 
testing under mild-moderate stress since a sex difference was found under basal 
testing only. 
 
There are reports of glucocorticoid-mediated effects on physical activity such as 
locomotion.  11βHSD1-KO mice showed 38% greater locomotor activity compared 
to WT controls (Yau et al. 2003).  Following, knock down of 11βHSD1, mice fed a 
high-fat diet increased their energy expenditure (determined by both respiratory 
quotients and locomotor activity) which protected them from obesity as well as 
insulin resistance (Li et al. 2012).  It was proposed therefore that mice with reduced 
tissue glucocorticoid clearance may gain more weight due to increased sedentariness 
and this may be more marked in female mice, rendering them susceptible to weight 
gain.  However, there were no differences in the physical activity of WT and 5αR1-




females respectively) is not the underlying mechanism of weight gain (females) or 
weight maintenance (males) in 5αR1-KO mice  
 
Specifically to address why female mice were observed to lose weight upon social 
isolation, behaviour of these mice was first studied in the basal "unstressed" state i.e. 
in group housing.  Propensity to anxiety was assessed in the EPM; a well-regarded 
testing system designed for the assessment of relative anxiety levels.  This test works 
by exploiting the rodents naturally curiosity and exploratory behaviour in a novel 
environment.  However, since the testing apparatus is raised high off the ground and 
comprises two opposing arms which have no side walls and thus represent a rather 
vulnerable space for the mouse, the time the mouse spends in or how often it enters 
this ―open zone‖, can be regarded as a reflection of how anxious (or ―un-anxious‖) a 
given animal is. 
 
Where the glucocorticoid load is increased within tissues (be it from endogenous or 
exogenous sources) or in the case of syndromes related to metabolic disturbances 
such as Cushing‘s and its associated conditions (obesity, type II diabetes mellitus 
etc.), there are often correlations with CNS disorders (Haskett 1985; Hudson et al. 
1987; Dorn et al. 1995; Kelly 1996).  Moreover, prolonged elevation of endogenous 
glucocorticoids resulting from HPA axis dysregulation can be psychologically 
detrimental (Raber 1998; Raber et al. 2000).  Anxiety is one affective disorder which 
is highly documented to occur in instances where there is concomitant glucocorticoid 
excess. 
 
Here, the time spent in each of the three maze zones (closed, open and centre) 
followed an expected pattern such that across all experimental groups the closed 
zone was most occupied during testing and the least time was spent exploring the 
open, most anxiogenic zone.  A moderate amount of time was spent in the centre 
decision-making area where the animal is generally still (due to the size of the area) 
or can be seen stretching its head curiously into the open zone.  The time spent in the 
closed zone was reduced in both male and female 5αR1-KO mice but the time in 




more entries into the open zone during testing; an observation which was not 
significant in females.  These data argue against our hypothesis that 5αR1-KO mice, 
and in particular female mice, would be more anxious; the 5R1-KO mice are if 
anything subtly less anxious, at least when group-housed.  However, this original 
hypothesis was based on observations made during single-housing so it is still 
possible that an increased tendency towards anxiety may be revealed upon social 
isolation (explored further in Chapter 5). 
 
The anxiolytic effect in males is somewhat more profound than in females, since 
5αR1-KO mice did make more entries into the open zone.  A potential explanation 
may have existed in the reduced generation of 5DHT, but this is unlikely given 
literature supporting the anxiolytic properties of 5DHT (Edinger et al. 2005).  Men 
are less likely to develop mood disorders and depression compared to women (Earls 
1987; Kessler 2003).  Moreover, male, testosterone-treated rats displayed signs of 
reduced anxiety vs. vehicle-treated animals when tested in the EPM (Bitran et al. 
1993).  In females, 5-reduced progesterone metabolites (ALLO) may serve as a 
natural anxiolytic steroid, which would be deficient in the 5R1-KOs, in particular 
the female mice.  However, this scenario would predict greater anxiety in female 
5αR1-KOs, again contrary to our findings.  It would indeed be insightful to measure 
not only basal corticosterone, testosterone, 5αDHT and ALLO levels in plasma but 
also to measure the concentrations of these steroid hormones within the brain.  This 
can be done via microdialysis which allows the sampling of substances from the 
interstitial fluid in live, freely-moving animals at any time of the day (for review see 
(Chefer et al. 2009)).  The microdialysis technique has been used to sample a wide 
number of substances (Chefer et al. 2009) and its effectiveness has been 
demonstrated in the brain (Hallstrom et al. 1989) and in the mouse (Rollema et al. 
1989).  It would be valuable both to future studies and to the interpretation of the 
existing study presented here to establish whether 5αR1-KO mice have significant 
accumulation of glucocorticoids specifically within the brain and whether the 
concentration of other 5αR1 substrates such as testosterone and progesterone and 





In this chapter, sex has been shown to have a modulatory effect on the presentation 
of the 5αR1-KO phenotype.  Metabolically, male 5αR1-KO mice were less well-off 
and although there was no considerable body weight difference they were 
hyperphagic, hyperglycaemic and hyperinsulinaemic.  Male 5αR1-KO mice also 
displayed reduced anxiety-like behaviour in the EPM.  Conversely, although female 
mice lacking 5αR1 were normophagic, they still gained more weight than WT 
controls on a normal chow diet suggesting the weight gain phenotype of 5αR1-KO 
mice is governed by something other than calorific consumption.  Nocturnal activity 
was not affected by genotype, although it would be useful to evaluate the basal 
metabolic rates of these animals in future studies by measuring their respiratory 
quotients and core body temperatures especially since 11βHSD1-KO mice have 
increased core temperatures (Morton et al. 2004). 
 
Some of the metabolic and behavioural changes described here commonly occur in 
instances where the concentration of glucocorticoids is raised excessively high and 
often for prolonged periods of time.  This can either be caused by or be a causal 
factor of HPA axis dysfunction where feedback on the axis is disrupted.  5αR1-KO 
mice were previously shown to have a dampened HPA axis response to acute stress 
possibly due to exaggerated negative feedback in the brain resulting from 5αR1 loss.  
The main aim of the following chapter was to elucidate the mechanisms which 








Chapter 4: The effects of 5R1 
disruption on pathways which 





Glucocorticoids play a regulatory role in many metabolic and homeostatic processes 
whilst also mediating the stress response (Munck et al. 1984).  The HPA axis is the 
main mechanism through which normal physiological concentrations of 
glucocorticoid hormones are maintained.  Activated by diurnal cues or stressors, the 
HPA axis mediates a cascade of neuroendocrine signals, ultimately leading to 
glucocorticoid release from the adrenals into the circulation.  Although beneficial in 
coping with stress short-term, the HPA axis response must be counter-regulated to 
prevent the deleterious effects of glucocorticoid excess.  This is achieved through 
negative feedback loops exerted by glucocorticoids themselves and mediated through 
GR and MR at various levels of the axis (hypothalamus [PVN] and anterior pituitary) 
but also in the hippocampus (Jacobson et al. 1991).  These feedback loops regulate 
glucocorticoid concentrations in the periphery and may also influence intracellular 
steroid concentrations.  In addition to central control of glucocorticoid concentrations 
by the HPA axis, availability of glucocorticoids to bind to GR can be influenced at a 
local level and in a tissue specific manner.  Within tissues such as the liver, adipose 
and brain, metabolic enzymes including 5αRs and 11βHSDs also influence local 
glucocorticoid levels.   
 
Disruption of enzymes such as 11HSD1 (which activates the inert 11-
dehydrocorticosterone into corticosterone) by genetic mutation (Kotelevtsev et al. 
1997; Harris et al. 2001) can critically influence GR signalling within tissues.  
Abnormal HPA axis control has been reported in 11HSD1-KO mice with elevated 
plasma corticosterone and ACTH levels basally and a prolonged corticosterone peak 
post-stress (Harris et al. 2001) implying increased HPA axis activity in response to 
enhanced glucocorticoid clearance within tissues.  11HSD1-KO mice also had 
hyperplasia of the adrenal glands which would facilitate increased glucocorticoid 
production in the absence of reduced active steroid exerting negative feedback upon 
the axis (Kotelevtsev et al. 1997).  These findings are clear evidence demonstrating 
that metabolic enzymes play an important role in regulating not only glucocorticoid 





Broadly, reduced 5αR1 activity in vivo may be expected to induce effects on HPA 
axis function which are opposite to those seen in mice with 11HSD1deficiency.  
5αR1-KO mice, with lesser ability to metabolise glucocorticoids and therefore 
potentially elevated glucocorticoid levels within tissues which express 5αR1, may 
therefore have increased negative feedback upon corticosteroid receptors involved in 
HPA axis regulation, facilitating reduced axial drive.  Indeed,  our group has shown 
previously that 5αR1-KO mice (both male and female) have normal circulating basal 
corticosterone levels and normal adrenal gland size and morphology but reduced 
HPA axis responsiveness (corticosterone) to acute stress (Figure 4.1; Livingstone et 
al. 2014b).  Furthermore, the 5αR isozymes show tissue-specific distribution 
patterns.  5αR1 predominates in the brain (Poletti et al. 1998) and is expressed at 
sites where it could influence the activity of the HPA axis including the anterior 
pituitary (Massa et al. 1972), hypothalamus and hippocampus in rats (Pelletier et al. 
1994) and the hypothalamus and pituitary in humans (Thigpen et al. 1993; Pelletier 
et al. 1994; Yokoi et al. 1996).  On the basis that 5αR1 is expressed in these brain 
areas (which also show high expression of corticosteroid receptors) and in higher  
abundance than 5αR2 (Lephart 1993; 1993; Thigpen et al. 1993; Lund et al. 2006), 
disruption of the axis in 5αR1-KOs is not surprising, with anticipated local increases 
in corticosterone, increasing negative HPA feedback mediated by GR and MR. 
 
4.1.1 Hypothesis 
Disruption of 5αR1 will result in altered expression of genes related to regulation of 
the HPA axis with a view to increased negative feedback. 
 
4.1.2 Aims 
 To investigate and determine the central mechanisms which underpin 








Figure 4.1  Attenuated acute HPA axis responses in 5αR1-KO mice. 
Lines show both male and female 5αR1-KO mice (dashed and dotted lines respectively) 
reach a significantly lower plasma [corticosterone] peak following a 15 min restraint stress 
compared to WT male and female mice (solid and dashed/dotted lines respectively).  Values 
are mean ± SEM for n = 6/group.  Data were compared by 2-way repeated measures 
ANOVA where ** = p<0.01.  Mice used were of the mixed genetic strain and were 6 months 





4.2.1 HPA axial control and the mechanism underlying 
reduced stress responses in 5αR1-KO mice 
4.2.1.1 Experimental outline 
Some of the mice studied here were previously used in the acute restraint 
experiments (cohort 1, Figure 4.1) and the second cohort was that studied in Chapter 
3 (cohort 2).  All animals were 6 month old WT and 5αR1-KO mice (male and 
female).  Archived tissues from cohort 1 were used to quantify the abundance of 
transcripts for GR and MR in the hippocampus, Crh in the PVN and GR, MR and 
Crhr-1 in the pituitary.  Tissues from cohort 2 were used to quantify the abundance 
of transcripts for GR and Avp in the hypothalamus. 
 
4.2.1.2 Animal maintenance  
All mice were obtained from an in-house breeding colony (2.6.1) and maintained 
under group-housing as described (2.6.3 ).  The mice studied were as follows: 
 
 6-month old, male, WT and 5αR1-KO mice (cohort 1, n = 9; cohort 2, n = 13) 
 6-month old, female WT and 5αR1-KO mice (cohort 1, n = 9; cohort 2, n = 13) 
 
4.2.1.3 Terminal procedures and tissue collection 
Section 2.6.10 described the method used for tissue collection following cull by 
decapitation (between 0800 and 1000 hrs). Whole brains were collected and snap 
frozen on dry ice. 
 
4.2.1.4 In situ hybridisation 
The abundance of GR and MR transcripts in hippocampal regions (DG and CA1-4) 
and Crh mRNA in the PVN of the hypothalamus from WT and 5αR1-KO mice were 





4.2.1.5 Quantification of mRNA expression by qPCR 
Total RNAs were extracted from the hypothalami and pituitaries (2.3.1.4) of WT and 
5αR1-KO mice and used to synthesise first strand cDNA by RT (2.3.2).  qPCR was 
performed (2.3.4) to quantify the expression of transcripts for GR and Avp in the 
hypothalamus and GR, MR and Crhr-1 in the pituitary of which the abundance was 
expressed as a ratio to appropriate reference genes which are highlighted in Table 4.1 
below.  These reference genes or combinations of genes were selected due to their 
lack of variation between groups (male and female, WT and 5αR1-KO mice). 
 
4.2.2 Statistical analyses 
All data are presented as mean ± SEM and were compared using either Student‘s 






Table 4.1  Reference genes used for qPCR in pituitary and hypothalamus 
P value indicates the results of a 2-way ANOVA between male and female, WT and 
5αR1-KO mice or Student‘s unpaired t-test between WT and 5αR1-KO mice within each 
of the two sexes.  The reference gene (or combination or reference genes) with the 
highest p value and thus least variation between experimental groups was selected. G = 
genotype and S = sex. 
Tissue Reference gene(s) p Value 


















4.3.1 Body and tissue weights 
Body and tissue weights for male and female, 5αR1-KO mice (cohort 1) are shown 
in Table 4.2 below. There were no significant differences in either body, adrenal or 
thymus weights between male WT and 5αR1-KO mice.  In female animals, body 
weight was significantly increased in 5αR1-KO mice vs. WT (p<0.05) but there was 
no difference in either adrenal or thymus weight (Table 4.2). 
 
For cohort 2 (as shown in Chapter 3 section 3.3.1) there were no body weight 
differences between male WT and 5αR1-KO mice at cull (Table 3.2).  In female 
mice from cohort 2, 5αR1-KO mice were consistently heavier over time (p<0.01) and 
also at cull compared to WT littermates (Figure 3.1, p<0.01). 
 
4.3.2 Alterations in pathways which regulate the HPA axis 
4.3.2.1 Corticosteroid receptors 
GR and MR mRNA expression was quantified in hippocampal and pituitary tissue of 
both male and female, WT and 5αR1-KO mice.  GR and MR transcripts were present 
across all hippocampal regions in both male and female mice (Figure 4.2, panels A-
D).  The abundance of MR but not GR transcripts in the brains of male 5αR1-KO 
mice was significantly reduced overall (p<0.01) reaching significance through post-
hoc testing in the CA2 region (p<0.05) compared to WT (Figure 4.2; B).  There was 
no difference in either GR or MR expression in hippocampus from female 5αR1-KO 
mice (Figure 4.2, C and D respectively).  In the pituitary, GR expression levels were 
upregulated in male but not female 5αR1-KO mice vs. WT (Figure 4.2; E; p<0.05).  
GR mRNA was more abundant in female vs. male pituitary in WT mice only (Figure 
4.2; E; p<0.01).  The opposite was true for MR transcripts, which were significantly 
more abundant in male vs. female mice overall, irrespective of genotype (Figure 4.2; 
F; p<0.05).  The abundance of transcripts for GR was quantified in the hypothalami 
of male and female, WT and 5αR1-KO mice.  In male mice, transcripts for GR were 
upregulated in 5αR1-KO mice vs. WT (Figure 4.2; G, p<0.05).  The opposite was 
seen in females where there was a trend towards reduced hypothalamic GR transcript 








26.3 ± 0.85 27.0 ± 0.76 >0.05 
Adrenal 
(mg) 
2.2 ± 0.08 2.1 ± 0.09 >0.05 
Thymus 
(mg) 




28.91 ± 0.99 32.27 ± 4.42 <0.05 
Adrenal 
(mg) 
2.26 ± 0.25 2.32 ± 0.24 >0.05 
Thymus 
(mg) 
34.07 ± 2.26 34.87 ± 2.91 >0.05 
 
Table 4.2  Body and tissue weights  
Body, adrenal and thymus weights were not different in male 5αR1-KO mice compared to 
WT.  Female 5αR1-KO mice were significantly heavier than WT (p<0.05) but adrenal and 
thymus weights were not different between genotypes.  Data are mean ± SEM for n = 12-
16/group and comparisons were made by unpaired Student‘s t-test. WT = wild-type and 
5αR1-KO = 5α-reductase type 1 knock-out. (Livingstone et al. 2014b for male mice and 




4.3.2.2 Crh and Avp neuropeptides and the CRH receptor (Crhr-1)  
The abundances of transcripts for Crh and Crhr-1 were quantified in the PVN of the 
hypothalamus, and the pituitary gland respectively, of WT and 5αR1-KO mice.  
Figure 4.3 A shows representative microscopy images for Crh expression in the PVN 
of female WT (A i) and 5αR1-KO (A ii) mice.  Figure 4.3, A iii demonstrates the 
lack of silver grains in a PVN section from a WT mouse using the sense probe which 
eliminates the possibility of non-specific binding.  The abundance of transcripts for 
Crh was reduced in 5αR1-KO mice vs. WT overall (Figure 4.3; B; p<0.01) with 
significance from post-hoc testing in both male (p<0.05) and female (p<0.01) mice.  
Sexually dimorphic alterations (effect of sex = p<0.05) in the abundance of Crhr-1 
transcripts between genotypes were found whereby, in females only, global KO of 
5αR1 reduced Crhr-1 mRNA abundance in the pituitary compared to WT (Figure 
4.3; C; p<0.05). 
 
The abundance of Avp transcripts was quantified in the hypothalami of male and 
female, WT and 5αR1-KO mice.  In male mice, there was a trend for reduced levels 
of Avp mRNA in 5αR1-KO mice vs. WT (Figure 4.3; D; p = 0.063) but Avp mRNA 






Figure 4.2  GR and MR mRNA expression profile in brain regions contributing to feedback control of the hypothalamic-pituitary adrenal axis 
GR and MR mRNA abundance was quantified in pyramidal neurons of the DG, CA1, CA2, CA3 and CA4 regions of the hippocampus.  Both GR (A, C) and MR (B, D) 
were expressed across all hippocampal regions in both male (A, B, black) and female (C, D, grey) mice. MR mRNA transcripts were less abundant in male 5αR1-KO 
mice (chequered) vs. WT (solid) overall (p<0.01), reaching statistical significance in the CA2 region (5αR1-KO; B; p<0.05) compared to WT.  In the pituitary (E-F), 
GR expression was upregulated in male 5αR1-KO mice compared to WT, whilst there was a 2 fold increase in GR mRNA abundance in female WT mice compared to 
WT males (E).  MR transcripts were more abundant in male pituitary than female (F, p<0.05), without any difference between genotypes (F).  In the hypothalamus, the 
abundance of GR transcripts was increased in male 5αR1-KO mice (G, p<0.05) but decreased in female 5αR1-KOs (H, trend, p=0.064) vs. WT controls of the same 
sex.  Bars are mean ± SEM for n=9-13/group. *=p<0.05 and **=p<0.01 determined by 2-way ANOVA with Fisher‘s LSD post-hoc tests where appropriate or 
Student‘s unpaired t-test.  GR = glucocorticoid receptor, MR = mineralocorticoid receptor, DG = dentate gyrus, CA1-CA4 = cornu ammonis regions 1-4, WT = wild-





Figure 4.3  Crh, Crhr-1and Avp mRNA expression in brain regions involved in 
regulating the hypothalamic pituitary adrenal axis  
A shows representative images of Crh transcript abundance in the PVN of the hypothalamus 
measured as silver grains for WT (i) and 5αR1-KO (ii) mice using the anti-sense probe and lack of 
silver grains in a WT animal using the control sense probe (iii). The abundance of Crh mRNA in the 
PVN (B) was reduced overall in mice with disruption of 5R1 (chequered, p<0.01), and reached 
significance in both male (black, p<0.05) and female (grey, p<0.01) mice compared to WT (solid). 
There was an overall effect of sex on Crhr-1 expression in the pituitary (C, p<0.05) but transcripts 
were only downregulated in female 5αR1-KO mice vs. WT (C, p<0.05) with no significant genotype 
differences in males. Hypothalamic Avp mRNA expression levels were downregulated in male mice 
lacking 5αR1 vs. WT (D; p=0.063) but there was no such difference in female animals (E). Values are 
mean ± SEM for n=9-13/group. Significance was determined by 2-way ANOVA with Fisher‘s LSD 
post-hoc tests where appropriate or Student‘s unpaired t-test. *=p<0.05, **=p<0.01.  . WT = wild-
type, 5αR1-KO = 5α-reductase type 1 knock-out, Crh = corticotrophin-releasing hormone, Crhr-1 = 







We hypothesised that global knock-out of 5αR1 would impair corticosteroid 
metabolism thereby leading to increased glucocorticoid levels at sites of the 
expression of the enzyme.  Previously in our group, it has been shown that basal 
corticosterone levels at the diurnal nadir were comparable between WT and 5αR1-
KO mice (Livingstone et al. 2014b).  This is not surprising as the HPA axis readily 
balances production with clearance to maintain a basal set-point.  However, genotype 
differences were revealed upon manipulation of the system, with 5αR1-KO mice 
having a dampened HPA axis response to acute restraint stress compared to WT 
controls (Livingstone et al. 2014b).  One explanation is that corticosteroid levels 
locally within brain structures known to mediate negative feedback on the axis, such 
as the hippocampus, hypothalamus and pituitary, may be increased and responsible 
for this dampened stress response.  Impaired clearance of glucocorticoids in the 
periphery would also be expected to exert an additional level of negative feedback on 
the axis. 
 
In the brain, glucocorticoids mediate their effects via both GR (low affinity) and MR 
(high affinity) which are expressed abundantly in the limbic system (such as the 
hippocampus) linking with their role in HPA axis regulation as well as in emotion 
and cognition (Ahima et al. 1990); discussed further in Chapter 5).  Glucocorticoids 
themselves are able to influence and directly alter corticosteroid receptor expression 
in the brain and other target tissues (Sapolsky et al. 1984; McEwan et al. 1986).  
Normal function of the HPA axis is maintained by the activity of GR and MR via 
negative feedback loops which can increase or decrease glucocorticoid release from 
the adrenals to maintain levels at an optimum physiological set-point.  Generally 
speaking, MR is less abundant than GR in the CNS (Keller-Wood et al. 2006) but 
also has a 10-fold higher affinity for glucocorticoids; for this reason it is thought that 
MR is mostly occupied at basal glucocorticoid levels during the circadian nadir (Reul 
et al. 1985; Oitzl et al. 1995).  The interpretation of this is that MR is responsible for 
the maintenance of basal HPA activity as well as the initiation of the stress response, 
and that GR modulates responses to stress-induced increases in [corticosterone] to 




al. 2005).  However, more recently it has been proposed that GR and MR work 
synergistically during the circadian peak (and post-stress) to shut off corticosterone 
release, or further still that MR alone can mediate negative feedback on the axis 
during periods when corticosterone concentrations are high (Bradbury et al. 1994; 
Reul et al. 1997; Arvat et al. 2001; Wellhoener et al. 2004).  Given that the majority 
of authors believe both receptors play a part in HPA axis regulation, it has been 
proposed that changes in the equilibrium between GR- and MR-mediated responses 
in the CNS may underlie dysregulation of the axis (de Kloet 1991).  Altered MR:GR 
balance could either exacerbate or inhibit an appropriate HPA axial response to stress 
as well as delayed recovery, predicting vulnerability to stress (Sapolsky 2000), as 
well as rendering individuals susceptible to metabolic disease and affective disorders 
(de Kloet 1991).  
 
In vivo, daily infusion of exogenous glucocorticoids over several days results in 
reduced function of the HPA axis at a basal level (Akana et al. 1997).  We proposed 
that attenuated HPA axis responsiveness to stress in the 5αR1-KO model may be due 
to glucocorticoid excess altering the balance of corticosteroid receptor expression as 
has been discussed before for similar models (de Kloet 1991; Sapolsky 2000). 
 
In the current study, corticosteroid receptor expression followed an expected pattern 
across all hippocampal regions whereby expression of both GR and MR increased 
from the DG across to CA1 and CA2, and was lower in CA3 and CA4 (Sousa et al. 
1989; Morimoto et al. 1996; Usuku et al. 2005; Nishi et al. 2007).  To first address 
the male phenotype, transcripts for GR were unchanged between genotypes in the 
hippocampus but were more abundant in the hypothalamus and pituitary of 5αR1-
KO mice vs. WT.  Deletion of forebrain GR has been shown to induce an 
exaggerated corticosterone efflux under stressful conditions (Boyle et al. 2005; 
Boyle et al. 2006) suggesting GR is crucial in eliciting negative feedback to control 
corticosterone levels both during and post-stress.  Increased GR in male 5αR1-KO 
mice is therefore in keeping with attenuated corticosterone release upon stress.  
Furthermore, it is encouraging to also compare these data with that from mice with 




have increased HPA activation due to loss of inhibition (Ridder et al. 2005; Harris et 
al. 2013).  However, whether changes in GR in 5R1-KO mice are due to locally 
elevated glucocorticoid levels is less clear, given that many reports suggest ADX 
results in GR upregulation (which is reversible upon glucocorticoid replacement), 
whilst high glucocorticoids downregulate the receptor (Burnstein et al. 1992; Joels et 
al. 1994).  Moreover increased central glucocorticoid levels might be anticipated to 
invoke suppression of basal circulating corticosterone; a phenotype which was not 
seen in 5αR1-KO mice. 
 
5αR1 is abundant in the hypothalamus (Campbell et al. 1989; Pelletier et al. 1994) 
and pituitary (Massa et al. 1972; Yokoi et al. 1996) and although the hippocampus is 
key in HPA axial control (Fendler et al. 1961; Knigge 1961; Feldman et al. 1980; 
Wilson et al. 1980) it is possible that 5αR1 expression in the hippocampus is low 
(Pelletier et al. 1994), however, the expression pattern for 5αR1 in the brain 
(particularly in mice) is not well documented.  If 5αR1 is indeed underrepresented in 
the hippocampus compared to the hypothalamus and pituitary, 5αR1-KO may be 
expected to induce less of an effect upon corticosteroid receptor mRNA expression 
in this brain region compared to others.  This may explain the region-specific 
upregulation of GR mRNA abundance in male 5αR1-KO mice, especially since the 
lower affinity GR is only occupied when corticosterone levels are high.  Moreover, 
circulating glucocorticoids have been shown to have more potent regulatory effects 
upon hippocampal MR expression compared to that of GR (Herman et al. 1993). 
 
MR over-expression studies have also shown an effect on HPA axis activity whereby 
increased MR specifically in the forebrain resulted in reduced corticosterone 
responses to acute restraint stress (Rozeboom et al. 2007).  ADX animals (whose 
circulating corticosterone is essentially removed), show hippocampal upregulation of 
MR mRNA (Vazquez et al. 1993).  In male mice lacking 5αR1, MR transcripts were 
downregulated in the hippocampus (possibly reflecting auto-regulation) but were 
unchanged in the pituitary.  MR binds corticosterone with a much greater affinity 
than GR and therefore may be more sensitive to smaller changes in clearance of the 




corticosterone may be elevated due to local loss of 5αR1, thus leading to 
overstimulation and desensitisation of MR ultimately resulting in downregulation of 
the receptor.  Reports from Karst et al. suggest MR is primarily involved in initiating 
the HPA axis cascade whilst GR is responsible for mediating negative feedback upon 
the axis (Karst et al. 2005).  Thus by physiologically lowering MR- and increasing 
GR expression within brain regions, the net effect would be reduced HPA axis 
activity to prevent further glucocorticoid production in 5αR1-KO mice.  These 
mechanisms would apply both basally to maintain physiologically optimal 
corticosterone levels in spite of reduced clearance and also during acute periods of 
stress where animals would be unable to reach corticosterone peaks comparable to 
WT and would dampen down their response more rapidly. 
 
The literature surrounding auto-regulation of GR and MR by ligand concentration is 
conflicting. Some reports suggest reduced hippocampal GR following ADX (Sheng 
et al. 2003) whilst others found no evidence at all for ADX-induced changes in 
corticosteroid receptor expression in the brain (Chao et al. 1989).  Although, in 
agreement with reduced GR after ADX, GR is downregulated in the hypothalamus in 
11βHSD1-KO mice (Harris et al. 2001).  Models of glucocorticoid excess such as 
obese Zucker rats with elevated corticosterone levels, had normal GR but decreased 
MR expression in the hippocampus (Mattsson et al. 2003) as was seen in the current 
study in 5αR1-KO mice.  There are also regional variations in GR and MR 
autoregulation for example, ADX has no effect on GR mRNA content in the 
hypothalamus (Peiffer et al. 1991) or MR expression in the neocortex (Herman et al. 
1993); conflicting with the upregulation seen in the hippocampus.  Indeed our data 
goes against the classical concept that ligand excess locally leads to desensitisation 
and downregulation of its receptor.  Instead we propose that increased GR-mediated 
negative feedback in the hypothalamus and pituitary could be an attempt to counter 
reduced peripheral glucocorticoid clearance and maintain normal corticosterone 
levels basally in plasma.  Additionally it could be that glucocorticoids are not 
sufficiently increased centrally in 5αR1-KO mice to induce receptor downregulation, 




Corticosterone concentrations in the brain have been quantified in a separate cohort 
of animals, the results of which are discussed in Chapter 5. 
 
As well as corticosteroid receptors, neuropeptides such as CRH, described as ―the 
link between hormonal-, metabolic- and behavioural responses to stress‖ (Kovács 
2013) play an important role in maintaining adequate HPA axis function.  CRH is 
synthesised and secreted into the hypothalamic-pituitary portal system by 
parvocellular neurons in the PVN (Owens et al. 1991).  This process is necessary for 
normal activation of the HPA axis to elicit an hormonal response to stress (Owens et 
al. 1991).  Several days of corticosterone treatment inhibited HPA responsiveness to 
acute stress (Wilkinson et al. 1981; Scribner et al. 1993) possibly due to increased 
negative feedback upon the axis; a process which most likely occurs at the level of 
the pituitary (ACTH) and the hypothalamus (CRH; Dallman et al. 1985).  The 
attenuated stress response in 5R1-KO mice is consistent with impaired central CRH 
signalling.  Indeed, male 5αR1-KO mice have reduced mRNA for Crh in the PVN 
but Crhr-1 is unchanged in abundance.  Reduced stimulation of the anterior pituitary 
by Crh may therefore result in reduced forward drive towards corticosterone 
production by the adrenals, protecting from excessive glucocorticoid production. 
 
The CRH-KO model has provided a useful tool with which to investigate the 
involvement of CRH in HPA axis responses to stress.  Several authors have 
demonstrated attenuated stress responses in these animals. For example, Makino et 
al. report blunted pituitary-adrenocortical responses via reduced plasma 
[corticosterone] vs. controls following restraint stress (Makino et al. 2005). Other 
authors also report limited increases in corticosterone secretion in response to both 
psychological (restraint) as well as physiological (insulin-induced hypoglycaemia) 
stressors in CRH-KO mice (Muglia et al. 1995; Jeong et al. 1999; Jacobson et al. 
2000).  Similarly, CRHR1-KO mice had severely blunted corticosterone responses 
although female mutant mice maintained a rudimentary corticosterone response to 





AVP alone has a weak effect on ACTH secretion but released concomitantly with 
CRH from the PVN of the hypothalamus, AVP interacts with CRH to potentiate 
ACTH secretion from the anterior pituitary; promoting glucocorticoid release from 
the adrenals (Lamberts et al. 1984).  CRH-producing neurons in the PVN co-express 
AVP, however, AVP levels are usually low basally and are dependent on the relative 
stress levels experienced by an organism (Williamson et al. 2005).  For example, 
AVP synthesis is upregulated in response to chronic stress and also following ADX 
(Whitnall 1988; 1993).  This is suggestive of a modulatory role for AVP whereby 
glucocorticoid levels are sustained by prolonged ACTH release which would 
otherwise be inhibited by negative feedback loops (Williamson et al. 2005).  Here 
Avp mRNA was reduced similarly to Crh which, along with altered corticosteroid 
receptor expression, may be a driver in reduced HPA axis responses to acute stress in 
at least in male 5αR1-KO mice. 
 
In support of the data here presented, endogenous glucocorticoids, dexamethasone 
treatment and stress are all known to reduce Crh expression in vivo; likely mediated 
by GR (Jingami et al. 1985; Beyer et al. 1988; Boyle et al. 2006; Sharma et al. 
2013).  Glucocorticoids (and stress) also attenuate Crhr-1 expression (Makino et al. 
1995) and activation of corticosteroid receptors suppresses both the synthesis and 
release of AVP as well as CRH from the PVN (de Kloet et al. 1998).  
Dexamethasone treatment reduces AVP concentrations in hypophyseal portal plasma 
(Fink et al. 1988).  Conversely, and in support of our findings, hypophyseal portal 
plasma AVP and CRH as well as transcripts for Crh in the PVN are increased 
following ADX (Fink et al. 1988; Luo et al. 1995).  Taken together, reduced Crh, 
Crhr-1 and Avp in the HPA axis system supports the model of glucocorticoid excess 
within tissues resulting in enhanced negative feedback mediated mainly by GR in 
male 5αR1-KO mice. 
 
5αR1 metabolises not only glucocorticoids but also other A-ring steroids including 
sex hormones such as testosterone and progesterone and unsurprisingly we have 
found strong sexual dimorphism in gene expression phenotypes throughout this study 




KO mice.  In females, no genotype difference was found in corticosteroid receptor 
expression in the hippocampus.  However, female mice expressed transcripts for MR 
at lower levels than males in the pituitary, whilst GR mRNA transcripts were more 
abundant in the female pituitary vs. the male in WT animals only.  This sexually 
dimorphic pattern of reduced MR and increased GR in females was reminiscent of 
the differences between the 5αR1-KO males vs. WT mice.  Therefore it is possible 
that the pattern of changes in GR and MR are related to the low androgen state, either 
demonstrated by female mice or by mice lacking 5R1 who are potentially deficient 
in 5αDHT in the brain.  Possibly the smaller change in 5DHT concentrations in 
female 5R1-KO mice rather than male 5R1-KOs (due to lower testosterone in 
females) may explain the lack of alteration in receptor levels. 
 
Despite similar changes in MR and GR transcripts, the gender differences in other 
aspects of the HPA axis were opposite in female mice vs. males when compared with 
5R1-KO males vs. WT.  For example, in the hypothalamus GR was upregulated 
and down regulated in male and female 5αR1-KO mice respectively vs. WT mice of 
the same gender.  Female mice have higher [corticosterone] than males, both basally 
and post-stress, as demonstrated by a number of authors (Critchlow et al. 1963; 
Dallman et al. 1987; Vamvakopoulos et al. 1994), and as has been seen previously in 
our lab when quantifying basal and stressed corticosterone (Livingstone et al. 
unpublished).  The low MR, high GR theory proposed by Karst et al. in male mice 
(Karst et al. 2005) for maintaining HPA activity in spite of 5αR1 loss does not fit 
with corticosteroid expression patterns and physiology in females.  However, 
downregulation of MR in the female hypothalamus suggests female 5αR1-KO mice 
may be more sensitive to reduced glucocorticoid clearance given their basal set-point 
is already increased relative to male animals.  The female 5αR1-KO data does fit 
with the classical receptor downregulation theory in response to high ligand 
concentrations, suggesting local glucocorticoids are increased at least in the female 
5αR1-KO hypothalamus. 
 
Close inter-relationships exist between the HPA and the hypothalamic-pituitary-




disruption of HPG function including the synthesis and release of sex steroids (Rivier 
et al. 1991; Tilbrook et al. 2000) but sex steroids induce reciprocal actions back upon 
the HPA axis.  Oestrogens and androgens (both substrates for 5αR1) act upon several 
levels of the HPA axis including CRH and AVP synthesis in the PVN, stress-induced 
ACTH release and ultimately corticosteroid synthesis (Dallman et al. 2002).  In 
addition to their effects on feed-forward components of the HPA axis, sex steroids 
are also implicated in the regulation of the negative feedback loops mediated by 
glucocorticoids (Young 1996).  The majority of studies which investigate HPA 
function are performed using male animals with the assumption that their sex steroid 
profile provides greater stability compared to females.  However, testosterone levels 
(also metabolised by 5αR1) vary with the circadian rhythm and are also dependent 
upon age, social status and reproductive experience (Bartke et al. 1973; Sencar-
Cupovic et al. 1976; Kalra et al. 1977; Simpkins et al. 1981; Winters et al. 1991; 
Seeman et al. 2001; Viau 2002).  In vivo, testosterone has been shown to attenuate 
the HPA axis stress response (Williamson et al. 2005) whilst in females ovariectomy 
leads to attenuated HPA axis responses but oestradiol replacement may induce HPA 
axis stimulation (Lesniewska et al. 1990; Norman et al. 1992).  Since 5R1-KO 
mice may have low 5DHT and higher oestradiol levels (Mahendroo et al. 1999), it 
is unlikely that changes in sex steroids underpin the attenuated HPA axis. 
 
This thesis demonstrates that both male and female WT animals show equivalent 
abundance of transcripts for Crh and Crhr-1.  Tissues from female animals lacking 
5αR1 have a down-regulation of mRNA for Crh and a corresponding decrease in 
transcripts for its main receptor (Crhr-1) in the brain (PVN of the hypothalamus).  
Similar to males, it is thought this reduced Crh and Crhr-1 in females may result in 
response to raised availability of corticosterone and therefore more negative 
feedback on axial drive.  Thus less Crh and reduced availability of its primary 
receptor would further reduce drive upon the axis and therefore glucocorticoid 
production by the adrenals.  Here, observations that transcripts for Crh (both males 
and females) and Crhr-1 (females only) are reduced, align well with a dampening of 
the HPA axis response.  However, although there were trends for reduced Avp in the 




again is evidence that there are profound differences between HPA axis function and 
regulation between male and female animals. 
 
To conclude, the results presented here are consistent with glucocorticoid excess 
within the brain.  5αR1-KO mice show altered corticosteroid receptor expression 
balance in brain areas involved in HPA axis regulation.  It may be that an imbalance 
between GR and MR along with loss of the potentiating effects of Avp in males and 
reduced Crh and Crhr-1 in females are the underlying mechanisms responsible for 
dampened responses to acute stress in 5αR1-KO mice. 
 
Changes in neuropeptide levels are not only associated with HPA axis dysfunction 
but also with the aetiology of anxiety and feeding disorders.  In light of reduced 
expression of neuropeptides such as Crh in 5αR1-KO mice, and previous 
observations of maladaptation to social isolation, the  behaviour of 5R1-KO mice 









Chapter 5: Behavioural alterations 
in 5αR1-KO mice housed under the 






In previous experiments performed by other research group members, obesity in 
female 5αR1-KO mice was modulated by environmental factors.  Specifically, 
female 5αR1-KO mice only developed obesity and fatty liver when housed together 
in groups.  This phenotype was reversible within 4 weeks of separation and single 
housing during which the extra weight was lost and 5αR1-KO mice became 
metabolically comparable to WT controls i.e. weighed the same and were no longer 
hyperinsulinaemic.  It was therefore hypothesised that female 5αR1-KO mice were 
predisposed to anxiety and susceptible to environmental stress induced by social 
isolation, although the mechanism of weight loss was unknown.  Certainly, a large 
number of studies have shown social isolation of rodents to be detrimental, 
modifying locomotor activity, thermoregulation, learning, memory and anxiety 
(Juraska et al. 1984; Bates et al. 1985; Jones et al. 1991; Hellemans et al. 2004; 
Võikar et al. 2005). 
 
Social isolation-induced changes involving peripheral, behavioural and 
neurochemical functions, have been identified leading to the theory of ―isolation 
syndrome‖ in mice which is most-likely related to chronic stress (Valzelli 1973).  
Moreover, individual housing of rodents brings about pathophysiological changes 
such as impaired HPA axis and sympathetic nervous system responses (Pashko et al. 
1980; Kim et al. 1996) and altered emotional and cognitive behaviours (Valzelli 
1973; Guidotti et al. 2001; Võikar et al. 2005).  Given the metabolic phenotype is 
attenuated during isolation, the female 5αR1-KO mice may cope differently with 
chronically stressful conditions and adjust their food intake accordingly.  
Importantly, chow intake is usually decreased in rodents during periods of chronic 
stress (Dallman et al. 2001), which could lead to weight loss, and this can be 
modulated by glucocorticoids (Pralong et al. 1993; Alfarez et al. 2008).  Both female 
and male 5R1-KO mice showed reduced peak plasma corticosterone levels 
following restraint compared to WT littermates (Livingstone et al. 2014b for male 
mice and Livingstone et al. unpublished for female mice, as shown in Chapter 4), 
potentially rendering them less able to initiate an acute stress response.  In Chapter 3, 




5αR1-KO mice actually had reduced anxiety compared to controls.  However these 
experiments were performed under group-housing conditions and anxiety may be 
revealed upon social isolation. 
 
Deviations away from the optimal physiological levels of glucocorticoid hormones 
(be this stress-induced or as a result of ageing) are also believed to exacerbate or be 
causal of the reduced cognitive ability seen with increasing age (Kaye et al. 1987; 
Rybakowski et al. 1992; Yau et al. 1995; Gregus et al. 2005; Lai et al. 2007; 
Rozeboom et al. 2007; Holsboer et al. 2008).  Indeed any type of stress and 
prolonged exposure to stress-related hormones can induce neuronal atrophy and 
death implicated in stress-induced neuronal degeneration and cognitive impairments 
(Alleva et al. 1996; Aloe et al. 2002).  Dysfunction of the HPA axis has been 
reported in association with several mental disorders which are also characterised by 
cognitive disturbances e.g. major depressive disorder (Deuschle et al. 1997; 
Strickland et al. 2002; Bhagwagar et al. 2005; Burke et al. 2005; Vreeburg et al. 
2009).  In preclinical models, stressed, middle-aged mice with memory-impairments 
have a corresponding and dramatic increase in corticosterone levels within the 
hippocampus (Beracochea et al. 2011) whilst in humans, several investigations have 
shown that acute administration of glucocorticoids impairs long-term memory 
retrieval in healthy volunteers (Roozendaal 2002; Het et al. 2005; Buchanan 2007).  
However, a key feature of acute glucocorticoid effects on physiological functions 
(and importantly on cognition), is that there is a fine line between what constitutes 
beneficial or ―normal‖ and what constitutes excessive and detrimental, with 
glucocorticoids both facilitating and impairing memory and its consolidation 
dependent on their physiological concentration. 
 
The hippocampus; a key locus for cognition and neuroendocrine control, is 
especially sensitive to even small changes (both increases and decreases) in local 
glucocorticoid concentrations (McEwen 1999).  In aged humans and rodents, an 
association exists between chronic corticosterone excess, hippocampal atrophy and 
resulting cognitive decline (Kizaki et al. 1998; Lupien et al. 1998) and ADX with 




impairments (Landfield et al. 1978).  Altered glucocorticoid metabolism in the brain 
is sufficient to modify behaviour and cognitive ageing which is mediated mainly by 
the hippocampus.  Examples include work by Yau and colleagues showing mice null 
for 11βHSD1 are protected from age-related cognitive deficits mediated by the 
hippocampus via a switch from GR- to MR-mediated cognitive control (Yau et al. 
2001; Yau et al. 2007; Sooy et al. 2010; Yau et al. 2011).  Despite aged 11βHSD1-
KO mice having raised plasma corticosterone, intra-hippocampal corticosterone 
levels were markedly reduced (Yau et al. 2001).  This shows that not only are 
glucocorticoids mediating their effects on cognitive ability via the hippocampus 
itself, but also that local glucocorticoid levels within the brain (as determined by the 
activity of metabolic enzymes) can act independently from those circulating in the 
periphery.  In addition, the selective 11βHSD1 inhibitor UE1961 significantly 
improves spatial memory in aged mice (Sooy et al. 2010).  Work in humans has 
mirrored the cognitive effects of glucocorticoid excess seen in rodents (Keenan et al. 
1995; Kirschbaum et al. 1996; Naber et al. 1996; Comijs et al. 2010; Potvin et al. 
2013). 
 
In this study, loss of 5αR1 in vivo, potentially causing local glucocorticoid excess, 
may be expected to induce an effect on cognition opposite to that shown in 
11βHSD1-KO mice and mice treated with an 11βHSD1 inhibitor whereby learning 
and memory capabilities would be attenuated, especially in aged mice.  Outcomes of 
studying cognition in 5αR1-KO mice may be predicted to correspond to premature 
age-associated cognitive impairments shown in transgenic mice with forebrain-
specific 11βHSD1 overexpression, even though glucocorticoid levels in the 






Impaired glucocorticoid metabolism in the brain of 5αR1-KO mice leads to 
glucocorticoid excess which may be associated with anxiety and cognitive 
deficiencies; exaggerated by the stress of social isolation as well as ageing. 
 
5.1.2 Aims: 
 To determine if 5αR1-KO mice are predisposed to anxiety under the chronic 
stress of social isolation. 
 To investigate if 5R1-KO mice are more susceptible to cognitive 






5.2.1 Genetic background 
Studies described thus far have used 5αR1-KO mice on a mixed genetic background.  
Behavioral experiments can generate data which is highly variable between 
individual animals, therefore the existing mixed strain mice were back-crossed onto a 
C57Bl/6j background to reduced variance and therefore increase the power of the 
experiment.  Mice were backcrossed for 10 generations (i.e. until >99% congenic) 
before breeding the experimental animals studied here. 
 
5.2.2 Experimental outline 
Female, WT and 5αR1-KO mice were housed in groups from weaning until the age 
of 5 months when they were split into experimental housing (single cages or retained 
in groups of 4 animals/cage for 4 wks prior to initiation of a battery of behavioural 
investigations.  All mice were subject to anxiety testing in both the EPM (2.6.8.1.1) 
and OFT (2.6.8.1.2) and were further tested in the Y-maze (2.6.8.1.3) and Morris 
water-maze (2.6.8.2) which assesses learning and spatial memory abilities.  Mice 
were rehoused in groups at age 7.5 months, remaining so until aged (13-14 months) 
when they were again subjected to experimental housing in identical groups as 
before.  The behavioural experiments were repeated after 4 wks of experimental 
housing (14-15 months old).  Additionally, prior to cull, morning blood samples 
(0730 – 0830 hrs) were taken by tail nick to determine basal plasma corticosterone 
concentrations.  Mice were culled 2 wks after the last behavioural experiment took 
place.  Culling and tissue collection was carried out as described (2.6.10). 
 
5.2.3  Experimental animals 
Mice were obtained from an in-house breeding colony (2.6.1) and maintained as 
described (2.6.3).  Body weight and food consumption was measured weekly (2.6.4) 
encompassing the social isolation period or equivalent time for group-housed 





 WT mice housed in groups of 4 animals/cage. 
 WT mice housed singly. 
 5αR1-KO mice housed in groups of 4 animals/cage. 
 5αR1-KO mice housed singly. 
 
5.2.4 Assessment of HPA axis function 
5.2.4.1 Basal corticosterone levels 
Basal tail-blood samples were collected in the morning (2.6.5) from young mice pre-
and post-behavioural testing (3 days before testing began and 3 days after testing was 
complete).  Corticosterone was quantified in plasma using a radioimmuno assay 
(2.4.5).  Blood was also collected (2.6.5) from aged mice after further behavioural 
testing (3 days after the last behaviour test only).  Corticosterone was quantified in 
these plasma samples by ELISA (2.4.4.2); the change in assay type was due to loss 
of sensitivity of the RIA. 
 
5.2.4.2 Abundance of transcripts of interest by qPCR 
Snap frozen hypothalami and pituitaries from WT and 5αR1-KO mice were used to 
extract total RNAs (2.3.1.4) which were used as a template to synthesise first strand 
cDNA by RT (2.3.2).  qPCR was performed (2.3.4) to quantify the expression of 
transcripts for GR, MR and Crh in the hypothalamus and GR, MR and Crhr-1 in the 
pituitary, of WT and 5αR1-KO mice.  Abundance was expressed as a ratio to 
appropriate reference genes which are highlighted in Table 5.1 below.  Reference 
genes were selected due to lack of difference between experimental groups. 
 
5.2.5 Terminal procedures and tissue collection 
Section 2.6.10 described the method of tissue collection following cull by 
decapitation (between 0800 and 1000 hrs).  Tissues including brain, hypothalamus, 






Table 5.1  Reference genes used for qPCR analysis.  
Ppia was used as a reference for gene expression studies in both the hypothalamus 
and the pituitary.  P value indicates the results of a 2-way ANOVA between WT and 
5αR1-KO mice housed both singly and in groups for the specified reference gene, 
demonstrating no statistical differences with housing or between genotypes. 
G = genotype and H = housing. 
  
Tissue Reference Gene p Value 
Hypothalamus Cyclophilin A (Ppia) 
G H 
0.40 0.92 






5.2.6 Quantification of brain corticosterone levels 
Steroids were extracted from half brains (halved in the sagittal plane) of aged WT 
and 5αR1-KO mice as described (2.5.1.2).  Corticosterone was quantified by LC-
MS/MS as described previously (2.5.2). 
 
5.2.7 Statistical analyses 
All data are presented as mean ± SEM and were compared using Student‘s unpaired 
t-test, 2-way ANOVA or 2-way repeated measures ANOVA with either Bonferroni 





5.3 Results 1 – metabolic profiling 
5.3.1 Body weight gain 
Figure 5.1 shows the weight gain for mice of both genotypes, without subdivision by 
housing.  Over the period of wks 4-20 when housed in groups, 5R1-KO mice 
weighed more than WT mice (Figure 5.1, p<0.0001).  Figure 5.2 (A-C) shows excess 
weight gain was attenuated during the period of experimental housing but more so in 
the singly-housed animals, which actually lost weight (more significant weight loss 
was seen in 5αRI-KO mice; see Figure 5.3 for Δ weight) thus there were no genotype 
differences in body weight between 20-30wks.  Once re-housed in groups at wk 30, 
overall 5R1-KO mice again became heavier until wk 53 (Figure 5.1, p<0.05).  
Again during the second period of experimental housing additional weight gain was 
attenuated in 5R1-KO mice who again became comparable to WT but under single-
housing only (Figure 5.2, C). 
 
Figure 5.3 highlights changes in weight at defined time-points with regards to the 
effects of single housing and other experimental interventions. The data was 
sectioned by housing to assess the effects of each intervention individually on weight 
gain.  At 4-20 wks, all animals were group-housed and 5αR1-KO mice gained more 
weight that WT (Figure 5.3, A, p = 0.051).  At the 20 wk point and for 4 wks 
thereafter, when half the cohort was separated into single-housing, group-housed 
mice continued to gain weight whilst singly-housed mice did not (Figure 5.3, A, 
p<0.001).  Moreover, between 20-24 wks there was a significant effect of genotype 
whereby singly-housed, 5αR1-KO mice lost more weight than WT (Figure 5.3, A, 
p<0.05).  Behavioral testing was carried out between 24-30 wks without any further 
effects on body weight gain.  Following this, all animals were returned to group-
housing from 30-53 wks old and gained weight but previously singly-housed animals 
gained significantly more (Figure 5.3, A, p<0.001); compensating for previous 
weight loss during social isolation.  Overall 5R1-KO mice gained more weight than 
WT mice during this period (Figure 5.1, p<0.05).  During further social isolation (53-
57 wks) all singly-housed mice lost weight whilst group-housed mice continued to 







Figure 5.1  Cumulative weight gain of ageing mice 
Graph shows weight gain over the 64 wk period for WT (black) and 5αR1-KO (grey) mice.  
Grey arrows represent the point at which half the animals were separated into single cages.  
During periods of group housing, 5R1-KO mice gained more weight than WT littermates 
(p<0.0001 for 4-20 wks and p<0.05 for 31-53 wks).  Each point represents a mean 
measurement ± SEM for n = 10-52/group.  Statistical differences were determined by 2-way 
ANOVA for repeated measures with Fisher‘s LSD post-hoc testing.  WT = wild-type and 






Figure 5.2  Cumulative weight gain under group- and single-housing 
A) shows weight gain over the 64 wk period for WT (black) and 5αR1-KO (grey) mice both group- (solid) and singly- (dashed) housed.  For clarity B) and C) show 
weight gain for group- and singly-housed mice alone, respectively.  Exaggerated weight gain in 5R1-KO mice was attenuated by single housing.  Grey arrows 
represent the point at which half the animals were separated out into single cages and the periods where behavioural testing took place are indicated on the graphs.  




Behavioral testing of aged mice induced weight loss in all experimental groups.  
Finally, from wks 62-64 when still half of the cohort remained in single-housing, 
there was a genotype trend for weight gain in previously socially isolated WT mice 
but 5αR1-KO mice previously housed singly did not put on weight (Figure 5.3, A, p 
= 0.09, int = p<0.05). 
 
5.3.2 Food intake 
In young animals, there were no genotype differences in calorific consumption in 
young animals (Figure 5.4, A), however, all animals housed in social isolation 
consumed significantly more calories compared to group-housed controls (Figure 
5.4, A, p<0.001).  Moreover, after ageing, 5αR1-KO mice consumed significantly 
less calories vs. WT (Figure 5.4, B, p<0.001); these measurements were only 
recorded for singly-housed mice. 
 
5.3.3 Tissue weights at cull 
Singly-housed mice had significantly heavier livers than those housed in groups 
(Table 5.2, p<0.05).  This group also had a marked decrease in the weight of the 
gonadal adipose pad compared to all group-housed mice (Table 5.2, p<0.05 and 
p<0.001 for absolute and body weight-corrected weight respectively).  There were no 






Figure 5.3  Effect of housing and behavioural testing on body weight 
At 4-20 wks, 5αR1-KO mice gained more weight vs. WT (p=0.051). At 20-24 wks, group-housed mice (solid) gained weight whilst singly-housed mice (chequered) 
did not (p<0.001) and singly-housed, 5αR1-KO mice (grey) lost weight vs. WT (black, p<0.05). When re-grouped (30-53 wks) all mice gained weight but previously 
singly-housed mice gained significantly more (p<0.001). During further social isolation (53-57 wks), all singly-housed mice lost weight whilst group-housed mice 
continued to gain weight (p<0.001). From wks 62-64 during experimental housing, there was a genotype trend and an interaction whereby socially isolated, WT mice 
gained weight and 5αR1-KO mice tended to gain less weight compared to genotype-matched, group-housed mice (p=0.09, int = p<0.05). Behavioural testing had no 
effect on weight when young but induced weight loss in all groups when mice were aged. Data are mean ± SEM for n = 15-17/group. Comparisons were made by 







Figure 5.4  Cumulative food intake for young and aged mice 
Panel A shows hyperphagia in young, singly-housed mice (both WT and 5αR1-KO; black 
dashed and grey dashed respectively), compared to all group-housed controls (solid black 
and solid grey for WT and 5αR1-KO respectively, p<0.001).  There was no difference 
between genotypes. When aged, singly-housed 5αR1-KO mice consumed significantly less 
food vs. WT controls (B, p<0.001).  Each point represents a mean measurement ± SEM for 
n = 8-17/group.  Comparisons were made by 2-way repeated measures ANOVA with 
Bonferroni post-hoc tests where appropriate. **=p<0.01 and ***=p<0.001 for housing 
effects in panel A and genotype effects in panel B. WT = wild-type and 5αR1-KO = 5α-





Body and Tissue Weights 
 
Group-Housed Singly-Housed p Value 




31.86±1.36 31.64±1.11 31.45±0.78 31.77±0.91 0.967 0.895 
Absolute Tissue Weight (mg) 
Liver 1194.56±54.57 1217.64±51.11 1358.48±44.21 1286.81±42.89 0.621 0.020 
Gonadal 
adipose 
1642.21±180.54 1753.54±164.92 1196.89±98.98 1325.26±134.51 0.425 0.005 
Tissue Weight/Body Weight (mg/g body weight) 
Liver 38.08±1.85 38.61±1.27 43.28±1.10 40.64±1.18 0.452 0.012 
Gonadal 
adipose 
49.42±3.45 54.51±3.87 37.20±2.46 40.70±3.14 0.196 0.0002 
 
Table 5.2  Body and tissue weights at cull 
Body weight was not different between groups at the time of cull.  Both liver and gonadal 
adipose weights were affected by housing but not genotype, whereby all singly-housed mice 
had significantly larger livers (p<0.05) and significantly less gonadal fat vs. group-housed 
animals (p<0.05 and p<0.001 for absolute and body weight-corrected weight respectively).  
Data are mean ± SEM and comparisons were made by 2-way ANOVA with Bonferroni post-
hoc testing for n=15-17/group.  Animals were aged 15 months. G = genotype, H = housing, 





5.4 Results 2 – Behavioural profiling 
5.4.1 Anxiety testing in YOUNG mice 
5.4.1.1  Elevated Plus Maze (EPM) 
5.4.1.1.1 Anxiogenic zone exploration 
An expected exploratory pattern was observed in the EPM whereby all mice spent 
the majority of the test time in the closed zone (~60%), roughly 25% of the time in 
the decision-making centre zone and only occasionally entered the open zone (~15% 
of the total test time; Figure 5.5).  However, both 5αR1-KO and WT littermates 
under each housing condition, spent an equal % of the total test time exploring the 
open, most-anxiogenic zone of the maze (Figure 5.5, A & B) and made a comparable 
number of entries into this zone (Figure 5.5, C & D). 
 
5.4.1.1.2 Locomotor activity 
There were no effects of either genotype or housing upon average speed, maximum 
speed or distance travelled during the EPM test time (Table 5.3). 
 
5.4.1.2 Open Field Test (OFT) 
5.4.1.2.1 Anxiogenic zone exploration 
In another common behavioural test designed for investigating anxiety, a similar 
pattern was seen.  Across all groups, animals spent the majority of the test time 
exploring the outer zone of the box (~80%) staying close to the walls for shelter, but 
would occasionally traverse the inner most anxiogenic zone to explore (~20% of the 
total test time).  WT and 5αR1-KO spent equal times exploring the inner zone 
whether housed in groups or in social isolation (Figure 5.5, E & F) and made a 
similar number of entries into this zone during the test (Figure 5.5, G & H). 
 
5.4.1.2.2 Locomotor activity 
There was a trend for 5αR1-KO mice to move with a greater maximum speed during 
testing compared to WT animals overall (Table 5.3, p = 0.065) but there was no 






Figure 5.5  Anxiety testing in young mice 
Graphs shown under EPM are representative of time spent in the closed, open and centre 
zones expressed as % of total test time for group- and singly-housed animals (A & B 
respectively). C & D show the number of entries into the open (anxiogenic) zone.  There 
were no differences between WT (solid) and 5αR1-KO (chequered) mice tested in the EPM 
under either housing condition.  Graphs under OFT represent the time (%) spent in each of 
the two zones (outer and inner) for group- and singly-housed mice, and the number of entries 
into the most anxiogenic, inner zone (E, F, G and H respectively). Data are mean 
measurements ± SEM for mice aged 6 months. n = 16-17/group and comparisons were made 
by 2-way ANOVA or Student‘s unpaired t-test.  EPM = elevated plus maze, OFT = open 






Table 5.3  Locomotor activity during anxiety testing in young mice 
During the EPM all mice covered an equal distance and at comparable speeds.  During the 
OFT, there was no effect of genotype or experimental housing on distance travelled or 
average speed.  However, under both housing conditions there was a trend for 5αR1-KO 
mice to reach a greater maximum speed during the OFT compared to WT animals overall (p 
= 0.065).  Data are mean ± SEM for mice aged 6 months. n = 16-17/group and comparisons 
were made by 2-way ANOVA with Bonferroni post-hoc tests where appropriate. EPM = 
elevated plus maze, OFT = open field test, WT = wild-type and 5αR1-KO = 5α-reductase 
type 1 knock-out, G = effect of genotype, H = effect of housing. 
  
Locomotor Activity Data for Young Mice 
Elevated Plus Maze (EPM) 
 
Group-Housed Singly-Housed p Value 
WT 5αR1-KO WT 5αR1-KO G H 
Distance 
(m) 
7.231±0.408 7.250±0.467 7.182±0.628 7.046±0.633 0.914 0.816 
   Ave speed     
(m/s) 
0.024±0.001 0.024±0.002 0.024±0.002 0.023±0.002 0.914 0.762 
   Max speed 
(m/s) 
0.217±0.020 0.271±0.035 0.210±0.019 0.259±0.059 0.159 0.802 
Open Field Test (OFT) 
 
Group-Housed Singly-Housed p Value 
WT 5αR1-KO WT 5αR1-KO G H 
Distance 
(m) 
17.979±1.528 17.372±1.703 15.703±0.971 17.286±1.341 0.731 0.407 
   Ave speed 
(m/s) 
0.060±0.005 0.058±0.006 0.052±0.003 0.058±0.004 0.721 0.407 
   Max speed 
(m/s) 




5.4.2 Anxiety testing in AGED mice 
5.4.2.1  Elevated Plus Maze (EPM) 
5.4.2.1.1 Anxiogenic zone exploration 
As was seen when the animals were tested at a young age, an expected pattern of 
exploration was observed where all mice spent the majority of the test time in the 
closed zone, less time in the centre and less still in the open zone.  However, this 
pattern was more marked in 5αR1-KO mice that were singly-housed.  Under single 
housing, 5αR1-KO mice spent significantly more time in the closed zone vs. WT 
(Figure 5.6, B, p<0.05).  This shift was accompanied by a corresponding decrease in 
the time spent in both the open and centre zones (Figure 5.6, B, both p<0.01).  
Moreover, singly-housed 5αR1-KO mice made less entries into the open zone 
compared to WT controls (Figure 5.6, D, p<0.05). 
 
5.4.2.1.2 Locomotor activity 
There were no differences in average speed, maximum speed or distance travelled 
between groups (Table 5.4). 
 
5.4.2.2 Open Field Test (OFT) 
5.4.2.2.1 Anxiogenic zone exploration 
After the period of ageing, animals re-tested in the OFT displayed a similar 
exploratory pattern whereby most time was spent in the outer zone of the box (~80-
90%) and less time in the inner, anxiogenic zone (~10-20% of the total test time; 
Figure 5.6, E & F).  There were no genotype differences and no effect of housing 
whereby all mice spent the same amount of time in the inner zone, and made the 
same number of entries into that zone (Figure 5.6, G & H). 
 
5.4.2.2.2 Locomotor activity 
Furthermore, although there were no effects of either experimental housing or 
genotype on average speed or distance travelled, there were trends (p = 0.0936 for 
genotype, p = 0.0621 for housing) for group-housed 5αR1-KO mice to reach a higher 







Figure 5.6  Anxiety testing in aged mice. 
Graphs shown represent time spent in the closed, open and centre zones for EPM (A & B) and in 
the inner and outer zones for OFT (E & F) for group- and singly-housed mice (upper & lower 
panels respectively). In the EPM, 5αR1-KO mice (chequered) spent most time in the closed 
(safe) zone vs. WT littermates (solid) suggesting a more anxious phenotype, but only when 
singly-housed (B). 5αR1-KO animals also made fewer entries into the anxiogenic (open) zone 
when singly- but not when group-housed (D & C respectively). There were no differences 
between genotypes in either time spent in each zone (E & F) or entries to the inner zone (G & H) 
for group- and singly-housed mice tested in the OFT. Bars represent mean measurements ± SEM 
for mice aged 6 months. n = 16-17/group and comparisons were made by 2-way ANOVA with 
Fisher‘s LSD post-hoc tests where appropriate or Student‘s unpaired t-test. * = p<0.05 and ** = 
p<0.01.  EPM = elevated plus maze, OFT = open field test, WT = wild-type and 5αR1-KO = 5α-





Table 5.4  Locomotor activity during anxiety testing in aged mice 
During the EPM all mice covered an equal distance and at comparable speeds when aged.  
During the OFT, there was no effect of genotype or experimental housing on distance 
travelled or average speed of travel.  However, there were trends for an effect of both 
genotype  and housing on maximum speed of travel and post-hoc tests revealed that under 
group-housing, 5αR1-KO mice reached a higher maximum speed than WT controls 
(p<0.05). Values are mean measurements ± SEM for mice aged 14-15 months. n = 16-
17/group and comparisons were made by 2-way ANOVA with Bonferroni post-hoc tests. 
EPM = elevated plus maze, OFT = open field test, WT = wild-type, 5αR1-KO = 5α-
reductase type 1 knock-out, G = effect of genotype, H = effect of housing. 
  
Locomotor Activity Data for Aged Mice 
Elevated Plus Maze (EPM) 
 
Group-Housed Singly-Housed p Value 
WT 5αR1-KO WT 5αR1-KO G H 
Distance 
(m) 
4.392±0.375 4.711±0.593 4.001±0.421 3.682±0.482 0.9996 0.1404 
   Ave Speed     
(m/s) 
0.015±0.001 0.016±0.002 0.013±0.001 0.012±0.002 0.9785 0.1383 
   Max Speed 
(m/s) 
0.171±0.009 0.166±0.006 0.177±0.006 0.161±0.006 0.1260 0.9500 
Open Field Test (OFT) 
 
Group-Housed Singly-Housed p Value 
WT 5αR1-KO WT 5αR1-KO G H 
Distance 
(m) 
10.833±0.860 13.045±1.029 11.751±1.108 11.724±1.759 0.3667 0.8677 
   Ave Speed 
(m/s) 
0.036±0.003 0.044±0.003 0.039±0.004 0.039±0.006 0.3644 0.8670 
   Max Speed 
(m/s) 




5.4.2.3 Effect of ageing on anxiety and locomotion 
There was an overall effect (trend) of genotype on Δ open arm entries between aged 
and young mice (Figure 5.7, A, p = 0.09).  Furthermore, singly-housed 5αR1-KO 
mice had a more pronounced decrease in open arm exploration (EPM) following 
ageing vs. group-housed animals of the same genotype (Figure 5.7, A, p<0.05).  
There was no effect of genotype or housing in the change in inner zone entries 
between aged and young mice tested in the OFT (Figure 5.7). 
 
Similarly, reduced locomotor activity in the EPM and OFT was observed when mice 
were tested after ageing (Figure 5.8; Δ distance travelled, Δ average speed and Δ 
maximum speed), with the exception of Δ maximum speed in the OFT for singly-
housed 5αR1-KO mice (Figure 5.8, F).  However, there were no statistical 






Figure 5.7  Change in anxiogenic behaviour between aged and young mice 
In the elevated plus maze, there was a trend towards an effect of genotype (p=0.09) and 
post=hoc testing showed singly-housed 5αR1-KO mice (chequered) had a significantly 
greater decline in open arm entries after ageing compared to group-housed genotype-
matched mice (A, p<0.05).  There were no differences in Δ inner zone entries for the open 
field test with ageing between any of the experimental groups.  Data are mean ± SEM for n = 
16-17/group.  Comparisons were made by 2-way ANOVA with Bonferroni post-hoc tests 
where appropriate. * = p<0.05. EPM = elevated plus maze, OFT = open field test, 






Figure 5.8  Change in locomotor activity during anxiety testing, calculated between aged and young mice 
In all groups, the negative values for Δ distance (A & D), Δ average speed (B & E) and Δ maximum speed (C & F) infer reduced locomotion between 
aged and young mice in terms of both distance and speed, with the exception of the Δ maximum speed for singly-housed 5αR1-KO mice in the OFT.  
There were no effects of genotype or housing. Data are mean ± SEM for n = 16-17/group and comparisons were made by 2-way ANOVA. EPM = 




5.4.3 Spatial learning and memory in YOUNG mice 
5.4.3.1 Y-maze  
5.4.3.1.1 Memory 
In the Y-maze, time spent in the novel arm during the retention phase was used as a 
measure of working memory.  When group-housed, there were no differences in 
novel arm exploration time between WT and 5αR1-KO mice after either the 1 min or 
2 hour ITI (Figure 5.9, A & B respectively; ITI = inter-trial interval).  All group-
housed mice explored the novel arm significantly more than chance (p<0.05).  Under 
single housing, 5αR1-KO mice had reduced novel arm exploration vs. WT following 
both the 1 min and 2 hour ITI (Figure 5.9, C & D, p<0.05).  However, singly-housed 
mice explored the novel arm significantly more than chance) only after the 1 min ITI 
(Figure 5.9, C, p<0.05).  Group- and singly-housed WT and 5αR1-KO mice made a 
similar number of entries into the novel arm following the 2 hour ITI, however, 
singly-housed mice made fewer entries vs. group-housed mice overall (Figure 5.9, E, 
p = 0.058). 
 
5.4.3.1.2 Locomotor activity 
During both the acquisition and retention phases of the 1 min ITI test, singly-housed 
mice travelled further (Figure 5.10, A and C respectively) and faster (Figure 5.10, B 
and D respectively) than group-housed mice overall (p<0.01).  There were no effects 
of genotype or housing during the acquisition or retention phases of the 2 hour ITI 
test (Figure 5.10, E-H). 
 
5.4.3.2 Water-maze 
Preparatory visual testing established that all animals were able to visually locate the 
platform in the absence of spatial cues.  In the water-maze spatial learning task, all 
animals were able to learn the escape task and find the location of the submerged 
platform during testing.  Daily training reduced the escape latencies of all mice over 
5 consecutive days (Figure 5.9, F) but there were no effects of genotype or housing 
on mean escape latencies of experimental groups (Figure 5.9, F).  There was also no 
difference in target quadrant swimming time during probe testing at 1 and 24 hours 





Figure 5.9  Y-maze and Morris water maze assessment of memory and learning capacity in young mice 
For Y-maze, histograms illustrate time spent in the novel arm as a measure of memory (A-D). There were no differences in novel arm exploration 
between WT (solid) and 5αR1-KO (chequered) mice housed in groups during either ITI test (A & B). Singly-housed, 5αR1-KO mice spent less time in 
the novel arm vs. WT controls, during both the 1 min (C) and 2 hour (D) ITI but the latter did not differ significantly from chance (33%). All animals 
made a comparable number of entries into the novel arm following the 2 hour ITI (E). In the water-maze, no statistical genotype or housing differences 
were found in either escape latencies (F) or in target quadrant swimming time (G). Data are mean ± SEM for 6 month old mice. n = 16-17/group and 
comparisons were made by Student‘s unpaired t-test, 2-way repeated measures ANOVA or 2-way ANOVA with Bonferroni post-hoc tests when 





Figure 5.10  Speed and distance travelled during the Y-maze in young mice 
During the acquisition and retention phases of the 1 min ITI, singly-housed mice travelled further (A & C respectively) and faster (B & D respectively) 
than group-housed mice overall (p<0.01).  During the 2 hour ITI there was no effect of either genotype or housing in both the acquisition and the 
retention phases (E-H).  Data are mean ± SEM for n = 16-17/group when mice were aged 6 months.  Comparisons were made by 2-way ANOVA with 





5.4.4 Spatial learning and memory in AGED mice 
5.4.4.1 Y-maze 
5.4.4.1.1 Memory 
Following the 1 min ITI, novel arm exploration was significantly greater than chance 
only in group-housed mice (Figure 5.11, A, p<0.05) and WT mice housed singly 
(Figure 5.11, B, p<0.05).  There were no differences in novel arm exploration time 
between WT and 5αR1-KO mice housed in groups following either the 1 min or 2 
hour ITI (Figure 5.11, A & C).  However, 5αR1-KO mice housed singly spent less 
time exploring the novel arm compared to WT littermates, but this was only seen 
during the 1 min ITI which did not differ from chance (Figure 5.11, B, p<0.05).  WT 
and 5αR1KO mice housed singly did not differ in their novel arm exploration times 
during the 2 hour ITI (Figure 5.11, D).  However, overall 5αR1-KO mice made 
significantly fewer entries into the novel arm vs. WT following the 2 hour ITI 
(Figure 5.11, E, p<0.05); a phenotype which was more marked in singly-housed 
mice.  
 
5.4.4.1.2 Locomotor activity 
An overall housing effect showed all singly-housed mice travelled further (Figure 
5.12, A and C) and faster (Figure 5.12, B and D) than group-housed mice during both 
1 min ITI phases (p<0.001).  During the retention phase there was an overall 
genotype effect on distance (C) and speed (D, Figure 5.12, p<0.05) and post-hoc tests 
revealed that 5αR1-KO mice travelled less distance (Figure 5.12, C, p<0.01) and 
slower (Figure 5.12, D, p<0.01) than WT mice when housed singly.  During the 2 
hour ITI acquisition phase, singly-housed mice covered less distance (E) and moved 
slower (F) compared to group-housed mice (Figure 5.12, E and F, p = 0.055).  
During the 2 hour ITI retention phase, there were trends towards a genotype effect 
for reduced distance and speed in 5αR1-KO mice vs. WT (Figure 5.12, G and H, p = 
0.07) and post-hoc testing showed reduced distance (Figure 5.12, G, p<0.01) and 





5.4.4.2 Water maze 
As with young mice, preparatory visual tests were done which ruled out visual 
deterioration with ageing.  All aged WT and 5αR1-KO mice were able to learn the 
location of the hidden platform equally well during training, as shown by a decrease 
in mean escape latencies for all groups over the 5 day training period (Figure 5.11, 
F).  However, on training day 1 5αR1-KO mice were slower to locate and escape 
onto the platform than WT overall (Figure 5.11, F, p<0.05) with no effect of housing.  
On all other training days, neither genotype nor housing had any effect on escape 
latency of aged mice.  Probe testing showed that all groups retained the platform 
location and spent equal time swimming in the target quadrant at both 1 and 24 hours 
since the last training trial (Figure 5.11, G). 
 
5.4.4.2.1 Effect of ageing 
Comparisons were then made between escape latencies of these animals when young 
and when they were re-tested at 14-15 months of age.  On day 1 of training, there 
was a trend towards a larger cognitive decline with ageing in 5αR1-KO mice overall 
(Figure 5.13, p = 0.078) with significance for WT vs. 5αR1-KO in group-housed 
mice (Figure 5.13, p<0.05) and WT vs. 5αR1-KO also for singly-housed mice 
(Figure 5.13, p<0.05).  After 5 days of training in the water maze, there was no 
difference in Δ escape latency from young to aged between any of the four groups 
(Figure 5.13).  These changes were not due to visual deterioration in the aged 






Figure 5.11  Y-maze and Morris water maze assessment of memory and learning capacity in aged mice 
Histograms show time spent in the Y-maze novel arm as a measure of memory (A-D). There were no differences in novel arm exploration between WT (solid) 
and 5αR1-KO (chequered) mice housed in groups during either ITI test (A & B). 5αR1-KO mice housed singly spent less time exploring the novel arm vs. WT, 
but only during the 1 min and not the 2 hour ITI (C & D respectively). In E, all 5αR1-KO mice made significantly fewer entries into the novel arm vs. WT 
during the 2 hour ITI (p<0.05). In the water-maze, 5αR1-KO mice had longer escape latencies overall vs. WT on Day 1 of training (F) but no statistical 
genotype or housing differences were found in target quadrant swimming time (G). Data are mean ± SEM for aged mice (14-15 months old) of n = 16-
17/group.  *=p<0.05 and comparisons were made by Student‘s unpaired t-test, 2-way repeated measures ANOVA or 2-way ANOVA with Bonferroni post-hoc 





Figure 5.12  Speed and distance travelled during the Y-maze for aged mice 
During the 1 min ITI, there was an overall effect of housing (p<0.001) such that all singly-housed mice travelled further (A & C) and faster (B & D) 
than group-housed mice.  Moreover, during the retention phase (C & D) there was an effect of genotype on both distance and speed (p<0.05) and 
singly-housed 5αR1-KO mice travelled less distance (C, p<0.01) and slower (D, p<0.01) that singly-housed WT mice.  During the 2 hour ITI, there was 
a similar overall effect of housing during the acquisition phase only (E & F, p = 0.055) but no genotype effect.  During the 2 hour ITI retention phase, 
there were trends towards a genotype effect (G & H, p = 0.07) and post-hoc testing showed reduced distance (G, p<0.01) and speed (H, p<0.01) in 
5αR1-KO vs. WT mice under single housing. Animals were 14-15 months old.  Data are mean ± SEM for n = 16-17/group.  Comparisons were made by 
2-way ANOVA with Bonferroni post-hoc tests where **=p<0.01. WT = wild-type, 5αR1-KO = 5α-reductase type 1 knock-out and ITI=Inter-trial-
interval. 
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Figure 5.13  Change in water-maze escape latency between aged and young mice 
Histograms represent the change in escape latencies between paired young and aged mice.  
On training day 1, there was a trend towards increased cognitive decline in 5αR1-KO mice 
overall (grey; p=0.078) with significance for WT vs. 5αR1-KO in group-housed mice (solid 
black and grey respectively, p<0.05) and WT vs. 5αR1-KO also for singly-housed mice 
(chequered black and grey respectively, p<0.05).  The change in escape latencies between 
young and aged mice on day 5 of training did not vary by either genotype or housing.  Bars 
represent mean measurements ± SEM for n = 16-17/group.  Statistical differences were 
determined by 2-way ANOVA followed by Bonferroni post-hoc tests where appropriate 
where *=p<0.05.  WT = wild-type and 5αR1-KO = 5α-reductase type 1 knock-out. 
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5.5 Results 3 – Characterisation of the HPA axis 
5.5.1 Basal plasma corticosterone 
5.5.1.1 YOUNG mice 
There was no difference in basal (AM) corticosterone levels between young WT and 
5αR1-KO female mice prior to experimental behavioural investigations (Figure 5.14, 
A).  Immediately following a battery of behavioural testing using 4 different 
experiments and 10 wks of experimental housing conditions, plasma corticosterone 
was measured once again.  There were no effects of either single-housing or 
behavioural testing on plasma corticosterone levels in young mice (Figure 5.14, B). 
 
5.5.1.2 AGED mice 
Post-behavioural testing and just prior to cull, 5αR1-KO mice overall showed a trend 
towards reduced plasma corticosterone levels compared to WT littermate controls 
(Figure 5.15, p = 0.06).  There was no effect of housing. 
 
5.5.2 Alterations in HPA regulatory pathways (AGED mice) 
5.5.2.1 Corticosteroid receptor expression 
In the hypothalamus, the abundance of transcripts for GR was dowregulated in 5αR1-
KO mice vs. WT under both housing conditions (Figure 5.16, A, p<0.05).  
Hypothalamic GR expression was upregulated in singly- vs. group-housed mice 
overall (Figure 5.16, A, p<0.001).  Similarly, the abundance of transcripts for MR in 
the hypothalamus was upregulated in singly- vs. group-housed mice overall (Figure 
5.16, B, p<0.01) with no additional effects of genotype. 
 
5.5.2.2 Crh and Crhr-1 in the hypothalamus and pituitary respectively 
There was no effect of genotype or housing on the abundance of transcripts for Crh 
in the hypothalamus (Figure 5.16, C).  However, Crhr-1 mRNA abundance in the 
pituitary was significantly upregulated in 5αR1-KO mice vs. WT overall (Figure 
5.16, F, p<0.05) with no additional effect of housing. 
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Figure 5.14  Plasma corticosterone levels at the diurnal nadir in young animals 
pre- and post-behavioural testing 
Basal plasma corticosterone levels in WT (solid fill) and 5αR1-KO (chequered) littermates 
did not differ prior to experimentation when all animals were group-housed (A). 
Experimental housing and behavioural testing had no effect on plasma corticosterone levels 
in any of the groups (B).  Animals were 5-7 months old and values are mean ± SEM where 
n=16-34/group. Comparisons were made by Student‘s unpaired t-test or 2-way ANOVA.  
WT = wild-type and 5αR1-KO = 5α-reductase type 1 knock-out. 
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Figure 5.15  Plasma corticosterone levels at the diurnal nadir in aged mice post-
behavioural testing 
Independent from housing, 5αR1-KO mice overall showed a trend towards reduced plasma 
corticosterone concentrations basally compared to WT controls (p = 0.06).  Animals were 
aged ~15 months.  Data are mean ± SEM for n = 16-17/group.  Comparisons were made by 
2-way ANOVA with Bonferroni post-hoc testing.  WT = wild-type and 5αR1-KO = 5α-
reductase type 1 knock-out. 
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Figure 5.16  Gene expression profile in the hypothalamus and pituitary of aged mice 
In the hypothalamus (A-C), transcripts for GR were downregulated in 5αR1-KO mice 
(chequered) housed both singly and in groups (A, p<0.05). Moreover, transcripts for GR 
were more abundant in singly- vs. group-housed mice overall (A, p<0.001).  MR mRNA was 
upregulated in singly- vs. group-housed mice in the hypothalamus, independent of genotype 
(B, p<0.01). Transcripts for Crh in hypothalamus and for GR and MR in the pituitary were 
not different between any of the experimental groups (C-E respectively). Transcripts for 
Crhr-1 were more abundant in 5αR1-KO mice vs. WT controls under both housing 
conditions (F, p<0.05). Bars represent mean ± SEM for mice aged ~15 months where n = 16-
17/group.  Comparisons were made by 2-way ANOVA with Bonferroni post-hoc tests where 
appropriate.  WT = wild-type, 5αR1-KO = 5α-reductase type 1 knock-out, GR = 
glucocorticoid receptor, MR = mineralocorticoid receptor , Crh = corticotrophin-releasing hormone 
and Crhr-1 = corticotrophin-releasing hormone receptor type 1. 
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5.6 Discussion 
The purpose of this set of experiments was to assess the behavioural effects of 5αR1 
loss in the brain and if such phenotypes were modified by the stress of social 
isolation.  5αR1-KO mice displayed anxiety-like behaviours during single-housing.  
Age-associated cognitive impairments were exaggerated in 5αR1-KO mice, and to a 
greater degree in animals subjected to social isolation. 
 
These experiments were performed using mice bred onto a C57Bl6/j background and 
initial confirmation was sought of continuity of the excess weight gain phenotype in 
5R1-KO mice and their exaggerated weight loss in response to social isolation.  
Across the experimental period, all animals gained weight over time but to which 
extent was modifiable by genotype, social isolation and behavioural testing.  From 
weaning (4 wks) up to 20 wks old, the only experimental interventions were weekly 
weighing and all mice were housed in groups.  During this time, 5αR1-KO mice 
were significantly heavier than WT controls.  As with the previous mixed strain, 
single housing induced weight loss in all C57Bl/6j mice but to a greater extent in 
5αR1-KOs.  Following re-grouping, all singly-housed mice regained weight and 
5αR1-KO mice were again significantly heavier than WT.  Exaggerated weight loss 
upon social isolation in aged 5R1-KO mice was also observed.  These data suggest 
that obesity-prone 5αR1-KO mice are more susceptible to the effects of social 
isolation stress but that the resulting weight loss is reversible upon return to group-
housing.  Social isolation is a known inducer of weight loss and a model of chronic 
stress (Yamada et al. 2000).  Chronic mild stress can lower body weight (Matthews 
et al. 1995; Forbes et al. 1996), due to loss of both lean and fat-tissue loss (Harris et 
al. 1998).  Indeed, here we showed singly-housed mice had reduced gonadal fat 
compared to group-housed mice overall, suggesting loss of fat mass contributed to 
weight reduction during social isolation.  Moreover, when corrected for total body 
weight, the significance of this result was enhanced meaning the contribution of fat 
to the total body weight was reduced in singly-housed mice. 
 
There are conflicting reports of stress-induced hyperphagia in both rodents (Levine et 
al. 1981) and humans (Stone et al. 1994), but also hypophagia in rodents (Dallman et 
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al. 2001). In this study, weight loss or attenuated gain ensued in young animals of 
both genotypes upon single-housing, despite, paradoxical hyperphagia.  As was also 
seen in prior investigations (see Chapter 3), food intake alone does not determine 
body weight and this phenotype is therefore suggestive of increased energy 
expenditure.  In contrast however, upon ageing, greater weight loss with singly-
housed in 5αR1-KO mice was associated with hypophagia.  
 
Social isolation induces increased locomotor activity in both mice and rats (Hilakivi 
et al. 1989; Heidbreder et al. 2000; Hickey et al. 2012) as was observed here for both 
WT and 5αR1-KO mice when tested in the Y-maze.  There was only limited 
evidence, in the OFT, that locomotor activity might be more vigorous in 5R1-KO 
mice.  Even though basal locomotion was not measured here, it is likely that 
increased physical activity is a main factor in weight loss during single housing.  
Another cause of weight loss on single housing is maladaptive thermogenesis.  This 
was not assessed here, but singly-housed 5αR1-KO mice may utilise more energy to 
maintain their body temperature. 
 
Stressful stimuli which induce weight loss in experimental animals are often linked 
to increased anxiety-like behaviours (Chourbaji et al. 2005; Kwak et al. 2009).  
Many authors have reported instances of glucocorticoid-induced anxiety, either 
through increased ligand or up-regulation of corticosteroid receptors (Seckl 2004; 
Kajiyama et al. 2010).  For example, anxiety was reduced in a forebrain-specific GR-
KO mouse model (Boyle et al. 2006) whilst prednisolone-treated mice displayed 
more anxiety-like behaviours in the EPM and OFT, possibly related to remodelling 
and damage to key brain structures such as the hippocampus (Kajiyama et al. 2010).  
If 5R1 was preventing glucocorticoid inactivation, then this may underpin a 
propensity for anxiety; basally or in response to stress. 
 
Behavioural phenotypes sensitive to social isolation can often be detected by 
assessing performance in mazes designed to test anxiety; the OFT and EPM involve 
conflicts between enclosed and open spaces.  For example, anxiety is exacerbated by 
single housing with significant decreases in time spent in the open arms of the EPM 
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(Hellemans et al. 2004).  When young, WT mice behaved as expected in tests 
designed to assess anxiety; spending the majority of the test time exploring 
designated ―safe‖ zones such as the enclosed arms of the EPM apparatus and the 
peripheral areas of the OFT box.  Moreover, there was no evidence for an anxious-
like phenotype in 5αR1-KO mice compared to WT controls under either housing 
condition.  However, following ageing, 5αR1-KO mice showed increased anxiety in 
the EPM, but only concomitantly with single housing.  It is possible that the anxious 
phenotype is revealed upon the rise in glucocorticoid levels associated with the 
normal ageing process.  Although differences were not detected in circulating 
corticosterone levels in singly-housed aged mice, plasma levels may not reflect those 
locally within the brain.  Attempts to measure brain (and liver) corticosterone 
concentrations were unsuccessful, due to levels being below the limits of 
quantification of the assay. 
 
The same aged animals were not more anxious compared to control when tested in 
the OFT.  One reason why the data obtained from behavioural testing is not always 
easily reproducible is that even minor environmental changes can have a large 
impact on the resulting phenotype.  A huge range of factors such as time of day and 
circadian rhythm, housing, temperature, noise and other external stressors, prior 
handling of the animals, gender, strain, environmental enrichment, olfactory cues and 
prior exposure to the experimenter can all alter behavioural phenotypes (Brett et al. 
1990; McIlwain et al. 2001; Võikar et al. 2004; Võikar et al. 2005).  Great care was 
taken to control for these variables wherever possible.  For example, all animals in 
cages were left together in a quiet room during the testing period, tests were always 
carried out between 0800 hrs and 0100 hrs each day and all groups were handled 
with equal frequency and provided with the same environmental enrichment.  
Furthermore, the OFT is often suggested as less a test of anxiety and more a test of 
locomotion and physical activity under mild stress.  Therefore, when interpreting 
data from the OFT, it is often difficult to separate measures of anxiety from other 
indices (File 2001).  Both young and aged 5αR1-KO mice overall travelled a similar 
distance and at an average speed comparable to controls in the OFT, but their 
maximum speed of travel was increased.  This may be interpreted as a measure of 
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anxiety or ―panic‖ behaviour rather than locomotion per se in which case 5αR1-KO 
mice are suggested to have an exaggerated anxious-like response to the OFT, thus 
searching more urgently for a means to escape.  
 
Glucocorticoids profoundly affect memory and other behaviours.  Moreover, their 
elevated levels lead to impaired spatial learning mediated through the hippocampus 
(Stenzel-Poore et al. 1994; McEwen et al. 1995; Yau et al. 2001; Boyle et al. 2006; 
Rozeboom et al. 2007; Wei et al. 2007; Yau et al. 2007; Kolber et al. 2008; 
Kajiyama et al. 2010).  In rodents, normal hippocampal function is required for 
adequate exploratory behaviour in any novel environment as well as for spatial 
memory (Britton et al. 1982; Gray 1982; Sutton et al. 1982; Lee et al. 1989).  
Glucocorticoid concentrations higher than normal biological levels may be 
neurotoxic and can negatively influence neuronal structure leading to its subsequent 
remodelling, whilst also interfering with electrophysiological processes such as LTP 
(Yau et al. 2007).  Indeed, glucocorticoids in excess inhibit neurogenesis (Mirescu et 
al. 2006), implicated not only in cognitive decline but also in the pathogenesis of 
both anxiety and depression in the adult mouse (Snyder et al. 2011). 
 
Many ageing studies have demonstrated that glucocorticoid exposure increases 
linearly from late middle age onwards in rodents (approximately 10 months and 
older) and in late old age in humans (Meaney et al. 1992; Sapolsky 1992; Lupien et 
al. 1994; Montaron et al. 2006).  Disruptions in learning and memory are typical of 
the ageing hippocampus and numerous studies exploring the effects of glucocorticoid 
excess or chronic stress have replicated features of the aged hippocampus.  For 
example cognitive impairments in aged rats (23-27 months old) and humans (60-80 
years old) correlate with elevated glucocorticoid secretion both basally and post-
stress (Issa et al. 1990; Lupien et al. 1994; Seeman et al. 1997). The contributory 
role of glucocorticoids is evident in studies of ADX at middle age, which reduces the 
neuronal loss commonly observed in aged rats (Landfield et al. 1981).  Indeed ADX 
and GR blockade, reducing life-long glucocorticoid exposure, preclude cognitive 
abnormalities in the aged hippocampus (Landfield et al. 1981; Talmi et al. 1996).  In 
the present study, a role for glucocorticoid metabolism by 5αR1 in the maintenance 
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of spatial memory was proposed.  It was hypothesised that glucocorticoid excess 
within the brains of 5αR1-KO mice may lead to cognitive impairments possibly as a 
result of neuronal damage within the hippocampus; the opposite of what has been 
seen in the 11β-HSD1 KO mouse model.  Aged, 11β-HSD1 deficient mice are 
protected from learning and memory impairments due to a lack of local 
glucocorticoid amplification in the brain which facilitates a switch from GR to MR-
mediated cognitive control (Yau et al. 2011). 
 
The Y-maze is a behavioural test used to determine memory capacity but is sensitive 
to stress.  Whilst the test itself induces little or no intrinsic stress, the outcome is still 
sensitive to chronic changes in glucocorticoid levels (Coburn-Litvak et al. 2003).  
Young, WT animals housed in groups performed as expected in the Y-maze test of 
memory, showing good motivation and intact spatial recognition memory across all 
Y-maze phases.  These mice spent more time exploring the novel arm than either of 
the other two arms.  This indicates they identified this arm as novel and 
―remembered‖ previously exploring the other areas of the maze based on their spatial 
memory of the extra-maze queues.  Single-housing alone did not affect memory 
assessed by Y-maze such that WT animals housed under social isolation performed 
equally well as group-housed, controls.  However young 5αR1-KO mice housed in 
social isolation spent less time in the novel arm following the 1 min and 2 hour ITI 
however, the time in the novel arm after the 2 hour ITI fell below the level of chance 
(33%) and so cannot be taken as reduced memory capacity.  The 1 min ITI is too 
short an interval for any difference to be attributable to memory loss alone.  This 
immediate Y-maze memory task assesses the spontaneous novelty exploration 
behaviour of mice and so is not dependent on hippocampal function (Sarnyai et al. 
2000).  It is merely an indicator of adequate vision and motivation to participate in 
the test and changed in novel arm exploration between groups following the 1 min 
ITI may instead reflect altered locomotor activity.  Paradoxically, this reduced novel 
arm exploration in singly-housed 5αR1-KO mice is not consistent with the increased 
locomotion normally seen under social isolation.  Indeed, when young, there were no 
differences between WT and 5αR1-KO mice in locomotive indices in the Y-maze, 
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although all singly-housed mice travelled further and faster vs. group-housed 
animals. 
 
Following ageing, there were some changes to the Y-maze phenotype.  5αR1-KO 
mice housed singly made fewer entries into the novel arm suggestive of reduced 
memory capacity.  Furthermore, the same housing effect on locomotion was seen in 
aged animals with singly-housed mice travelling further and faster during testing.  As 
seen in young animals, singly-housed 5αR1-KO mice spent less time in the novel 
arm following the 1 min ITI, possibly because they covered less distance and 
travelled at a reduced speed than matched WT mice.  Reduced locomotion and 
exploratory behaviour has been attributed to other behavioural changes e.g. 
depression (Kalueff et al. 2004; Mineur et al. 2006).  Although distinctions exist, 
there is broad overlap between the symptoms of depressive illnesses and anxiety 
disorders in humans and the two may be expected to coincide in animal models also.  
Therefore it would be useful to assess these animals for depression in further studies.  
Investigations could include the use of such tests including the forced swim test 
and/or the tail suspension test commonly used to determine the efficacy of anti-
depressants in pre-clinical studies using animal models of depression. 
 
As with the anxiety phenotype, it may be that the chronic stress effects of social 
isolation may be additive to deficient glucocorticoid clearance within the brains of 
5αR1-KO mice leading to cognitive impairments possibly mediated through 
glucocorticoid-mediated hippocampal dysfunction.  There is evidence to suggest that 
social isolation leads to memory impairment and that this phenotype is more 
pronounced in older mice (Hellemans et al. 2004).  Further cognitive assessment was 
carried out using the Morris water-maze which is widely utilised to study spatial 
learning and memory, mostly facilitated by the hippocampus (Morris et al. 1982). 
 
All mice performed as expected during water-maze testing in this study whereby 
escape latency i.e. elapsed time to locate the hidden platform submerged in opaque 
water, decreased across five consecutive training days.  The data presented here do 
not show cognitive deficits in the learning abilities of 5αR1-KO mice when 
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compared to WT animals neither when young nor when aged.  However, when 
looking at the decline in cognitive ability over time between paired animals when 
young and again when old, there is a greater cognitive decline associated with ageing 
in 5αR1-KO mice compared to WT controls.  This phenotype reached significance in 
both group- and singly-housed mice.  This is consistent with our hypothesis that a 
lack of adequate glucocorticoid metabolism has induced an exacerbated ageing 
phenotype in 5αR1-KO mice in relation to cognition, albeit subtle.  Again, this 
contrasts as expected with enhanced spatial learning and memory mediated by the 
hippocampus seen in aged 11β-HSD1 null mice (Yau et al. 2007).  The effect size 
seen was small but may have been greater if the mice had been aged for a further 
period; a typical life span may extend to 24 months. 
 
An important consideration when assessing the effects of 5αR1-KO in the brain is 
that not only is the enzyme involved in metabolising active glucocorticoid molecules, 
it is also the vital rate limiting step in neurosteroidogenesis in the brain.  The de novo 
synthesis of neurosteroids within the CNS was first demonstrated in the early 1990s 
by Baulieu et al. (Baulieu et al. 1990).  By interacting with neurotransmitter-gated 
ion channels at neuronal synapses located throughout the central and peripheral 
nervous systems, neurosteroids can rapidly alter neuronal excitation or inhibition.  
Later in the mid-90s, it was discovered that 5αR1 plays an essential role in 
synthesising the neurosteroid ALLO from progesterone by pyramidal neurons in the 
brain (Cheney et al. 1995).  The conversion is stimulated during acute periods of 
stress when ALLO levels increase significantly (Vallee et al. 2000); a process which 
can be inhibited dose-dependently by the use of finasteride (a 5R inhibitor) in rats 
(Mukai et al. 2008).  ALLO (as well as its precursor 5α-dihydroprogesterone; 5α-
DHP) positively modulates the action of the major inhibitory neurotransmitter in the 
brain (γ-aminobutyric acid; GABA; Puia et al. 1990; Herd et al. 2007) in a direct, 
non-genomic manner by inducing allosteric changes in the ionotropic receptor 
GABAA.  Increased influx of negatively charged ions enhances GABA‘s inhibitory 
effects upon neuronal firing.  These receptors are widely distributed in the 
glutamatergic neurons of the cortex and limbic areas, such as the hippocampus and 
the amygdala, two of the main brain structures involved in the regulation of 
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emotionality and behaviour. ALLO allosterically alters GABAA.  Through its 
modulation of local neuronal activity, ALLO has endogenous anxiolytic and 
sedative-like properties, and together with progesterone plays a modulatory role in 
the pathogenesis of psychotic disorders in rodents (Rupprecht et al. 1999; Khisti et 
al. 2002). 
 
Indeed, associations have been made between impaired neurosteroid biosynthesis, 
and behavioural dysfunctions in rodents such as anxiety, depression and changes in 
contextual fear conditioning responses (Pinna et al. 2003; Uzunova et al. 2006; Kita 
et al. 2008; D'Aquila et al. 2010).  Decreased ALLO is associated with emotional 
instability, aggression and increased locomotor activity in novel environments (Pibiri 
et al. 2008) which is also shown to be inducible by social isolation (Matsumoto et al. 
1999; Dong et al. 2001). 5αR1 mRNA was markedly down-regulated (up to 37%) in 
the frontal cortex, hippocampus and the amygdala (areas know to be associated with 
behaviour and emotion) in mice socially isolated for 4 wks (Agis-Balboa et al. 2007).  
Therefore the release of this inhibitory brake within 5αR1-KO mice may cause an 
altered behavioural adaptation to stress by influencing neural circuitry in the CNS.  
Also, in clinical studies, decreases in ALLO concentrations in serum, plasma and 
cerebrospinal fluid are linked to anxiety spectrum disorders, depression and post-
traumatic stress disorder (PTSD; Rapkin et al. 1997; Romeo et al. 1998; Uzunova et 
al. 1998; Nappi et al. 2001; Rasmusson et al. 2006). 
 
Given the sexual dimorphism within the obesity phenotype and the propensity 
towards increased sensitivity to environmental stress in the female mice from our 
preliminary 5αR1-KO model, it is likely that further factors may play a modulatory 
role over and above glucocorticoids.  Behavioural phenotypes may be more 
pronounced in female mice whose progesterone levels are endogenously much 
higher due to peripheral sources.  Reduced ALLO in 5αR1-KO mice (particularly 
females) may render them more susceptible to anxiety.  To fully elucidate the role of 
ALLO, its fluctuations would have had to have been more closely monitored in 
female mice since at least some of the substrate, progesterone, is peripherally derived 
and displays cyclical fluctuations which directly affect the concentrations of 
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neurosteroid (Rapkin et al. 1997).  Future studies will be necessary to quantify 
ALLO in the brain, since from current data it cannot be concluded whether anxiety 
and cognitive deficits in aged, socially isolated 5αR1-KO mice are due to increased 
corticosterone or reduced ALLO in the brain.  If 5αR1-KO mice had reduced 
neurosteroid biosynthesis within the brain, ALLO replacement studies may also be 
carried out to see if the social isolation phenotype can be reversed.  
 
It is also noteworthy that neurosteroids such as pregnenolone (PREG) and ALLO are 
involved in HPA axis regulation.  As an example, i.p. injection of PREG stimulated 
HPA activity via increased hypothalamic AVP resulting in raised ACTH and 
corticosterone levels in the circulation (Naert et al. 2007).  The same authors also 
reported ALLO-induced activation of the axis where all of CRH, AVP, ACTH and 
corticosterone were increased following i.p. injection to rats.  Again lack of ALLO 
may therefore account in part for the previously reported attenuated stress response 
in mixed strain 5R1-KO mice. 
 
Basal plasma corticosterone did not differ by genotype in young mice, but levels 
were reduced in aged 5αR1-KO mice overall, consistent with attenuated stress 
responses reported previously, but not glucocorticoid excess.  Within the brain 
however, GR mRNA was downregulated in the hypothalamus of 5αR1-KO mice 
which is consistent with receptor downregulation in response to high ligand 
concentrations.  This result is similar to findings in Chapter 4 in young mixed strain 
mice (females only).  However, the abundance of transcripts for Crh was not affected 
by genotype, in contrast to prior findings which showed a significant downregulation 
of hypothalamic Crh in young 5αR1-KO mice of the mixed strain (Chapter 4).  Also 
in contrast to findings in mixed strain animals, Crhr-1 was increased in the pituitary 
in aged 5αR1-KO mice.  Given these differences the question was posed whether 
these were effects of ageing or whether the HPA phenotype of the C57Bl/6j strain 
differed from the mixed background (explored in the following chapter). 
 
As well as strain, housing also influenced mRNA abundance of transcripts which are 
key in HPA axis regulation.  In the hypothalamus, social isolation induced 
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upregulation of transcripts for both GR and MR.  Some reports suggest social 
isolation of rodents has no effect on GR or MR mRNA abundance in the CNS 
(Schrijver et al. 2002; Weiss et al. 2004) but hypothalamic MR and GR mRNA is 
upregulated in socially isolated pigs (Kanitz et al. 2009).  Here, increased GR and 
MR expression is consistent with increased negative feedback on the HPA axis in 
light of the chronic stress of social isolation i.e. in an effort to limit or terminate the 
chronic stress response.  Indeed, acute stress responses are usually downregulated 
during periods of chronic stress (Katz et al. 1981; Rich et al. 2005). 
 
To summarise, in this chapter there is no evidence to suggest an anxious phenotype 
in 5R1-KO mice, our proposed model of apparent glucocorticoid excess, when 
tested whilst young.  Following considerable ageing, and a period of social isolation 
and at an age when glucocorticoid levels were higher still, 5αR1-KO mice were 
anxious compared to controls.  Moreover, there is some evidence that 5αR1-KO mice 
have an exaggerated cognitive decline following ageing in spite of reduced plasma 
levels of corticosterone basally.  Strain related differences in the effect of 5αR1 loss 
on key regulatory features of the HPA axis have been highlighted here.  The true 
extent of this strain difference and the potential mechanism behind it is explored in 
Chapter 6 but due to time constraints this could only be studied in young mice. 
 
 




Chapter 6: Influence of genetic 
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6.1 Introduction 
Chapter 5 highlighted potential discrepancies between phenotypes seen in 5αR1-KO 
mice on a congenic C57Bl/6j background and those seen previously in mixed strain 
(C57Bl/6j/SvEv/129), 5αR1-KO mice.  In previous studies, female, mixed strain, 
5αR1-KO mice gained more weight when fed a normal chow diet; a phenotype 
which was sensitive to social isolation whereby animals lost weight and became 
comparable to WT (Livingstone et al. unpublished).  These animals also had 
metabolic phenotypes including hyperphagia, insulin resistance (but stable plasma 
glucose) and increased adipose tissue (all fat pads) compared to WT controls.  The 
data reported in this thesis using 5R1-KO mice on a C57Bl/6j background, 
recapitulated the excess weight gain, which was again attenuated upon single 
housing.  However, the magnitude of excess weight gain on the C57Bl/6j 
background seemed less than the mixed strain when both young and aged, and 
adipose tissue mass did not become statistically significantly heavier than controls.  
Moreover, on the C57Bl/6j background, 5αR1-KO mice were hypophagic.  Although 
age is a potential confounding factor between experiments, it is also possible that 
strain is a phenotypic modulator in 5αR1-KO mice. 
 
It is not uncommon for phenotypic differences (including different degrees of HPA 
axis activity) to exist between strains and many authors have reported such 
phenomena in both mice and rats.  For example, comparisons between Fischer 344 
and LOU/C rat strains revealed LOU/C rats had lower corticosterone across the 
circadian cycle overall, and that their stress responses were of a lesser magnitude 
(Marissal-Arvy et al. 2007).  Strain differences can affect the responsiveness of the 
HPA axis to changes in glucocorticoid metabolism.  129/MF1 mice with transgenic 
disruption in the 11βHSD1 gene had elevated corticosterone levels both basally and 
post-stress and hypertrophied adrenals (Kotelevtsev et al. 1997; Harris et al. 2001) 
but 11βHSD1-KO mice on a C57Bl/6j background also had hypertrophied adrenals 
and elevated stressed corticosterone responses but in the absence of altered basal 
levels (Carter et al. 2009).  The same authors also reported increased GR mRNA in 
the hippocampus and PVN of C57Bl/6j but not 129/MF1 mice indicating 
compensatory responses in C57Bl/6j mice to normalise feedback control of the HPA 
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axis.  Therefore, this raises the question of whether mice with loss of 5αR1 bred onto 
a C56Bl/6j background may adapt differently from the original mixed strain mice.  
The following set of experiments was designed to directly compare the phenotype of 
5R1-KO mice on mixed vs. C57Bl/6j strain. 
 
6.1.1 Hypothesis 
It was hypothesised that glucocorticoid clearance would be attenuated to a lesser 
degree in 5αR1-KO mice of the C57Bl/6j strain compared to those of the mixed 
strain and that this would manifest as less disruption of metabolism and less 
suppression of HPA axis stress responses. 
 
6.1.2 Aims 
 To validate deficiency of 5αR1 in mice bred onto the C57Bl/6j strain. 
 To determine if 5αR1-KO mice of the C57Bl/6j strain were glucose intolerant 
and hyperinsulinaemic similar to mixed strain mice. 
 To determine if HPA axis responses to acute stress in 5αR1-KO mice were 
reduced similarly to mixed strain mice. 
 To determine the efficiency of glucocorticoid clearance in WT and 5αR1-KO 
mice and to elucidate whether this differed between strains. 
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6.2 Methods 
6.2.1 Validation of disruption of Srd5a1 in 5αR1-KO 
backcrossed onto the C57Bl/6j background 
6.2.1.1 Experimental outline 
Whole brains from female 5αR1-KO mice (and WT controls) on each genetic 
background were obtained after cull.  C57Bl/6j and mixed strain mice were 15 and 7 
months old respectively.   
 
6.2.1.2 PCR 
RNA was extracted from liver, brain and prostate (positive control; sections 2.3.1.1 
and 2.3.1.2) and reverse transcribed (2.3.2).  Using the primers shown in Table 2.1 of 
the main methods in Chapter 2, PCR was performed according to 2.3.3 to determine 
the presence or absence of transcripts for Srd5a1 and Srd5a2 in brains and livers of 
WT and 5αR1-KO mice on both genetic backgrounds.  Bands were visualised as 
described 2.3.3.1.  PCR was also performed using primers for 11βHSD1 Table 2.1 as 
a positive control. 
 
6.2.2 Assessing the phenotype of C57Bl/6j 5αR1-KO mice 
6.2.2.1 Metabolic Biochemistry 
Plasma was obtained from non-fasted trunk blood from female, WT and 5αR1-KO 
mice on a C57Bl/6j genetic background described in the previous chapter (aged 15 
months at cull).  Plasma glucose (hexokinase assay, 2.4.2) and insulin levels (ELISA, 
2.4.1) were compared. 
 
6.2.2.2 Assessment of acute HPA axis responses to stress 
A further cohort of C57Bl/6j mice (male and female, WT and 5αR1-KO mice aged 6 
months) were used to study responsiveness of the HPA axis.  Following acute 
restraint stress (2.6.9.1), plasma corticosterone was quantified by ELISA (2.4.4). 
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6.2.3 Glucocorticoid clearance in mixed strain and C57Bl/6j 
mice 
6.2.3.1 Experimental outline 
Mice cohorts studied were as follows: 
 
 Mixed strain 
- Male WT (n=8) 
- Male 5αR1-KO (n=9) 
- Female WT (n=7) 
- Female 5αR1-KO (n=8) 
 C57Bl/6j strain 
- Male WT (n=5) 
- Male 5αR1-KO (n=8) 
- Female WT (n=9) 
- Female 5αR1-KO (n=8)
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Mice (6 months old and obtained/maintained as described in 2.6.1 and 2.6.3) were 
used to determine the efficiency of glucocorticoid clearance both acutely and 
chronically.  Following chronic glucocorticoid administration, the abundance of 
transcripts for enzymes (other than 5R1) which determine glucocorticoid levels in 
tissues were quantified by qPCR. 
 
6.2.3.2 Adrenalectomy 
Prior to experimentation, all animals underwent adrenalectomy surgery to remove 
any natural disparities in endogenous corticosterone flux from the adrenal glands 
both basally and during acute corticosterone treatment.  Bilateral adrenalectomy 
(2.6.9.2) was performed on weight- and aged-matched mice (approximately 27-30 g 
at 5 months old). 
 
6.2.3.3 Assessment of acute glucocorticoid clearance 
To assess clearance of acutely administered corticosterone, ADX mice were injected 
subcutaneously (s.c.) with corticosterone (2 µg in 10% ethanol with 0.025% β-
cyclodextrin in 0.9% saline).  Blood was collected by venesection at time 0 
(immediately prior to injection) and at 15, 30, 60 and 90 mins following the 
injection.  Plasma corticosterone levels were determined by ELISA (2.4.4). 
 
6.2.3.4 Assessment of chronic glucocorticoid clearance 
To assess clearance of chronically administered corticosterone, ADX mice were 
implanted with osmotic minipumps (2.6.9.2.1) loaded to deliver 100 μg of 
corticosterone per day in 1:1 DMSO:propylene glycol at a flow rate of 0.5 μL/hr.  
Mice were culled after 2 wks of infusion and tissues collected as in 2.6.10.  
Corticosterone was quantified from plasma by ELISA (2.4.4) and hepatic levels by 
LC-MS/MS (2.5.2) following steroid extraction from the liver (2.5.1). 
 
6.2.3.5 qPCR to quantify mRNA abundance in liver 
Following chronic corticosterone infusion, total RNAs were extracted from snap 
frozen livers (2.3.1.1) and used to synthesise first strand cDNA by RT (2.3.2).  Using 
the primers and probes designated in Table 2.2, qPCR (2.3.4) was performed to 
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quantify the expression of transcripts for Srd5a1 (5αR1), Akr1d1 (5βR), Akr1c6 
(3αHSD) and Hsd11b1 (11βHSD1).  The abundance of transcripts of interest were 
expressed as a ratio to the mean of the transcript levels of a combination of reference 
genes as outlined in Table 4.1.  The combination of reference genes was selected due 
to a lack of variation between experimental groups. 
 
6.2.4 Terminal procedures 
All mice were humanely culled and tissues collected onto dry ice as described in 
section 2.6.10. 
 
6.2.5 Statistical analyses 
Data are presented as mean ± SEM and were analysed by unpaired Student‘s t-tests, 
2-way repeated measures ANOVA or 2-way ANOVA followed by Bonferroni post-
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Table 6.1  Reference genes used for qPCR analysis.  
The mRNA abundances of the above three genes were combined and used as the mean 
reference against which the abundance of transcripts of interest in the liver was 
normalised.  P value indicates the results of a 2-way ANOVA for the combined reference 









Cyclophilin A (Ppia) 
TATA-box binding protein (Tbp) 
18s ribosomal RNA (Rn18s) 
Male Female 
G S G S 
0.979 0.685 0.948 0.672 
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6.3 Results 
6.3.1 Model validation 
6.3.1.1 Validation of 5αR1-KO in tissues of interest 
Genotyping from ear samples obtaining during breeding had confirmed global 5αR1- 
disruption in the DNA but in light of strain-related phenotypic differences, validation 
of complete 5αR1-KO at the level of the RNA was sought, in case of alternative 
transcripts.  Transcripts for Srd5a1 were not detected in brain or liver samples from 
5αR1-KO mice of both the C57Bl/6j and mixed genetic strains (Figure 6.1, A) and, 
as a positive control for sample and process integrity, Hsd11b1 mRNA was 
demonstrated to be expressed in all samples (Figure 6.1, B).  Moreover, Srd5a2 
mRNA was not detected in either brain or liver samples from WT or 5αR1-KO mice 
of either strain (Figure 6.2), but was detected in prostate, the positive control. 
 
6.3.1.2 Bioinformatics 
There also remained the possibility of alternative splicing of the Srd5a1 gene to 
produce multiple mRNA variants and thus potentially more than one 5αR1 protein.  
The Srd5a1 gene was blasted on the Ensembl Genome Browser online and revealed 
there were two possible transcripts resulting from the gene (Table 6.2).  The first was 
the conventional transcript known to produce the functional 5αR1 protein (Srd5a1-
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Figure 6.1  PCR result showing no Srd5a1 expression in 5αR1-KO mice 
mRNA for Srd5a1 was not detected in the brains or livers of 5αR1-KO mice from either of 
the two genetic backgrounds (A).  B shows PCR for Hsd11b1 as an amplification control.  
Also shown are negative controls (no reverse transcriptase enzyme) for each sample, and an 
overall positive and negative control for each reaction. B = brain, L = liver, WT = wild-type 
and 5αR1-KO = 5α-reductase type 1 knock-out. 
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Figure 6.2  Srd5a2 expression in brain and liver 
mRNA for Srd5a2 was not detected in whole brain or liver of either WT or 5αR1-KO mice 
of both genetic strains.  Prostate tissue was used as a positive control.  The three negative 
controls were no reverse transcriptase enzyme, water and a known negative sample of liver.  
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Table 6.2  Alternative splicing and transcript options for the Srd5a1 gene 
This table highlights the details of the two possible transcripts encoded by the Srd5a1 gene.  
Srd5a1-001 is the conventional transcript, which translates the functional 5αR1 protein.  
Srd5a1-002 is a processed transcript and would not result in a translated 5αR1 protein.  bp = 
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6.3.2 The metabolic phenotype of female C57Bl/6j, 5αR1-KO 
mice 
6.3.2.1 Body weight 
As shown in Chapter 5 (5.3.1), body weight gain was increased in 5αR1-KO mice 
and this phenotype was attenuated during periods of social isolation.  Excess body 
weight gain in 5R1-KO mice on the C57Bl6/j strain was less than that observed in 
mixed strain mice (broadly 1g heavier in C57Bl/6j mice vs. 2.9 g heavier in mixed 
strain mice at 15 wks old), which can be seen in Figure 3.1and Figure 5.2 in Chapters 
3 and 5 respectively.  
 
6.3.2.2 Plasma glucose and insulin levels 
Plasma glucose levels (non-fasting) were not different between WT and 5αR1-KO 
mice and there was no effect of housing (Figure 6.3, A and B for group- and singly-
housed mice respectively).  Insulin levels were increased in 5αR1-KO mice housed 
in groups vs. WT mice (Figure 6.3, C, p<0.01).  There was no genotype effect on 
plasma insulin in singly-housed animals (Figure 6.3, D). 
 
6.3.2.3 HPA axis responses to acute restraint stress 
Basal corticosterone concentrations were higher in females over males, and the data 
were within the appropriate physiological ranges (Figure 6.4 A and B).  Broadly, the 
WT HPA axis response was comparable between the two strains; see by comparison 
of Figure 6.4 (C57Bl/6j strain) vs. Figure 4.1 (mixed strain).  However, differential 
to mixed strain, 5αR1-KO mice of the C57Bl/6j strain showed HPA axis responses 
following acute restraint stress which were comparable to control (Figure 6.4).  WT 
and 5αR1-KO animals of the C57Bl/6j strain had similar peak concentrations of 
corticosterone and had comparable recovery phases for both male and female mice 
(Figure 6.4, A and B respectively).  
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Figure 6.3  Non-fasted plasma glucose and insulin levels for AGED C57Bl/6j mice at 
cull. 
The top two panels show that plasma glucose concentrations were not different in non-
fasted, trunk blood samples from group- and singly-housed, WT (solid) and 5αR1-KO 
(chequered) mice (A and B respectively).  However, group-housed, 5αR1-KO mice had 
significantly higher circulating insulin levels vs. WT controls (C) but there were no 
differences in comparable mice housed singly (D).  Data are mean measurements ± SEM for 
n=15-17/group.  Comparisons were made by Student‘s unpaired t-test where ** = p<0.01.  
All animals were aged 15 months and from the C57Bl/6j strain.  WT = wild-type and 5αR1-
KO = 5α-reductase type 1 knock-out. 
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Figure 6.4  Plasma corticosterone concentrations during an acute restraint stress test. 
A and B show the degree of corticosterone release in response to acute restraint stress for 
male (black) and female (grey), WT (solid lines) and 5αR1-KO (hatched lines).  Plasma 
corticosterone did not differ by genotype either basally or following restraint in male (A) and 
female (B) mice.  Values are mean measurements ± SEM where n = 12/group.  Mice were 6 
months old and from the C57Bl/6j strain. Comparisons were made between groups by 2-way 
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6.3.3 Glucocorticoid clearance and the effect of strain 
6.3.3.1 Plasma corticosterone levels following acute and chronic 
infusion 
6.3.3.1.1 Male animals 
Basal corticosterone concentrations were comparable between both genotypes and 
strains (Figure 6.5, A).  Following an acute corticosterone challenge, mixed strain 
WT mice had elevated plasma corticosterone across the time course compared to 
C57Bl/6j WT mice (Figure 6.5, A, P<0.01).  Post-hoc testing revealed corticosterone 
levels remained significantly more elevated in WT, mixed strain mice compared to 
WT C57Bl/6j mice at 60 and 90 mins post injection (Figure 6.5, A, p<0.01).  For 
mixed strain mice, corticosterone was lower in 5αR1-KO mice compared to WT 
controls (Figure 6.5, A, p<0.05).  In C57Bl/6j mice there was a trend for higher 
corticosterone in 5αR1-KO mice vs. WT (Figure 6.5, A, p=0.07).  Following chronic 
infusion, plasma corticosterone did not differ between any of the groups.  However, 
there was an interaction such that corticosterone levels were differentially affected by 
5αR1-KO in each of the two genetic strains (Figure 6.5, C, p<0.05). 
 
6.3.3.1.2 Female animals 
In females, plasma corticosterone levels did not differ by strain or genotype either 
basally or following acute corticosterone treatment (Figure 6.5, B).  There was also 
no difference between experimental groups in trunk corticosterone following chronic 
infusion (Figure 6.5, D). 
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Figure 6.5  Plasma corticosterone levels following acute and chronic corticosterone 
infusion 
Prior to injection, basal corticosterone levels were comparable between experimental groups 
in both male and female animals (A and B respectively).  After corticosterone 
administration, in male mice there was an overall effect of strain (p<0.01) whereby plasma 
corticosterone was lower in C57Bl/6j vs. mixed strain mice. In males, corticosterone was 
lower and higher in 5αR1-KO mice vs. WT for mixed (p<0.05) and C57Bl/6j (p=0.07) 
strains respectively (A).  In females (B), neither strain nor genotype affected plasma 
corticosterone levels over the time-course. Following chronic corticosterone infusion, there 
was an interaction in male mice (C, p<0.05) showing that corticosterone levels were 
differentially affected by 5αR1-KO in each of the two strains but there was no effect of 
genotype (C).  In females, plasma corticosterone levels were comparable between each of the 
experimental groups following chronic corticosterone infusion (D). Data are mean ± SEM 
for n=5-9/group. Mice were 6 months old.  Comparisons were made by 2-way ANOVA or 2-
way ANOVA for repeated measures with Bonferroni post-hoc tests where appropriate.  ** = 
p<0.01 for effect of strain. WT = wild-type and 5αR1-KO = 5α-reductase type 1 knock-out. 
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6.3.3.2 Hepatic corticosterone levels following chronic infusion 
6.3.3.2.1 Male animals 
After 4 weeks of infusion, hepatic corticosterone concentrations were higher in 
mixed strain vs. C57Bl/6j mice overall (Figure 6.6, A, p = 0.05) but there was no 
effect of genotype.  
 
6.3.3.2.2 Female animals 
Hepatic corticosterone concentrations were comparable between strains (Figure 6.6, 
B).  In both mixed strain and C57Bl/6j mice, hepatic corticosterone levels were 
increased in 5αR1-KOs vs. WT controls (Figure 6.6, B, p<0.05).   
 
6.3.3.3 Effect of strain on hepatic expression of metabolic enzymes 
In both strains and sexes, transcripts for Srd5a1 were not detected in 5αR1-KO mice 
(Figure 6.7, A).  In WT males, there was a strain effect whereby transcripts for 
Srd5a1 were less abundant in C57Bl/6j mice vs. mixed strain mice (Figure 6.7, A, 
p<0.05).  In both strains transcripts for Srd5a1 were less abundant in WT females vs. 
WT males (Figure 6.7, A, p<0.001 and p<0.01 for mixed and C57Bl/6j strains 
respectively).  There was no overall effect of genotype or strain on Akr1d1 mRNA 
expression (Figure 6.7, B), however, transcripts for Akr1d1 were significantly 
affected by sex but differentially in each strain.  In mixed strain mice, transcripts for 
Akr1d1 were more abundant in WT females vs. WT males (Figure 6.7, B, p<0.01) 
whilst in C57Bl/6j mice, 5αR1-KO females showed higher Akr1d1 expression than 
5αR1-KO males (Figure 6.7, B, p<0.05).  There were no overall genotype or sex 
effects on Hsd11b1 mRNA abundance in any of the experimental groups (Figure 6.7, 
C).  However, there was an overall effect of strain whereby transcripts for Hsd11b1 
were more abundant in mixed strain mice vs. C57Bl/6j mice (Figure 6.7, C. p<0.01), 
and especially so in females (p<0.05).  There were no effects of genotype, strain or 
sex on the abundance of transcripts for Akr1c6 (Figure 6.7, D).   
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Figure 6.6  Hepatic corticosterone levels following chronic corticosterone infusion 
Following chronic corticosterone infusion, there was a significant effect of strain upon 
hepatic corticosterone content in male mice whereby levels were higher in mixed strain vs. 
C57Bl/6j mice (A, p=0.05) overall. In female animals, corticosterone was elevated in 5αR1-
KO mice vs. WT in both mixed and C57Bl/6j strains (B; p<0.05) but there was no effect of 
strain alone.  Data are mean ± SEM for n=5-9/group and * = p<0.05.  Mice were 6 months 
old.  Comparisons were made by 2-way ANOVA with Bonferroni post-hoc tests where 
appropriate. WT = wild-type and 5αR1-KO = 5α-reductase type 1 knock-out. 
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Figure 6.7  Hepatic expression of genes for metabolic enzymes following chronic 
corticosterone infusion 
Srd5a1 mRNA was not detected in 5R1-KO animals in both genetic backgrounds and sexes 
(A).  In WT animals, transcripts for Srd5a1 were less abundant in C57Bl/6j mice vs. mixed 
strain mice (A, p<0.05). There was also an effect of sex on Srd5a1 expression in WT animals 
whereby transcripts were less abundant in female WT mice vs. male WT mice of both strains 
(A, p<0.001 and p<0.01 for mixed and C57Bl/6j strains respectively). Akr1d1 mRNA 
expression was significantly affected by sex (B) but differentially in each strain.  In mixed 
strain WT mice, transcripts for Akr1d1 were more abundant in females vs. males (B, p<0.01) 
whilst in C57l/6j mice, females showed higher Akr1d1 expression than males but only 
reaching significance in mice lacking 5αR1 (B, p<0.05).  There was an overall effect of 
strain on the abundance of transcripts for Hsd11b1 (C. p<0.01) whereby levels were greater 
in mixed strain mice vs. C57Bl/6j mice overall, especially in females (p<0.05).  There were 
no effects of genotype, strain or sex on the abundance of transcripts for Akr1c6 (D).  Data are 
mean ± SEM for n=5-9/group (mice were 7 months old at cull). Comparisons were made by 
2-way ANOVA with Bonferroni post-hoc tests where appropriate. One symbol = p<0.05, 
two symbols = p<0.01 and three symbols = p<0.001 whilst # represents effects of sex and Φ 
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6.4 Discussion 
Here, we have demonstrated that the phenotype of mice deficient in 5R1 is 
influenced by background strain.  Although there were similarities e.g. excess weight 
gain and hyperinsulinaemia (both abolished by social isolation), the magnitude of the 
metabolic dyshomeostasis was less marked in the congenic mice and the suppressed 
HPA axis response to acute stress was not evident.  It was proposed this disparity 
may be attributable to the genetic manipulation making less impact on corticosterone 
clearance efficiency in C57Bl/6j strain mice, rendering this strain less susceptible to 
the effects of 5αR1 loss.  
 
Firstly, disruption of 5R1 in the 5αR1-KO model on the congenic background was 
validated.  Transcripts for Srd5a1 were not detected in the brains or livers of KO 
animals from either genetic background confirming integrity of breeding and 
genotyping processes.  The Srd5a1 gene was blasted using software on the Ensemble 
Genome Browser website showing that only one other transcript (Srd5a1-002; as 
opposed to the conventionally recognised transcript Srd5a1-001) may arise from 
alternative splicing activities.  However Srd5a1-002 is a processed transcript which 
does not result in a translated protein product.  Thus, even if transcription of its 
mRNA sequence is intact in 5αR1-KO mice, this would not impact on the phenotype 
of our 5αR1-KO model, by generating a functional enzyme.  It was possible that the 
lack of functional 5R1 could be compensated for by increased expression of 5R2 
(or also 5βR).  However, Srd5a2 mRNA was absent in tissues of interest from both 
WT and 5αR1-KO, ruling out compensatory expression of the type 2 isozyme in 
response to loss of 5αR1, at least in liver.  Moreover, the abundance of mRNA for 
Akr1d1 was comparable between WT and 5αR1-KO mice. 
 
Various aspects of the phenotype of the 5R1-KO mice previously reported on the 
mixed strain were probed on the congenic background.  As shown in Chapter 5, the 
excess weight gain of 5αR1-KO mice on the congenic line was present but less 
marked than on the mixed strain (broadly 1 g heavier at 15 wks old vs. 2.9 g heavier 
in mixed background). The C57BL6/j 5αR1-KO mice were euglycaemic but 
hyperinsulinaemic under group-housing, recapitulating the mixed strain phenotype.  
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However, the data for each background could not be compared directly due a 
difference in age but also since mixed strain mice were fasted and C57Bl/6j mice 
were not.  Single housing caused weight loss and attenuated hyperinsulinaemia in the 
congenic strain, again a similar ―rescue‖ phenotype seen before in the mixed strain 
5R1-KO mice.  However, in the congenic line this was associated with hypophagia, 
not previously observed, potentially suggesting more refined balance of energy 
homeostasis in the C57Bl/6j background.  Therefore, overall the metabolic 
phenotype was present on both backgrounds but more marked on the mixed strain. 
 
On the contrary, HPA axis responses to acute stress were not similarly affected by 
5αR1 loss in each of the two strains.  Mixed strain 5αR1-KO mice had basal 
corticosterone levels comparable to WT but significantly lower levels following a 
short period of restraint stress.  In the C57Bl/6j strain both basal and post-restraint 
stress corticosterone levels were comparable between WT and 5αR1-KO mice.  
Strain differences in HPA axis responses are not uncommon and C57Bl/6j mice are 
recognised as being quite resistant to physiological challenges including stress 
(Shanks et al. 1990; Anisman et al. 1998), showing particularly tight control of 
glucocorticoid secretion overall.  In contrast, BalbC mice, for example, have large 
adrenals and an exaggerated stress response (Zaharia et al. 1996).  Furthermore, 
following acute restraint stress, plasma corticosterone and insulin levels were lower 
whilst glucose was higher in C57Bl/6j mice compared to other strains such as DBA/2 
BLAL/c and NOD (Harizi et al. 2007).  These differences may also be associated 
with phenotypic discrepancies when mice are assessed in behavioural tests such as 
the EPM.  For example, the effects of social isolation on anxiety (increased) and 
locomotion (hyperactive) were less evident in C57Bl/6j compared to DBA/2 mice 
(Võikar et al. 2005).  Furthermore, C57Bl/6j mice learned the water maze task better 
than the DBA/2 mice (Võikar et al. 2005); therefore differences in behaviour of the 
5R1 KO mice may have been easier to detect on the mixed strain, rather than the 
C57BL/j mice tested in Chapter 5.  Further examples of how strain can influence 
neuroendocrine pathways include, increased HPA axis activity following acute stress 
(i.e. corticosterone levels were increased) in LAL compared to SAL mice whilst 
chronic psychological stress induced long-term changes in the HPA axis in LAL 
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(upregulated hypothalamic Crh and hippocampal DG GR mRNA) but not SAL mice 
(Veenema et al. 2004).  Importantly, strain has been shown to affect the HPA 
phenotype of mice with genetic disruption of Hsd11b1, a model of altered 
glucocorticoid metabolism, anticipated to influence glucocorticoid action in the 
opposite manner to the 5R1-KO model studied here. 
 
The fact that the HPA axis corticosterone responses to stress was not reduced in 
C57Bl/6j 5R1-KO mice was unexpected but may help explain why the brain 
transcript profile for factors which regulate activity of the axis was different between 
mouse strains.  In Chapter 3, female mixed strain 5αR1-KOs had less Crh and Crhr-1 
mRNA in the PVN and pituitary respectively but in female C57Bl/6j 5αR1-KO mice 
(Chapter 5), Crh was not different and Crhr-1 was paradoxically increased.  In 
female 5αR1-KO mice, hypothalamic and pituitary GR was downregulated consistent 
with glucocorticoid excess in mixed strain animals but GR was only downregulated 
in the hypothalamus and not pituitary in C57Bl/6j mice.  These two mouse cohorts 
were culled at different ages (mixed strain at 7 months and C57Bl/6j strain at 15 
months), which could potentially be the cause of the above discrepancies, but it is 
also possible that these effects are due to the genetic backgrounds of the mice used. 
 
More marked phenotypes in the mixed over C57Bl/6j strain may reflect the fact that 
disruption of 5R1 was having a greater magnitude of impact on glucocorticoid 
clearance in the mixed strain.  This could be due to differential contributions of 
5R1 between strains, or differential compensation of other metabolic pathways.  
Thus to assess glucocorticoid clearance efficiency, mice received corticosterone both 
acutely and chronically.  Firstly, mice were adrenalectomised to remove endogenous 
corticosterone; avoiding the possibility of the HPA axis correcting circulating levels.  
Basal corticosterone levels were not reduced to zero in ADX mice (mean of 28 and 
76 nM for males and females respectively) but did not differ between experimental 
groups.  It is unlikely this is due to residual cross-reactivity of the antibody used for 
the ELISA analysis.  Instead it is proposed that extra-adrenal glucocorticoid 
production via the action of metabolic enzymes in physiological systems such as the 
CNS (Mellon et al. 1989; Strömstedt et al. 1995; Gomez-Sanchez et al. 1996) and 
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adipose tissue (Napolitano et al. 1998; Wake et al. 2007; Hernandez-Morante et al. 
2009) may account for residual corticosterone in the circulation following ADX. 
 
In male mice, corticosterone levels rose higher in WT mixed strain mice compared 
to WT C57Bl/6j mice following acute corticosterone treatment and indeed remained 
high over the test period.  Moreover, whilst levels in WT C57Bl/6j had returned 
almost to baseline at 90 mins post-injection, corticosterone remained high in WT 
mixed strain mice across the time-course.  This is suggestive of a slower rate of acute 
glucocorticoid clearance (or delayed HPA axis resolution) in mixed strain compared 
to congenic C57Bl/6j mice.  Moreover, hepatic corticosterone levels were higher in 
mixed strain mice compared to C57Bl/6j congenics, again suggestive of more 
efficient hepatic clearance in C57Bl/6j mice overall. 
 
Surprisingly in male mice, corticosterone clearance was differentially influenced by 
5αR1-KO in each strain.  Without the contribution of 5αR1 in regulating peripheral 
corticosterone levels, 5αR1-KO animals would be expected to clear the infused 
corticosterone bolus more slowly and therefore levels in the plasma would be 
increased vs. WT.  This was only evident in the C57BL6/j strain; corticosterone 
levels across the acute time-course were increased in C57Bl/6j 5αR1-KO mice but 
paradoxically decreased in 5αR1-KO animals of the mixed strain.  It is unclear why 
this arose, but one explanation is that the levels of corticosterone achieved in the 
C57BL6/j strain were considerably lower than the mixed strain and also showed a 
profile demonstrating clearance after a peak level.  It is possible that clearance 
systems were saturated in the mixed strain and the anticipated pattern would be 
revealed if tested with a lower dose of corticosterone which may reflect a more 
normal physiological response. 
 
Chronic corticosterone infusion resulted in plasma levels which were comparable 
between experimental groups, however, similar to acute treatment, 5αR1-KO 
affected plasma corticosterone in opposite ways in each of the two strains.  For 
example, although differences did not reach significance, it seemed that 
corticosterone was decreased and increased in 5αR1-KO mice of the mixed and 
 
  214 
C57Bl/6j strains respectively.  It was also possible that other enzyme pathways were 
adapting differently between strains, confounding the experimental findings. 
 
In males only (WT), transcripts for Srd5a1 in the liver were more abundant in mixed 
strain mice vs. C57Bl/6j mice, perhaps contributing to the increased susceptibly of 
mixed strain mice to the metabolic effects of 5αR1 loss.  Furthermore, independent 
from both sex and genotype, C57Bl/6j mice had slightly reduced abundance of 
Hsd11b1 compared to mixed strain animals, which could be somewhat protective 
from the effects of 5αR1 loss and result in overall less corticosterone reactivation, at 
least in the liver.  There were no male specific genotype or strain effects of 5αR1-KO 
on hepatic expression of mRNAs relating to other metabolic enzymes and it seems 
unlikely that these findings explain the strain difference observed. 
 
In female mice, there was no difference between strains in plasma corticosterone 
concentrations following either acute injection or chronic infusion, suggesting that 
glucocorticoid clearance rates are comparable between female mixed strain and 
C57Bl/6j congenic mice.  Indeed, no substantial differences in the levels of 
transcripts of metabolic enzymes were observed between females of the two strains, 
although transcripts for hepatic Hsd11b1 were slightly less abundant in C57Bl/6j vs. 
mixed strain mice.  Furthermore, hepatic corticosterone levels were similar between 
strains.  Although differences in clearance could not be observed between female 
WT or 5R1-KO mice on either strain, the corticosterone concentrations in the liver 
were significantly higher in 5αR1-KO mice following chronic infusion, in keeping 
with impaired glucocorticoid inactivation in that organ.  Compensatory changes were 
not observed in other enzymes to account for the lack of change in overall clearance 
in liver, but this may have happened either in other tissues (e.g.) adipose or in other 
enzyme systems which were not tested here e.g. 6-hydroxylase.  Notably, again the 
levels of corticosterone achieved after acute injection were similar to the male mixed 
strain, so possibly too high to detect a difference due to saturation. 
 
In both strains but even more so in mixed strain mice, transcripts for Srd5a1 in the 
liver were more abundant in male than female WT animals.  Differential Srd5a1 
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expression between the sexes of mice is not well reported in the literature but in the 
brain its expression does not differ by sex (Tsuruo 2005).  In rat liver (Gustafsson et 
al. 1976) and humans (as measured by urinary metabolites; Andrew et al. 1998) 
5αR1 activity is reportedly higher in females over males.  With intrinsically higher 
Srd5a1 expression in peripheral tissues such as the liver, male 5αR1-KO animals 
would be anticipated to be more prone to metabolic disturbances, in contrast to the 
findings underpinning the hypothesis of this thesis.  In light of no sex-specific 
differences in Srd5a1 expression in the brain (Tsuruo 2005), it may be that reduced 
ALLO synthesis particularly in females plays an important role in the pathogenesis 
of CNS disturbances related to loss of 5αR1. 
 
In summary, in male mice there is evidence to suggest mixed strain mice are less 
able to clear excess glucocorticoids from the periphery than C57Bl/6j congenic 
animals.  This in part may explain why HPA axis responses to acute stress were 
reduced in 5αR1-KO mice of the mixed but not C57Bl/6j strain; if peripheral levels 
reflect those in the CNS, excessively high levels of corticosterone would enhance 
negative feedback on the HPA axis, dampening the stress response.  In this study, 
female animals were studied at length and it was in this sex particularly that strain 
differences were first apparent.  However, there is no evidence to suggest strain-
specific differences in global glucocorticoid clearance either acutely or chronically, 
although excess glucocorticoids accumulate in the liver.  Two further explanations 
may be found in the age of mice, or in the activity of 11βHSD1.  Here we showed 
that C57Bl/6j mice have lower Hsd11b1 mRNA in the liver.  Given 5R1 and 
11HSD1 share NADPH as a co-factor within the mitochondria, it is possible that 
their activities may adapt in relation to one another.  Furthermore, some of the 
phenotypic differences were reported between young mixed strain mice and others 
aged C57Bl/6j mice; however, HPA axis responses were tested in mixed and 
C57Bl/6j mice which were age-matched.  This indeed correlates with the literature 
which suggests that C57Bl/6j mice are especially able to adjust the set-point of the 
HPA axis according to conditions to tightly control glucocorticoid secretion and are 
fairly resistant to stress (Shanks et al. 1990; Zaharia et al. 1996; Anisman et al. 1998; 
Harris et al. 2001; Yau et al. 2001; Carter et al. 2009). 
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7.1 Overview 
The aim of this study was to investigate the role of 5αR1 in regulating the HPA axis 
and syndromes associated with its dysfunction e.g. metabolic disturbances including 
obesity and diabetes and behavioural disorders such as anxiety and cognitive 
impairment.  Basal glucocorticoids were not different between WT and 5αR1-KO 
mice but the abundance of genes which transcribe regulatory components of the HPA 
axis was modified by global 5αR1 loss which may be the main mechanism 
underlying reduced HPA axis responses to acute stress seen previously in 5αR1-KO 
mice.  Female 5αR1-KO mice were heavier than controls with increased adiposity in 
both strains whilst group-housed.  Social isolation induced weight loss in this cohort, 
particularly in mice lacking 5αR1 which were also hypophagic when aged.  There 
was evidence of sexual dimorphism whereby male 5αR1-KO mice were not heavier 
than controls despite hyperphagia. All 5αR1-KO mice showed fasting 
hyperinsulinaemia which was sufficient to maintain normal plasma glucose levels.  
Although 5αR1-KO mice were glucose intolerant, insulin tolerance to exogenous 
insulin treatment was intact. 
 
In male 5αR1-KO mice, mRNA expression of hypothalamic feeding peptides was 
consistent with compensatory reductions in orexigenic proteins to either limit or 
reduce calorific consumption.  No effect of genotype on mRNA expression of 
hypothalamic feeding peptides was observed in female mice.  Nocturnal physical 
activity in the home cage was comparable between genotypes for both males and 
females however, under single housing and acute mild stress, socially isolated mice 
were more active which in part may explain the weight loss seen in these animals.  
Behaviourally, anxiety was only observed in female C57Bl/6j 5αR1-KOs when aged 
and singly-housed.  This same group of animals also had an exaggeration of the 
normal cognitive decline seen with ageing.  Intriguingly, many of the above 
phenotypes were modifiable by factors including strain, sex and age which is 
discussed further below. 
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7.2 The effect of strain 
There were apparent effects of strain on parameters which contribute to HPA axial 
control.  For example, Crh and Crhr-1 mRNA was downregulated in the PVN and 
pituitary respectively of female mixed strain 5αR1-KO mice (consistent with reduced 
forward HPA drive) but in female C57Bl/6j 5αR1-KO mice, Crh was not different 
and Crhr-1 was paradoxically increased.  The latter is not consistent with reduced 
HPA axis responses and indeed, corticosterone release following acute stress was not 
different between genotypes of the C57Bl/6j strain.  The male phenotype was also 
subject to modification by strain; mixed strain 5αR1-KO mice had dampened HPA 
axis stress responses most likely due to reduced Crh and the potentiating effects of 
Avp but corticosterone release following restraint was not affected by genotype in 
C57Bl/6j mice as in females.  Moreover, mixed strain 5αR1-KO mice with reduced 
HPA axis responsiveness did not have gene expression adaptations completely 
consistent with glucocorticoid excess at the level of the HPA axis; again a phenotype 
modifiable by strain.  GR mRNAs were upregulated in male mice lacking 5αR1 in 
both the hypothalamus and pituitary.  In female 5αR1-KO mice, pituitary GR was 
downregulated which is potentially consistent with glucocorticoid excess in mixed 
strain animals but GR was only downregulated in the hypothalamus and not pituitary 
in C57Bl/6j mice.  Therefore strain-related differences in the effect of 5αR1 loss on 
key regulatory features of the HPA axis have been highlighted here and would be an 
important consideration in future experiments. 
 
We went on to demonstrate prolonged corticosterone clearance (males) and higher 
expression of Hsd11b1 in mixed strain vs. C57Bl/6j mice.  These may be important 
findings in explaining the strain related phenotypic differences and are suggestive of 
mixed strain mice being exposed to glucocorticoid levels in excess of those in 
C57Bl/6j mice thus rendering them more susceptible to the detrimental effects of 
5αR1-KO loss.  Figure 7.1 shows a schematic summary of the main results of this 
thesis and how they compared between mouse strains. 
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Figure 7.1  Summary of the 5αR1-KO phenotype and a comparison between the two mouse strains 
Comparison of the 5αR1-KO metabolic, genetic and behavioural phenotypes in mixed strain and C57Bl/6j mice. 
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7.2.1 How important is genetic background? 
In this study, we have highlighted the possibility of strain-specific 5αR1-KO 
phenotypes.  We have also shown to some extent that mixed strain mice cleared 
glucocorticoids less efficiently which may be attributable to intrinsically lower 5αR1 
activity in this particular mouse strain.  Not only is this of importance during the 
planning of future investigations, but it also indicates the importance of 
understanding individual variations in 5αR1 activity which may exist in the human 
population e.g. ethnic origin.  For example, individuals with low 5R1 activity may 
be more susceptible to the effects of glucocorticoid excess, 5αR dysregulation or 
treatment with 5αRIs.  Investigations into a link between ethnicity and the risk of 
developing drug-related side effects would be an important development in deciding 
whether the benefits of treatment actually out-weigh the risk of detrimental effects. 
 
7.3 The effect of sex 
Sex impacted upon a number of phenotypes throughout this study.  Firstly, whilst 
female 5αR1-KO mice gained more weight, had heavier adipose depots and yet were 
normophagic vs. WT, there was no genotype difference in male mice, even though 
male 5αR1-KO mice were hyperphagic vs. WT.  Moreover, male mice generally 
were hyperglycaemic and hyperinsulinaemic compared to females and in males, 
5αR1-KO mice had higher fasting glucose and insulin levels vs. WT. It is known that 
female sex hormones e.g. oestrogen, can act protectively against the development of 
metabolic disorders including obesity and diabetes (Le May et al. 2006; Pettersson et 
al. 2012) therefore, it is not altogether surprising that our data show not only a poorer 
metabolic profile for males overall, but also for males lacking 5αR1 in particular. 
 
HPA axial control also appears to be modified by 5αR1 differentially in the two 
sexes.  Although in male 5αR1-KO mice, transcripts for MR in the hippocampus and 
GR in the pituitary were downregulated and upregulated respectively vs. WT, such 
effects were not seen in females.  Moreover, a completely opposite effect of 5αR1 
loss was seen in each sex in terms of GR mRNA abundance in the hypothalamus, 
where levels increased and decreased in male and female 5αR1-KO mice, 
respectively, in comparison to WT controls.  Moreover, although Crh mRNA was 
 
221 
downregulated in the PVN in 5αR1-KO mice of both sexes, a corresponding 
decrease in Crhr-1 mRNA was seen in female 5αR1-KO mice only.  We, and others 
(Handa et al. 1994), have demonstrated higher plasma corticosterone concentrations 
in female mice overall i.e. both basally and post-stress.  With testosterone and 
oestrogen playing significant roles in HPA axis regulation (suppression and 
activation, respectively; Handa et al. 1994), sex-specific differences in 5αR1-KO-
induced modifications to essential components of the axis may be expected.  Thus, 
not only glucocorticoid levels and therefore the degree of corticosteroid receptor 
activation within tissues, but also activation of testosterone and oestrogen receptors 
and their respective ligand concentrations could potentially be influenced by global 
5αR1-loss, contributing to disruption of the HPA axis in 5αR1-KO mice (Handa et 
al. 2009). 
 
7.4 The effect of ageing 
One of the main aims of chapter 5 was to elucidate whether increasing age 
exacerbated any cognitive decline hypothesised to be associated with 5αR1-KO.  In 
rodents, normal ageing is associated with a physiological rise in glucocorticoids 
(Sapolsky 1992) and, in rats, their levels correlate closely with the degree of 
hippocampal dysfunction and spatial learning impairment (Landfield et al. 1978; 
Landfield et al. 1981).  Although 5αR1-KO mice were not cognitively impaired at 6 
months of age, there was some evidence for a marginally exaggerated cognitive 
decline in 5αR1-KO mice vs. WT following ageing and re-testing at 14-15 months 
old.  One potential hypothesis is that if indeed glucocorticoid metabolism is reduced 
in 5αR1-KO mice, this may lead to a greater than normal increase in corticosterone 
within the brain during the ageing process resulting in an exaggeration of the ageing 
phenotype. Although it was attempted, it was not possible to measure glucocorticoids 
in the brain and therefore this theory could not be adequately proven.  However, 
there is some evidence for age-dependent changes in the activity of 5αR enzymes 
generally (Tunn et al. 1988).  Moreover, the 5αR1/2 metabolite 5αDHT is implicated 
in the pathogenesis of benign prostatic hyperplasia (BPH; Marcelli et al. 1999); a 
disorder which is largely seen in ageing men which again may indicate age-related 
modifications in the activity of 5αR enzymes.  
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In addition, female, 5αR1-KO mice subjected to chronic social isolation stress were 
only anxious when aged and no such phenotype was seen in these mice when 
younger.  This finding again suggests that ageing may provide an additive effect; 
potentially raising corticosterone levels to an even higher level than could be solely 
attributable to the loss of 5αR1 activity alone. 
 
7.5 5αR1-KO mice as a model of glucocorticoid 
excess 
Here we have shown phenotypes which are consistent with glucocorticoid excess, 
particularly in the brain.  For example, Cushing‘s syndrome is associated with an 
increased incidence of psychiatric disturbances; most commonly anxiety and 
depression (Haskett 1985; Dorn et al. 1995; Kelly 1996; Kelly et al. 1996; 
Ragnarsson et al. 2012), but there are also associations with cognitive impairment 
(Toffanin et al. 2011; Ragnarsson et al. 2012).  5αR1-KO mice were indeed mildly 
anxious and marginally cognitively impaired.  However, the fact that these 
phenotypes were only apparent after ageing and during social isolation stress 
suggests only a subtle effect of glucocorticoid excess and that their levels may only 
be mildly increased.  Indeed, single housing itself is a known chronic stressor and 
glucocorticoids increase with age in both humans and rodents (Meaney et al. 1992; 
Sapolsky 1992; Lupien et al. 1994; Montaron et al. 2006), hence the additive effect 
may be detrimental. 
 
The expression of corticosteroid receptors in 5αR1-KO mice was not entirely 
consistent with glucocorticoid excess and shows rather strong sexual dimorphism.  
Therefore, it is possible that concomitant to increased glucocorticoids, the phenotype 
resulting from 5αR1 deficiency may be due to reduced biosynthesis of a number of 
other steroids, in particular neurosteroids such as ALLO within the brain.  It is 
plausible that the increased susceptibility of female 5αR1-KO mice to CNS 
disturbances as well as some of the sexual dimorphism seen with many of the 
phenotypes, may in part be attributable to reduced ALLO production by 5αR1, 
especially in relation to the neurosteroids anxiolytic and neuroprotective properties 
(Rupprecht et al. 1999; Khisti et al. 2002; Ghoumari et al. 2003; Ahmad et al. 2005; 
 
223 
Ugale et al. 2007).  Equally compelling is the fact that ALLO is reduced following 
social isolation (Matsumoto et al. 1999; Dong et al. 2001) which would have a 
similar effect to raised corticosterone.  Future studies could look at ALLO levels 
locally within the brain (possibly even the amygdala specifically) via microdialysis 
techniques as well as ALLO replacement therapy to determine if such treatment may 
―rescue‖ the anxious phenotype. 
 
Metabolically, the 5αR1-KO mouse was a model consistent with glucocorticoid 
excess.  In humans, glucocorticoid excess can occur as a result of pituitary/adrenal 
tumours or treatment with synthetic glucocorticoids for inflammatory conditions 
giving rise to metabolic and cardiovascular disturbances including dyslipidaemia, 
insulin resistance and type II diabetes mellitus, central obesity, CVD and 
hypertension (Schacke et al. 2002; Walker 2007); the collective name for which is 
often termed ―the metabolic syndrome‖.  Despite striking symptomatic crossover 
between patients with Cushing‘s syndrome and those with metabolic syndrome, one 
important difference is that Cushing‘s syndrome is associated with pronounced 
glucocorticoid hypersecretion (Boscaro et al. 2001) whilst the metabolic syndrome 
does not present with elevated circulating glucocorticoids (Walker 2007).  Broadly 
speaking, 5αR1-KO mice showed features of the metabolic syndrome consistent with 
tissue glucocorticoid excess but in the absence of raised corticosterone in the 
circulation.  Furthermore, we showed that metabolic symptoms were sexually 
dimorphic and were also subject to modification by strain.  Male mice lacking 5αR1 
were more susceptible to some metabolic disturbances such as hyperglycaemia, 
hyperinsulinaemia and hyperphagia whilst females were susceptible to others 
including obesity and hepatic steatosis.  In the absence of raised glucocorticoids in 
the circulation, it is likely local increases within tissues such as the liver, brain and 
adipose tissue may drive such metabolic dysfunction.  During this study it was not 
possible to detect corticosterone in the brain but hepatic levels were increased in 
female 5αR1-KO mice following chronic corticosterone infusion.  Future studies 
may be directed towards quantifying corticosterone in the adipose tissue as well as 
tissue levels of other 5αR1 metabolites/substrates such as testosterone, 5αDHT, 
progesterone and 5αDHP as well as ALLO.  
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7.6 Disruption of 5αR in humans 
7.6.1 Pharmacological 
Drugs targeted to inhibit 5αRs (5αRIs) such as dutasteride (dual 5αR1 and 5αR2 
inhibitor (Bramson et al. 1997) and finasteride (largely 5αR2 but also weakly inhibits 
5αR1; Liang et al. 1985; Andersson et al. 1990; Russell et al. 1994) are commonly 
used for the treatment of BPH to reduce intraprostatic concentrations of 5α-DHT 
(Gormley et al. 1992; Roehrborn et al. 2002; Roehrborn et al. 2004).  However, their 
use has been implicated with an increased incidence of depression and anxiety 
(Altomare et al. 2002; Rahimi-Ardabili et al. 2006).  Most studies which have been 
done to assess CNS effects of 5αRIs, have focussed on the use of finasteride (which 
readily crosses the BBB) and its ability to reduce androgen and neurosteroid 
production by 5αR2.  However, here we did not detect 5αR2 in the brain showing 
loss of 5αR1 can specifically mediate anxiety and cognitive deficiencies in 5αR1-KO 
mice. 
 
Moreover, the synthesis of neurosteroids which are produced from adrenal or 
gonadal steroids in the brain (Stoffel-Wagner 2003 for reviews; Dubrovsky 2006) 
requires 5αR activity and finasteride has been shown to diminish neurosteroid 
biosynthesis (Purdy et al. 1991; Finn et al. 2004).  Not only are neurosteroids such as 
ALLO anxiolytic and anti-psychotic (Rupprecht et al. 1999; Khisti et al. 2002; Ugale 
et al. 2007), they also have neuroprotective and neurogenesis properties (Ghoumari 
et al. 2003; Ahmad et al. 2005).  Therefore, whilst it is clear that CNS effects in 
5αR1-KO mice are indeed mediated by the type 1 isozyme (if due to local as 
opposed to peripheral activity), it is unknown whether increased glucocorticoids, 
reduced neurosteroids, reduced androgens or a combination of all three underlies 
anxiety and cognitive decline in this study. 
 
One final consideration with reference to the use of 5αRIs, is the effect of 5αR3 
blockade.  Currently, the efficacy of 5αRIs against the type 3 isozyme is less well 
studied but finasteride and dutasteride potently inhibit 5αR3 activity in vitro 
(Yamana et al. 2010).  However, although 5αR3 is not thought to contribute to 
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glucocorticoid clearance, there are suggestions of its contribution to the reduction of 
androgens and neurosteroids (Cantagrel et al. 2010; Azzouni et al. 2012). 
 
7.6.2 Genetic 
7.6.2.1 5αR deficiency 
Human 5αR deficiencies are described mainly for mutations in the SRD5A2 gene 
which are inherited in an autosomal recessive nature (Thigpen et al. 1992); none are 
reported for SRD5A1. Although, SRD5A2 deficiency is mostly studied in the context 
of androgens and a lack of 5αDHT production (Moore et al. 1976; Andersson et al. 
1991; Jenkins et al. 1992; Wilson et al. 1993), the tissue distribution of 5αR2 in 
humans (liver and some evidence for expression in the brain) and its capacity to 
metabolise androgens and glucocorticoids suggests 5αR2-deficient individuals may 
have some degree of symptoms associated with impaired glucocorticoid clearance in 
the liver and brain e.g. metabolic and behavioural disturbances, but such effects are 
yet to be documented. 
 
7.6.3 5αR up-regulation 
In both men and women, conditions such as obesity and insulin resistance correlate 
with elevated 5αR activity (Andrew et al. 1998; Rask et al. 2002; Tomlinson et al. 
2008).  In women, increased 5αR activity is often associated with polycystic ovarian 
syndrome (PCOS; Vassiliadi et al. 2009).  However, since these studies measure 
only urinary steroid metabolite excretion, it is impossible to delineate 1) whether 
both 5αR1 and 5αR2 contribute to the effects of increased 5αR metabolites, and 2) 
whether 5αR upregulation shows tissue specificity.  In this study we showed a lack 
of 5αR1 also resulted in metabolic disturbances such as weight gain and 
hyperinsulinaemia, so it is possible that up-regulation in metabolic conditions is a 
protective mechanism.  Lastly, monitoring the contribution of increased/decreased 
androgen activation or neurosteroid biosynthesis in future studies; both clinical and 




7.6.4 Single nucleotide polymorphisms (SNPs) 
In the human population there are also instances of single nucleotide polymorphisms 
(SNPs) in the SRD5A1 gene.  As with 5αR2 deficiency, these are most often 
associated with the implications for reduced sex steroid metabolism (Klotsman et al. 
2004; Setlur et al. 2010; Hein et al. 2012), however, in our 5αR1-KO mouse model 
there is evidence of the enzyme‘s role in the pathogenesis of both metabolic and 
CNS disorders.  Therefore, it is probable that deactivating SNPs in the human 
SRD5A1 gene may have effects over and above those associated with reduced sex 
steroid reduction. 
 
7.7 Future experiments and further work 
Future studies would first and foremost be directed towards quantifying 
corticosterone levels in tissues including adipose tissue and the brain to ascertain the 
degree of glucocorticoid excess in 5αR1-KO mice.  This could be done by steroid 
extraction followed by LC-MS/MS and possibly also microdialysis techniques to 
allow measurements from within the brains of live animals at selected time points.  
Additionally, the interpretation of further studies would be enhanced by measuring 
intra-tissue levels of other 5αR1 metabolites/substrates including testosterone, 
5αDHT, progesterone, 5αDHP and in particular ALLO.  From the current data it 
cannot be concluded whether anxiety and cognitive deficits in aged, socially isolated 
5αR1-KO mice are due to increased corticosterone or reduced ALLO in the brain or 
both.  If 5αR1-KO mice were found to have reduced neurosteroid biosynthesis within 
the brain, ALLO replacement studies may also be carried out to see if the social 
isolation phenotype can be reversed. 
 
From a behavioural aspect, future ageing studies would ideally be carried out in mice 
who have been aged beyond the time point specified here, for example it may be 
optimal to test mice when young (~6 months), middle-aged (~12 months) and then 
considerably aged (~24 months) to optimise the phenotypic result.  Additionally, it 
may be interesting to assess 5αR1-KO mice for depression in further studies.  
Investigations could incorporate the use of such tests including the forced swim test 
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and/or the tail suspension test commonly used to determine the efficacy of anti-
depressants in pre-clinical studies using animal models of depression. 
 
To continue assessment of the 5αR1-KO metabolic phenotype, it would be useful to 
evaluate the basal metabolic rates of these animals in future studies by measuring 
their respiratory quotients and core body temperatures especially since 11βHSD1-KO 
mice have increased core temperatures (Morton et al. 2004). 
 
Finally, to complement genetic studies and further validate the deleterious effects of 
glucocorticoid excess in neuronal circuits related to appetite, metabolic homeostasis, 
stress responses and behaviour with ageing, 5αR1 could be inhibited 
pharmacologically through the use of inhibitors such dutasteride in future in vivo 
studies.  Following drug treatment, which could be delivered for example by osmotic 
mini pump, s.c. injection or even orally, drug brain levels could be measured by LC-
MS/MS to determine BBB penetration.   Tissue (brain/liver/adipose) glucocorticoid 
levels and urinary 5α metabolite excretion could also be quantified to determine the 
extent to which drugs such as finasteride and dutasteride inhibit glucocorticoid 
clearance both centrally and peripherally. 
 
7.8 Concluding remarks 
A-ring reduction of steroid hormones including glucocorticoids but potentially other 
steroids also e.g. progesterone and testosterone, is important in maintaining not only 
metabolic but also CNS function.  Here we have shown a fairly novel role for 5αR1 
in determining the outcome of chronic stress and ageing whereby it appears that the 
activity of the enzyme is somewhat protective under such circumstances.  Therefore, 
metabolic and CNS side effects in, for example, aged men treated with 5αRIs may in 
future be more closely monitored in terms of anxiety and accelerated cognitive 
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